Pembrolizumab plus Chemotherapy in Metastatic Nonâ

New England Journal of Medicine
378, 2078-2092
DOI: 10.1056/nejmoa1801005

Citation Report

#	Article	IF	Citations
1	Pembrolizumab synergizes with chemotherapy. Nature Reviews Clinical Oncology, 2018, 15, 402-403.	12.5	5
2	Treatment of Advanced Nonâ€“Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy. Journal of Oncology Practice, 2018, 14, 537-538.	2.5	13
3	Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment. Oncotarget, 2018, 9, 32552-32553.	0.8	4
4	Navigating Through New, First-Line Treatment Options for Lung Cancer. Journal of Oncology Practice, 2018, 14, 539-540.	2.5	0
5	Systemic Therapy for Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancers. Journal of Clinical Oncology, 2018, 36, 2571-2574.	0.8	6
6	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 3575-3584.	0.6	36
7	Broader indications for checkpoint inhibitors in NSCLC. Journal of Thoracic Disease, 2018, 10, 5190-5191.	0.6	0
8	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancerâ€”where are we?. Translational Lung Cancer Research, 2018, 7, 682-690.	1.3	29
9	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Translational Lung Cancer Research, 2018, 7, 647-660.	1.3	66
10	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. Journal of Thoracic Disease, 2018, 10, S3241-S3243.	0.6	2
11	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4034-S4037.	0.6	5
12	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Translational Lung Cancer Research, 2018, 7, 691-702.	1.3	8
13	Immunotherapy in tyrosine kinase inhibitor-naÃ¯ve advanced epidermal growth factor receptor-mutant non-small cell lung cancerâ€”driving down a precarious road in driver-mutated lung cancer. Translational Lung Cancer Research, 2018, 7, S377-S380.	1.3	3
14	The combination strategies will be ready the right first-line choice for squamous lung cancer patients?. Translational Lung Cancer Research, 2018, 7, S349-S351.	1.3	2
16	Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493.	0.6	42
17	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. Translational Lung Cancer Research, 2018, 7, 631-638.	1.3	68
18	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. Journal of Thoracic Disease, 2018, 10, 5186-5189.	0.6	1
19	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. Journal of Thoracic Disease, 2018, 10, S2195-S2197.	0.6	3

#	Article	IF	Citations
20	Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?. Journal of Thoracic Disease, 2018, 10, S3994-S3998.	0.6	17
21	A new era of treating advanced lung cancer is upon us. Translational Lung Cancer Research, 2018, 7, S202-S205.	1.3	2
22	PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. Translational Lung Cancer Research, 2018, 7, S287-S289.	1.3	4
23	Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Translational Lung Cancer Research, 2018, 7, S208-S210.	1.3	9
24	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. Journal of Thoracic Disease, 2018, 10, 6378-6382.	0.6	13
25	Atezolizumab in non-squamous non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S3155-S3159.	0.6	4
26	Non-small cell lung cancer: land of conquest for immunotherapy. Journal of Thoracic Disease, 2018, 10, 5184-5185.	0.6	0
27	Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. Translational Lung Cancer Research, 2018, 7, S221-S224.	1.3	2
28	Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S218-S220.	1.3	0
29	Combining immunotherapy with radiation therapy in thoracic oncology. Journal of Thoracic Disease, 2018, 10, S2492-S2507.	0.6	16
30	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. Translational Lung Cancer Research, 2018, 7, S198-S201.	1.3	8
31	Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma. Medicine (United States), 2018, 97, e13427.	0.4	1
32	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S225-S227.	1.3	7
33	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. Journal of Thoracic Disease, 2018, 10, S4069-S4072.	0.6	3
34	30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?. ERJ Open Research, 2018, 4, 00030-2018.	1.1	16
35	Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?. Annals of Translational Medicine, 2018, 6, S120-S120.	0.7	3
36	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. Journal of Oncology Practice, 2018, 14, 529-535.	2.5	41
45	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Current Urology Reports, 2018, 19, 109.	1.0	47

#	Article	IF	Citations
46	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer, 2018, 18, 1082.	1.1	42
47	Advances in evidenceâ€based medicine for immunotherapy of nonâ€small cell lung cancer. Journal of Evidence-Based Medicine, 2018, 11, 278-287.	2.4	22
49	Checkpoint Inhibitor Pneumonitis â€" Real-World Incidence and Risk. Journal of Thoracic Oncology, 2018, 13, 1812-1814.	0.5	10
50	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133
51	Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Current Oncology Reports, 2018, 20, 94.	1.8	43
52	Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. BMC Cancer, 2018, 18, 1105.	1.1	48
53	The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 7369-7383.	1.0	19
54	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
55	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 5178-5183.	0.6	2
56	Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Nonâ€"Small Cell Lung Cancer. JAMA Network Open, 2018, 1, e183023.	2.8	5
57	Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC). Current Breast Cancer Reports, 2018, 10, 282-288.	0.5	1
59	Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nature Communications, 2018, 9, 5450.	5.8	157
60	The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Management and Research, 2018, Volume 10, 6823-6833.	0.9	113
61	ASCO 2018 NSCLC highlightsâ€"combination therapy is key. Memo - Magazine of European Medical Oncology, 2018, 11, 266-271.	0.3	12
62	Two-Round Mixed Lymphocyte Reaction for Evaluation of the Functional Activities of Anti-PD-1 and Immunomodulators. Immune Network, 2018, 18, e45.	1.6	10
63	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon, 2018, 4, e01039.	1.4	37
64	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. , 2018, 6, 155.		82
65	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatmentâ€"are we barking up the wrong tree?. Translational Lung Cancer Research, 2018, 7, S275-S279.	1.3	36

#	Article	IF	Citations
67	Lâ€™immunothÃ©rapie de premiÃ¨re ligne pour les CBNPC de stades avancÃ©s (sans addiction oncogÃ©nique). Revue Des Maladies Respiratoires Actualites, 2018, 10, 380-384.	0.0	0
69	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. Journal of Clinical Medicine, 2018, 7, 542.	1.0	64
70	Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis. Lung Cancer, 2018, 126, 194-200.	0.9	44
71	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine, 2018, 10, 93.	3.6	121
74	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. Seminars in Oncology, 2018, 45, 176-180.	0.8	5
75	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2018, Volume 12, 2857-2873.	2.0	10
76	Establishment of a prospective multicenter cohort for advanced nonâ€small cell lung cancer in China (CAPTRAâ€Lung study). Thoracic Cancer, 2018, 9, 1795-1800.	0.8	3
77	Predictive pathology of lung cancer immunotherapy response. Lancet Respiratory Medicine,the, 2018, 6, 731-733.	5.2	3
78	The adolescence of cancer immunotherapy: from aÂdifficult childhood to aÂpillar of modern anticancer therapy. Memo - Magazine of European Medical Oncology, 2018, 11, 82-83.	0.3	0
80	Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study. Journal of Hepatology, 2018, 69, 1396-1397.	1.8	41
81	Multiplex Immuno-Liquid Chromatographyâ€“Mass Spectrometryâ€“Parallel Reaction Monitoring (LCâ€“MSâ€“PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues. Journal of Proteome Research, 2018, 17, 3932-3940.	1.8	15
82	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326.	13.5	985
83	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv192-iv237.	0.6	1,571
84	Amphiphilic block copolymer NPs obtained by coupling ricinoleic acid/sebacic acids and mPEG: Synthesis, characterization, and controlled release of paclitaxel. Journal of Biomaterials Science, Polymer Edition, 2018, 29, 2201-2217.	1.9	6
85	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Caseâ€“Control Study. Cancer Immunology Research, 2018, 6, 1453-1458.	1.6	35
86	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9, 3868.	5.8	211
87	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1436-1437.	0.5	7
88	Pembrolizumab plus Chemotherapy for Squamous Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2040-2051.	13.9	2,676

#	Article	IF	Citations
89	Local ablative treatment for synchronous single organ oligometastatic lung cancerâ€"A propensity score analysis of 180 patients. Lung Cancer, 2018, 125, 164-173.	0.9	27
90	Immunotherapy-based combinations: an update. Current Opinion in Oncology, 2018, 30, 345-351.	1.1	25
91	Diagnostic and Predictive Immunohistochemistry for Nonâ€"Small Cell Lung Carcinomas. Advances in Anatomic Pathology, 2018, 25, 374-386.	2.4	15
92	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1969-1976.	0.9	24
93	Optimisation of chemotherapy in the era of immunotherapy. European Respiratory Journal, 2018, 52, 1801698.	3.1	1
94	Should chemotherapy plus immune checkpoint inhibition be the standard frontâ€line therapy for patients with metastatic nonâ€"small cell lung cancer?. Cancer, 2018, 124, 4592-4596.	2.0	7
95	ABOUND.2L+: A randomized phase 2 study of nanoparticle albuminâ€bound paclitaxel with or without CCâ€486 as secondâ€line treatment for advanced nonsquamous nonâ€small cell lung cancer (NSCLC). Cancer, 2018, 124, 4667-4675.	2.0	12
97	Pneumonitis in Nonâ€"Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology, 2018, 13, 1930-1939.	0.5	282
98	Durvalumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880415.	1.4	22
99	How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. Annals of Oncology, 2018, 29, 2157-2160.	0.6	2
100	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open, 2018, 3, e000406.	2.0	84
101	Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Research, 2018, 78, 5729-5730.	0.4	11
102	Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). Journal of Thoracic Oncology, 2018, 13, 1958-1961.	0.5	72
103	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. Cancer Treatment Reviews, 2018, 71, 47-58.	3.4	37
104	Highlights from the 2018 WIN Symposium, 25â€"26 June 2018, Paris: designing the future of precision oncology. Ecancermedicalscience, 2018, 12, 871.	0.6	0
105	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018, 379, 2108-2121.	13.9	3,097
106	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	2.1	60
109	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661879413.	1.0	35

#	Article	IF	Citations
110	Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy. Cancer Research, 2018, 78, 5191-5199.	0.4	66
111	T Cellâ€“Inflamed versus Non-T Cellâ€“Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunology Research, 2018, 6, 990-1000.	1.6	297
112	Hyperprogressive Disease in Patients With Advanced Nonâ€“Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncology, 2018, 4, 1543.	3.4	567
113	Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy, 2018, 10, 1023-1025.	1.0	11
114	Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. Journal of Medical Economics, 2018, 21, 1191-1205.	1.0	78
116	Roles of the RANKLâ€“RANK axis in antitumour immunity â€” implications for therapy. Nature Reviews Clinical Oncology, 2018, 15, 676-693.	12.5	77
117	Pembrolizumab plus Chemotherapy in Lung Cancer. New England Journal of Medicine, 2018, 379, e18.	13.9	64
118	Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2018, 18, 1015-1021.	1.4	18
119	Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer. Cancer Genomics and Proteomics, 2018, 15, 387-393.	1.0	4
120	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncology, The, 2018, 19, 1338-1350.	5.1	337
121	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Annals of Oncology, 2018, 29, 2175-2182.	0.6	20
122	What a dog transmissible tumor can teach us about cancer regression. Molecular and Cellular Oncology, 2018, 5, e1472059.	0.3	0
123	Adenosquamous carcinoma of the lung. OncoTargets and Therapy, 2018, Volume 11, 4829-4835.	1.0	70
124	Delineating the Role of PD-1/PD-L1 Blockade in Advanced SCLC. Journal of Thoracic Oncology, 2018, 13, 1242-1244.	0.5	7
125	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research, 2018, 2018, 1-17.	0.9	147
126	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Journal of Thoracic Disease, 2018, 10, 6636-6652.	0.6	33
127	A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction. Japanese Journal of Lung Cancer, 2018, 58, 996-1000.	0.0	2
128	Myeloid Regulatory Cells: New and Exciting Players in the Immunology of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 703-704.	2.5	2

#	Article	IF	Citations
129	Emerging biomarkers for immune checkpoint inhibition in lung cancer. Seminars in Cancer Biology, 2018, 52, 269-277.	4.3	67
130	A New Standard of Care for Advanced Lung Cancer. New England Journal of Medicine, 2018, 378, 2135-2137.	13.9	18
131	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. Cancer Treatment Reviews, 2018, 68, 69-79.	3.4	51
132	The Immune Landscape of Nonâ€“Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 24-38.	2.5	14
133	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patientsâ€™ selection. Critical Reviews in Oncology/Hematology, 2018, 129, 27-39.	2.0	39
134	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 137-145.	0.4	24
135	Human Vaccines & Immunotherapeutics: News. Human Vaccines and Immunotherapeutics, 2018, 14, 1306-1307.	1.4	0
136	T Lymphocyteâ€“Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22
137	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Critical Reviews in Oncology/Hematology, 2018, 130, 1-12.	2.0	16
138	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. Current Treatment Options in Oncology, 2018, 19, 43.	1.3	10
139	Durvalumab for the treatment of non-small cell lung cancer. Expert Review of Respiratory Medicine, 2018, 12, 627-639.	1.0	38
140	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers, 2018, 10, 245.	1.7	34
141	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers, 2018, 10, 248.	1.7	258
142	The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. Journal of Thoracic Oncology, 2018, 13, 1058-1059.	0.5	5
143	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
144	A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101). International Journal of Clinical Oncology, 2018, 23, 1060-1069.	1.0	0
145	Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum. Journal of Thoracic Oncology, 2018, 13, 1062-1075.	0.5	99
146	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. OncoTargets and Therapy, 2018, Volume 11, 4051-4064.	1.0	15

#	Article	IF	Citations
147	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced nonâ€“small-cell lung cancer. European Journal of Cancer, 2018, 101, 114-122.	1.3	45
148	Editorial: Controversies in the Local Management of Lung Cancer. Frontiers in Oncology, 2018, 8, 233.	1.3	1
149	New windows open for immunotherapy in lung cancer. Nature, 2018, 558, 376-377.	13.7	38
150	New options on the horizon for nononcogene addicted non-small-cell lung cancer. Future Oncology, 2018, 14, 19-28.	1.1	2
151	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers, 2018, 10, 204.	1.7	37
152	Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. BioDrugs, 2018, 32, 311-317.	2.2	48
153	BRAF Mutationsâ€”A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?. Journal of Thoracic Oncology, 2018, 13, 1055-1057.	0.5	3
154	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 2018, 7, 151.	1.0	11
155	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 807-821.	2.3	394
156	A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. Immunity, 2018, 49, 11-13.	6.6	12
157	â€œKeepingâ€•a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle, 2018, 17, 1696-1707.	1.3	39
158	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
159	Frontline immunotherapy for NSCLC: alone or not alone?. Nature Reviews Clinical Oncology, 2018, 15, 593-594.	12.5	10
160	Definitive concurrent chemoradiotherapy in a patient with stage IV non-small cell lung cancer due to cervical lymph node metastases. International Cancer Conference Journal, 2018, 7, 131-133.	0.2	1
161	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers, 2018, 10, 236.	1.7	31
162	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changinâ€™. Clinical Lung Cancer, 2018, 19, 461-463.	1.1	2
163	Treatment of advanced non-small cell lung cancer in the elderly. Expert Review of Respiratory Medicine, 2018, 12, 783-792.	1.0	9
164	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). Lung Cancer, 2018, 124, 117-124.	0.9	46

#	Article	IF	Citations
165	Current and future developments of immunotherapy in lung cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 122-131.	0.3	1
166	Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?. ESMO Open, 2018, 3, e000421.	2.0	9
167	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology, 2018, 9, 1739.	2.2	174
168	Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. European Respiratory Journal, 2018, 52, 1800884.	3.1	24
169	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. PLoS ONE, 2018, 13, e0202725.	1.1	15
170	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced nonâ€“small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer, 2018, 125, 273-281.	0.9	69
171	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 324-334.	0.9	56
172	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. Current Treatment Options in Oncology, 2018, 19, 46.	1.3	16
173	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncology, The, 2018, 19, 1180-1191.	5.1	811
174	Sex as a predictor of response to cancer immunotherapy. Lancet Oncology, The, 2018, 19, e378.	5.1	1
175	Sex as a predictor of response to cancer immunotherapy â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e380-e381.	5.1	7
176	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. Drugs and Aging, 2018, 35, 819-834.	1.3	16
177	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87.	1.4	8
178	Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. Scientific Reports, 2018, 8, 11738.	1.6	21
179	Emerging therapies in advanced hepatocellular carcinoma. Experimental Hematology and Oncology, 2018, 7, 17.	2.0	85
180	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781.	5.2	167
181	Presence of few PDâ€1â€expressing tumorâ€infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for nonâ€small cell lung cancer: An exploratory case series. Thoracic Cancer, 2018, 9, 1305-1311.	0.8	7
182	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Medical Oncology, 2018, 35, 132.	1.2	52

#	Article	IF	Citations
183	Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1018-1026.	2.3	7
184	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 2018, 378, 2288-2301.	13.9	2,808
185	Spotlight on atezolizumab and its potential as an oncology agent. Expert Review of Anticancer Therapy, 2018, 18, 719-722.	1.1	3
186	Immunotherapy combinations emerging in non-small-cell lung cancer. Immunotherapy, 2018, 10, 627-629.	1.0	0
187	Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity, 2018, 48, 1077-1080.	6.6	33
188	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treatment Reviews, 2019, 72, 15-27.	3.4	37
189	PseudoprogresiÃ³n en una paciente con adenocarcinoma pulmonar metastÃ¡sico tratada con nivolumab. Archivos De Bronconeumologia, 2019, 55, 168-169.	0.4	0
190	Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?. Current Problems in Cancer, 2019, 43, 43-53.	1.0	1
191	Rash and Pruritus With PDâ€1 Inhibitors in Cancer Patients: A Metaâ€Analysis of Randomized Controlled Trials. Journal of Clinical Pharmacology, 2019, 59, 45-54.	1.0	3
192	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
193	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
194	Comprehensive analysis of differentially expressed long nonâ€coding RNAs in nonâ€small cell lung cancer. Oncology Letters, 2019, 18, 1145-1156.	0.8	20
195	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Letters, 2019, 464, 5-14.	3.2	148
196	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	3.6	45
197	Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. , 2019, 7, 205.		72
198	Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. Immunotherapy, 2019, 11, 657-665.	1.0	1
199	Immune checkpoint inhibitorsâ€induced neuromuscular toxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S74-S85.	1.4	42
200	Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Investigational New Drugs, 2019, 37, 1266-1273.	1.2	38

#	Article	IF	Citations
201	Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. Translational Oncology, 2019, 12, 1425-1431.	1.7	21
202	Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer. Lancet Oncology, The, 2019, 20, 1334-1335.	5.1	6
203	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. Translational Lung Cancer Research, 2019, 8, 202-207.	1.3	12
204	Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Nonâ€“Small-Cell Lung Cancer Data Set. JCO Clinical Cancer Informatics, 2019, 3, 1-13.	1.0	69
205	Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. Oncotarget, 2019, 10, 3129-3143.	0.8	71
206	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology, 2019, 30, 1653-1659.	0.6	220
209	Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Nonâ€“Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clinical Lung Cancer, 2019, 20, 442-450.e4.	1.1	83
210	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Lung Cancer, 2019, 136, 30-36.	0.9	32
211	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS ONE, 2019, 14, e0220570.	1.1	20
212	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. Immunotherapy, 2019, 11, 993-1003.	1.0	16
213	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology, 2019, 15, 2371-2383.	1.1	4
214	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 1149-1160.	1.0	9
215	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of Clinical Oncology, 2019, 37, 2360-2367.	0.8	52
216	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. Immunotherapy, 2019, 11, 913-920.	1.0	13
217	The estrogen pathway as a modulator of response to immunotherapy. Immunotherapy, 2019, 11, 1161-1176.	1.0	7
218	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. Future Oncology, 2019, 15, 1667-1678.	1.1	13
219	Nonâ€“Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	1.4	1,153
220	Supplementary granulocyte macrophage colonyâ€stimulating factor to chemotherapy and programmed deathâ€ligand 1 blockade decreases local recurrence after surgery in bladder cancer. Cancer Science, 2019, 110, 3315-3327.	1.7	17

#	Article	IF	Citations
221	Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer. Respiratory Research, 2019, 20, 185.	1.4	21
222	Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer . Cancer Management and Research, 2019, Volume 11, 7707-7719.	0.9	45
223	Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. BMJ Open, 2019, 9, e028056.	0.8	1
224	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. Journal of Clinical Medicine, 2019, 8, 998.	1.0	28
225	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	7.7	240
226	Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 1003.	1.7	43
227	Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1283.	3.4	220
228	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1276.	3.4	670
229	Pembrolizumab for the treatment of cervical cancer. Expert Opinion on Biological Therapy, 2019, 19, 871-877.	1.4	24
230	Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy. Biomaterials, 2019, 218, 119359.	5.7	64
231	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	2.0	18
232	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 1919-1928.	0.6	13
233	Rational application of the firstâ€line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A metaâ€analysis. Cancer Medicine, 2019, 8, 5033-5046.	1.3	9
234	Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. Lung Cancer, 2019, 134, 202-209.	0.9	35
235	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. Journal of Clinical Medicine, 2019, 8, 1014.	1.0	41
236	Immune-Related Adverse Events: A Case-Based Approach. Frontiers in Oncology, 2019, 9, 530.	1.3	31
237	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1011.	1.0	45
238	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0

#	Article	IF	Citations
239	The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nature Communications, 2019, 10, 3108.	5.8	69
240	A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer . OncoTargets and Therapy, 2019, Volume 12, 4955-4973.	1.0	9
241	FMNL1 down-regulation suppresses bone metastasis through reducing TGF-Î²1 expression in non-small cell lung cancer (NSCLC). Biomedicine and Pharmacotherapy, 2019, 117, 109126.	2.5	22
242	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Frontiers in Immunology, 2019, 10, 1654.	2.2	101
243	Possible Biomarkers for Cancer Immunotherapy. Cancers, 2019, 11, 935.	1.7	35
244	Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 2019, 16, 465-483.	1.9	119
245	New emerging targets in cancer immunotherapy: the role of TIM3. ESMO Open, 2019, 4, e000497.	2.0	72
246	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2019, 2, e196879.	2.8	161
247	Systemic immuneâ€inflammation index, neutrophilâ€toâ€lymphocyte ratio, plateletâ€toâ€lymphocyte ratio can predict clinical outcomes in patients with metastatic nonâ€smallâ€cell lung cancer treated with nivolumab. Journal of Clinical Laboratory Analysis, 2019, 33, e22964.	0.9	171
248	Resistance to immune checkpoint inhibitors. Next steps and combinational approaches. Memo - Magazine of European Medical Oncology, 2019, 12, 123-127.	0.3	6
249	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature Communications, 2019, 10, 3251.	5.8	55
250	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. OncoImmunology, 2019, 8, e1641390.	2.1	22
251	Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice. Oncology, 2019, 97, 228-235.	0.9	13
252	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. , 2019, , 65-84.		0
253	Clinical Experience of Patients Referred to a Multidisciplinary Cardio-Oncology Clinic: An Observational Cohort Study. Current Oncology, 2019, 26, 322-327.	0.9	23
254	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, 2019, 11, 1033.	1.7	160
255	Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Critical Reviews in Oncology/Hematology, 2019, 142, 26-34.	2.0	49
256	Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S364-S368.	1.3	18

#	Article	IF	Citations
257	Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. PLoS ONE, 2019, 14, e0220306.	1.1	21
258	Clinical utility of ramucirumab in non-small-cell lung cancer . Biologics: Targets and Therapy, 2019, Volume 13, 133-137.	3.0	6
260	Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. Advances in Radiation Oncology, 2019, 4, 541-550.	0.6	6
261	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. AAPS Journal, 2019, 21, 79.	2.2	53
262	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer . Lung Cancer: Targets and Therapy, 2019, Volume 10, 47-56.	1.3	12
263	Programmed deathâ€“ligand 1 expression on direct Papâ€stained cytology smears from nonâ€“small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathology, 2019, 127, 470-480.	1.4	31
264	Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. Oncogene, 2019, 38, 5921-5932.	2.6	27
265	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 67.	6.9	54
266	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134, 210-217.	0.9	12
267	Durable Response After 2 Doses of Pembrolizumab in a Patient With Nonâ€“Small-Cell Lung Cancer With an Isolated Brain Metastasis. Clinical Lung Cancer, 2019, 20, e552-e554.	1.1	1
268	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	0.6	9
269	Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-Î± antibody infliximab. Drug Discoveries and Therapeutics, 2019, 13, 164-167.	0.6	14
270	Improving the prognosis for lung cancer patients. Acta OncolÃ³gica, 2019, 58, 1077-1078.	0.8	11
271	Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 693-699.	1.4	20
272	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 369-386.	0.6	19
273	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 2019, 11, 920.	1.7	10
274	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberculosis and Respiratory Diseases, 2019, 82, 179.	0.7	48
275	EGFR Targeted Therapy. Current Cancer Research, 2019, , 1-30.	0.2	2

#	Article	IF	Citations
276	Tumour Treating Fields for mesothelioma: controversy versus opportunity. Lancet Oncology, The, 2019, 20, 1623-1625.	5.1	3
277	Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. Immuno-Oncology Technology, 2019, 3, 1-7.	0.2	20
281	Solubility and thermodynamics of polymorphic indomethacin in binary solvent mixtures. Journal of Molecular Liquids, 2019, 295, 111717.	2.3	12
282	Pemetrexed exposure predicts toxicity in advanced nonâ€“small-cell lung cancer: A prospective cohort study. European Journal of Cancer, 2019, 121, 64-73.	1.3	16
283	Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Future Science OA, 2019, 5, FSO421.	0.9	26
284	New challenges in tubulointerstitial nephritis induced by drugs. Nefrologia, 2019, 39, 339-342.	0.2	1
285	Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2019, 9, 972.	1.3	17
286	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resistance Updates, 2019, 47, 100646.	6.5	81
287	Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. Frontiers in Oncology, 2019, 9, 944.	1.3	17
288	Exposure to antiâ€PDâ€1 causes functional differences in tumorâ€infiltrating lymphocytes in rare solid tumors. European Journal of Immunology, 2019, 49, 2245-2251.	1.6	4
289	Rapid, Greener and Ultrasound Irradiated Oneâ€Pot Synthesis of Anticancer Activity. ChemistrySelect, 2019, 4, 11125-11129.	0.7	13
290	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. Journal of Thoracic Disease, 2019, 11, 3794-3807.	0.6	3
291	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1692-1700.	2.2	193
292	The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. International Immunopharmacology, 2019, 77, 105975.	1.7	7
293	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
294	Cytokine Release Syndrome Resulting From Antiâ€“Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists. Journal of Oncology Practice, 2019, 15, 502-504.	2.5	8
295	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1699.	1.7	81
296	Immune checkpoint inhibitorâ€associated pituitaryâ€adrenal dysfunction: A systematic review and metaâ€analysis. Cancer Medicine, 2019, 8, 7503-7515.	1.3	35

#	Article	IF	Citations
297	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. Cancers, 2019, 11, 1683.	1.7	38
299	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer, 2019, 138, 88-94.	0.9	54
300	Comparisons between tumor burden and other prognostic factors that influence survival of patients with nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2019, 10, 2259-2266.	0.8	18
302	The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Anticancer Research, 2019, 39, 6231-6240.	0.5	30
303	Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. BMC Cancer, 2019, 19, 1074.	1.1	30
304	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Nonâ€“Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. Frontiers in Pharmacology, 2019, 10, 1260.	1.6	18
305	PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet, The, 2019, 394, 1882-1884.	6.3	16
306	Antitumor activity of an engineered decoy receptor targeting CLCF1â€“CNTFR signaling in lung adenocarcinoma. Nature Medicine, 2019, 25, 1783-1795.	15.2	43
308	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Frontiers in Pharmacology, 2019, 10, 1453.	1.6	24
309	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers, 2019, 11, 1782.	1.7	53
310	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. Future Oncology, 2019, 15, 3633-3646.	1.1	8
311	Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Focusing on Organ-Specific irAEs and the Critical Role of Steroids. Journal of Thoracic Oncology, 2019, 14, e233-e234.	0.5	6
312	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32
313	The role and therapeutic implications of T cells in cancer of the lung. Clinical and Translational Immunology, 2019, 8, e1076.	1.7	25
314	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. Head and Neck, 2019, 41, 4-18.	0.9	40
315	The hubris and humility of cancer pharmacology in the post immunoâ€oncology era. Pharmacology Research and Perspectives, 2019, 7, e00527.	1.1	3
316	A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). Lung Cancer, 2019, 138, 65-71.	0.9	32
317	KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1â€“49%. Journal of Thoracic Disease, 2019, 11, S1963-S1965.	0.6	6

#	Article	IF	Citations
318	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. Journal of Thoracic Disease, 2019, 11, 3909-3919.	0.6	2
319	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. Journal of Thoracic Disease, 2019, 11, 3757-3768.	0.6	29
320	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. Targeted Oncology, 2019, 14, 707-717.	1.7	15
322	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
323	PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S139-S146.	1.3	11
324	Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer. Lung Cancer Management, 2019, 8, LMT12.	1.5	10
325	Targeting PKCÎ¹-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Communication and Signaling, 2019, 17, 137.	2.7	21
326	Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice. Expert Review of Respiratory Medicine, 2019, 13, 217-228.	1.0	9
327	Chemotherapeutic regimen influences the results of chemotherapy plus immunotherapy. Immunotherapy, 2019, 11, 1259-1261.	1.0	0
328	Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers, 2019, 11, 1619.	1.7	9
329	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 2006-2012.	0.8	52
330	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptorâ€tyrosine kinase inhibitors in patients with <scp>EGFR</scp>â€mutant nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3244-3254.	1.7	32
331	Systemic Therapy for Locally Advanced and Metastatic Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 764.	3.8	720
332	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. OncoImmunology, 2019, 8, e1655360.	2.1	76
333	Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study. International Journal of Hyperthermia, 2019, 36, 826-833.	1.1	21
334	Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. Journal of Clinical Oncology, 2019, 37, 2714-2718.	0.8	23
335	New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4136.	1.8	249
336	Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.		154

#	Article	IF	Citations
337	Pembrolizumab in lung cancer: current evidenceÂand future perspectives. Future Oncology, 2019, 15, 3327-3336.	1.1	4
338	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2019, 136, 45-51.	0.9	84
339	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Advances in Therapy, 2019, 36, 2600-2617.	1.3	80
341	Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report. Case Reports in Oncology, 2019, 12, 564-567.	0.3	2
342	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	5.7	160
343	Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization. Current Urology Reports, 2019, 20, 64.	1.0	21
344	Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of â‰¥1% by the USA Food and Drug Administration. Annals of Oncology, 2019, 30, 1686-1688.	0.6	20
345	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecologic Oncology, 2019, 155, 51-57.	0.6	14
346	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer, 2019, 136, 122-128.	0.9	38
347	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Experimental Hematology and Oncology, 2019, 8, 19.	2.0	30
348	First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. Journal of Thoracic Disease, 2019, 11, 2899-2912.	0.6	15
349	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. Cancers, 2019, 11, 1269.	1.7	25
350	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 2019, 11, 1271.	1.7	27
351	Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence. Journal of Visualized Experiments, 2019, , .	0.2	3
352	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987036.	1.4	45
353	Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Frontiers in Immunology, 2019, 10, 2254.	2.2	51
354	Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 2019, 10, 2250.	2.2	267
355	Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer, 2019, 136, 98-101.	0.9	31

#	Article	IF	Citations
356	Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1527-1535.	2.0	30
357	Evolution of treatment strategies for oligometastatic NSCLC patients â€“ A systematic review of the literature. Cancer Treatment Reviews, 2019, 80, 101892.	3.4	45
358	Neoadjuvant immunotherapy in patients with resectable nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1471-1474.	0.4	17
359	Chemoimmunotherapy for stage IV non-small-cell lung cancer. Lancet Oncology, The, 2019, 20, e466.	5.1	5
361	Metadherin enhances vulnerability of cancer cells to ferroptosis. Cell Death and Disease, 2019, 10, 682.	2.7	44
362	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted Oncology, 2019, 14, 505-525.	1.7	40
363	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986976.	1.4	31
364	New options for combination therapy for advanced non-squamous NSCLC. Expert Review of Respiratory Medicine, 2019, 13, 1095-1107.	1.0	15
365	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitorâ€“related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e31-e43.	2.5	97
366	Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy. Anticancer Research, 2019, 39, 4987-4993.	0.5	38
367	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer, 2019, 137, 108-112.	0.9	10
368	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. OncoImmunology, 2019, 8, e1657375.	2.1	56
369	Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients . Cancer Management and Research, 2019, Volume 11, 8201-8207.	0.9	34
370	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, 546-549.	1.3	3
371	A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors . Lung Cancer: Targets and Therapy, 2019, Volume 10, 95-105.	1.3	3
372	Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer in the United States. JAMA Network Open, 2019, 2, e1911952.	2.8	47
373	Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain. New England Journal of Medicine, 2019, 381, 1268-1277.	13.9	10
374	A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy . Cancer Management and Research, 2019, Volume 11, 7135-7140.	0.9	5

#	Article	IF	Citations
375	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Frontiers in Oncology, 2019, 9, 953.	1.3	97
376	Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. OncoImmunology, 2019, 8, e1665974.	2.1	14
377	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Translational Lung Cancer Research, 2019, 8, 450-460.	1.3	18
378	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Translational Lung Cancer Research, 2019, 8, 413-428.	1.3	95
379	Nivolumab plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2019, 381, 2020-2031.	13.9	1,866
380	Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers. Future Oncology, 2019, 15, 3097-3101.	1.1	1
381	Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression. Journal of Thoracic Oncology, 2019, 14, e231-e233.	0.5	2
382	Hyperprogressive disease with immunotherapy: new directions. Journal of Thoracic Disease, 2019, 11, S1877-S1880.	0.6	6
383	Pathologic response after modern radiotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S124-S134.	1.3	9
384	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resistance Updates, 2019, 46, 100644.	6.5	133
385	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology, 2019, 93, e1093-e1103.	1.5	107
386	The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Critical Reviews in Oncology/Hematology, 2019, 143, 148-152.	2.0	60
387	Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Lung Cancer, 2019, 137, 56-63.	0.9	43
388	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. Seminars in Oncology Nursing, 2019, 35, 150926.	0.7	7
389	Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer . OncoTargets and Therapy, 2019, Volume 12, 8151-8159.	1.0	11
390	Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC . OncoTargets and Therapy, 2019, Volume 12, 7329-7336.	1.0	19
391	Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2019, 31, 24-28.	1.1	17
392	First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis. Immunotherapy, 2019, 11, 311-320.	1.0	8

#	Article	IF	Citations
393	Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiation Oncology, 2019, 14, 18.	1.2	41
394	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Medical Sciences (Basel, Switzerland), 2019, 7, 14.	1.3	33
395	Immunotherapy for LELC: Case Report and a Focused Review. Clinical Lung Cancer, 2019, 20, e393-e401.	1.1	15
396	Immune Checkpoint Inhibitors in Realâ€World Treatment of Older Adults with Nonâ€“Small Cell Lung Cancer. Journal of the American Geriatrics Society, 2019, 67, 905-912.	1.3	78
397	Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood, 2019, 133, 1607-1610.	0.6	23
398	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Research, 2019, 12, 855-861.	5.8	39
399	Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncology, The, 2019, 20, e92-e102.	5.1	68
400	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia, 2019, 33, 844-862.	3.3	131
401	Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis. Immunotherapy, 2019, 11, 189-199.	1.0	57
402	Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?. Immunotherapy, 2019, 11, 161-166.	1.0	5
403	Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. Immunotherapy, 2019, 11, 149-153.	1.0	8
404	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro-Oncology, 2019, 21, 730-741.	0.6	63
405	Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. Clinical Medicine Insights: Oncology, 2019, 13, 117955491882131.	0.6	7
406	Efficacy and safety of nivolumab for metastatic biliary tract cancer . OncoTargets and Therapy, 2019, Volume 12, 861-867.	1.0	31
407	The innate immune architecture of lung tumors and its implication in disease progression. Journal of Pathology, 2019, 247, 589-605.	2.1	32
408	Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. Lung Cancer, 2019, 129, 75-79.	0.9	113
410	Marked responses to pemetrexed chemotherapy for metastatic adenocarcinoma of the parotid gland: Case series. Head and Neck, 2019, 41, E99-E103.	0.9	1
411	Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is â€˜promotedâ€™!. Annals of Oncology, 2019, 30, 165-167.	0.6	5

#	Article	IF	Citations
412	Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy, 2019, 11, 407-428.	1.0	53
413	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. Archivos De Bronconeumologia, 2019, 55, 124-125.	0.4	3
414	Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data . Cancer Management and Research, 2019, Volume 11, 4297-4312.	0.9	47
415	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 2019, 30, 1321-1328.	0.6	842
416	Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO Precision Oncology, 2019, 3, 1-8.	1.5	73
418	Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis . Cancer Management and Research, 2019, Volume 11, 3957-3969.	0.9	5
419	Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression. Acta Pharmaceutica Sinica B, 2019, 9, 937-951.	5.7	19
420	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20
421	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 116, 182-189.	1.3	36
422	Immune Checkpoint Inhibitor Outcomes for Patients With Nonâ€“Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. Journal of Clinical Oncology, 2019, 37, 1927-1934.	0.8	220
423	Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research, 2019, 178, 3-43.	0.2	16
425	Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. BioMed Research International, 2019, 2019, 1-13.	0.9	21
426	Advances in cancer immunotherapy 2019 â€“ latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	3.5	401
427	Prospects for a personalized peptide vaccine against lung cancer. Expert Review of Vaccines, 2019, 18, 703-709.	2.0	9
428	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. Annals of Oncology, 2019, 30, 1448-1459.	0.6	146
429	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer, 2019, 134, 167-173.	0.9	9
430	Testing monotherapy and combination therapy in one trial with biomarker consideration. Contemporary Clinical Trials, 2019, 82, 53-59.	0.8	1
431	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	2.0	38

#	Article	IF	Citations
432	Diagnostic value of ProGRP for small cell lung cancer in different stages. Journal of Thoracic Disease, 2019, 11, 1182-1189.	0.6	20
433	First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer, 2019, 134, 245-253.	0.9	35
434	Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Annals of Oncology, 2019, 30, 1479-1486.	0.6	336
435	Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic nonâ€“small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer, 2019, 134, 174-179.	0.9	92
436	Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature, 2019, 571, 570-575.	13.7	227
437	Neutrophilâ€“lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB) . OncoTargets and Therapy, 2019, Volume 12, 4235-4244.	1.0	53
438	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemotherapy and Pharmacology, 2019, 84, 227-240.	1.1	50
439	When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology, 2019, 20, 60.	1.3	30
440	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancerâ€”A Phase 1 Study. JAMA Oncology, 2019, 5, 1332.	3.4	153
441	Advanced-Stage Nonâ€“Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1134-1155.	0.5	61
442	In Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence. ACS Nano, 2019, 13, 7442-7462.	7.3	104
443	PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients. Cancer Genetics, 2019, 237, 10-18.	0.2	11
444	Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine, 2019, 179, 906.	2.6	189
445	Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 661-674.	1.9	333
446	MicroRNAs aid the assessment of programmed death ligandï¿½1 expression in patients with nonâ€‘small cell lung cancer. Oncology Letters, 2019, 17, 5193-5200.	0.8	14
447	Current status of immune checkpoint inhibition in early-stage NSCLC. Annals of Oncology, 2019, 30, 1244-1253.	0.6	98
448	Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Archives of Pharmacal Research, 2019, 42, 560-566.	2.7	29
449	Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date . Cancer Management and Research, 2019, Volume 11, 4893-4904.	0.9	10

#	Article	IF	Citations
450	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. Journal of Clinical Medicine, 2019, 8, 762.	1.0	53
451	A year at the forefront of general thoracic surgery. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 248-251.	0.4	0
452	Five-Year Overall Survival for Patients With Advanced Nonâ€'Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 2019, 37, 2518-2527.	0.8	811
453	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. Journal of Clinical Oncology, 2019, 37, 2511-2513.	0.8	22
454	Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. Oncotarget, 2019, 10, 3294-3301.	0.8	13
455	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1897-1905.	1.2	4
456	Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced nonâ€ssmall cell lung cancer. Cancer Medicine, 2019, 8, 4023-4031.	1.3	44
457	SYNTHÃˆSE NÂ° 2. Revue Des Maladies Respiratoires Actualites, 2019, 11, 47-54.	0.0	0
458	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. PLoS ONE, 2019, 14, e0217991.	1.1	5
459	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer, 2019, 134, 127-140.	0.9	156
460	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opinion on Investigational Drugs, 2019, 28, 513-523.	1.9	21
461	Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer. Chest, 2019, 156, 383-391.	0.4	84
462	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 561-568.	1.1	58
463	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	0.9	2
464	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine, 2019, 6, 119.	1.2	145
465	Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer, 2019, 135, 104-109.	0.9	5
466	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e126-e140.	1.8	28
467	The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. British Journal of Radiology, 2019, 92, 20181031.	1.0	20

#	Article	IF	Citations
468	Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 195-197.	1.3	2
469	Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters, 2019, 458, 123-135.	3.2	40
470	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	3.1	115
471	Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, 2019, 15, 2287-2302.	1.1	42
472	ESMO 2018â€"personal highlights. Memo - Magazine of European Medical Oncology, 2019, 12, 67-70.	0.3	0
473	Advanced Nonâ€"Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e187-e197.	1.8	33
474	A Career in Lung Cancer: Pushing Beyond Chemotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 583-589.	1.8	4
475	The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer. Lancet Oncology, The, 2019, 20, 889-891.	5.1	5
476	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	5.1	1,133
477	Commentary: Cautious optimism for induction immunotherapy in resectable lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 277-278.	0.4	1
478	Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 772-781.	3.0	144
479	Value-Added Decisions in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 122-131.	1.8	5
480	Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. Journal of Translational Medicine, 2019, 17, 137.	1.8	13
481	Nuevos retos en las nefritis tubulointersticiales inducidas por fÃ¡rmacos. Nefrologia, 2019, 39, 339-342.	0.2	4
482	Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Nonâ€"Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1066.	3.4	0
483	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	0.5	79
484	Immune-Related Adverse Events and Outcomes in Patients with Advanced Nonâ€"Small Cell Lung Cancer: A Predictive Marker of Efficacy?. Journal of Thoracic Oncology, 2019, 14, 963-967.	0.5	16
485	Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Management, 2019, 8, LMT11.	1.5	58

#	Article	IF	Citations
486	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Nonâ€“small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. Clinical Lung Cancer, 2019, 20, 331-338.e4.	1.1	47
487	AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. Future Oncology, 2019, 15, 1963-1973.	1.1	25
488	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	0.9	2
489	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1â€“Expressing NSCLC. Journal of Thoracic Oncology, 2019, 14, 793-801.	0.5	50
490	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 762-765.	0.6	43
491	Patients Selection for Immunotherapy in Solid Tumors: Overcome the NaÃ¯ve Vision of a Single Biomarker. BioMed Research International, 2019, 2019, 1-15.	0.9	37
492	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
493	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 2483-2491.	0.5	3
494	PDâ€(L)1 inhibitors vs. chemotherapy vs. their combination in frontâ€line treatment for NSCLC: An indirect comparison. International Journal of Cancer, 2019, 145, 3011-3021.	2.3	15
495	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. Journal of Thoracic Disease, 2019, 11, S347-S351.	0.6	6
496	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 999.	2.2	47
497	A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 351-358.	1.1	8
498	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 138, 178-189.	2.0	31
499	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	1.7	45
500	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Frontiers in Oncology, 2019, 9, 264.	1.3	87
501	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1915.	1.8	61
502	Modeling Cancer with Flies and Fish. Developmental Cell, 2019, 49, 317-324.	3.1	68
503	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 1033-e617.	1.9	3

#	Article	IF	Citations
504	First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. , 2019, 7, 120.		61
505	Landmark Trials in Oncology. , 2019, , .		0
506	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International Journal of Clinical Oncology, 2019, 24, 731-770.	1.0	100
507	Combination immunotherapy: the emerging treatment that removes cancerâ€™s â€œcloak of invisibilityâ€• BMJ: British Medical Journal, 2019, 365, l1824.	2.4	1
508	Expanding Therapeutic Options for Older Adults: Caseâ€Based Updates in Breast and Lung Cancer. Journal of the American Geriatrics Society, 2019, 67, 1012-1019.	1.3	2
509	Immunotherapy in Nonâ€“Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. Journal of Clinical Oncology, 2019, 37, 1863-1867.	0.8	76
510	Beyond DNA repair: the novel immunological potential of PARP inhibitors. Molecular and Cellular Oncology, 2019, 6, 1-4.	0.3	18
511	Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer. Clinical Therapeutics, 2019, 41, 982-991.	1.1	1
512	Cancer nanomedicine for combination cancer immunotherapy. Nature Reviews Materials, 2019, 4, 398-414.	23.3	658
513	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
514	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144.	1.9	52
515	Emerging therapies for non-small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 45.	6.9	111
516	KEYNOTE-024: goodbye to chemotherapy?. Journal of Thoracic Disease, 2019, 11, S428-S432.	0.6	3
517	A Bicistronic Adenoviral Vector Carrying Cytosine Deaminase and Granulocyte-Macrophage Colony-Stimulating Factor Increases the Therapeutic Efficacy of Cancer Gene Therapy. Human Gene Therapy, 2019, 30, 999-1007.	1.4	8
518	Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology, 2019, 30, 998-1004.	0.6	361
519	Immunotherapy in Nonâ€“Small Cell Lung Cancer. Which Patients and at Which Stage?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1277-1279.	2.5	8
520	Redefining Treatment Paradigms in First-line Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4881-4887.	3.2	10
521	PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cellâ€“inflamed phenotype. Blood, 2019, 133, 2279-2290.	0.6	87

#	Article	IF	Citations
522	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2019, 14, 1095-1101.	0.5	159
523	Electromagnetic Navigation Placement of Intratumoral Gold Fiducials for Stereotactic Radiation Therapy in Lung Cancer. Archivos De Bronconeumologia, 2019, 55, 169-171.	0.4	0
524	Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. Oncology Letters, 2019, 17, 4011-4015.	0.8	8
525	Hyperprogressionâ€"Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncology, 2019, 5, 743.	3.4	7
526	First-Line Therapy for Wild-Type Patients. , 2019, , 87-102.		1
527	Epidermal Growth Factor Receptorâ€"Mutant Nonâ€"Small-Cell Lung Cancer. , 2019, , 115-131.		0
528	Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Nonâ€"Small Cell Lung Cancer (NSCLC). , 2019, , 133-142.		0
529	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	0.5	9
530	Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer, 2019, 130, 179-186.	0.9	31
531	Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology, 2019, 30, 839-844.	0.6	256
532	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. Anticancer Research, 2019, 39, 1463-1468.	0.5	5
533	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	1.7	51
534	Commentary: Postoperative blood transplantation for nonâ€"small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 2480-2481.	0.4	1
535	Immunotherapy in Nonâ€"Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602.	3.2	447
536	Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist, 2019, 24, S21-S30.	1.9	22
537	A new standard of care for patients with surgically unresectable stage III nonâ€small cell lung cancer. Cancer, 2019, 125, 2148-2153.	2.0	1
538	Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Medical Oncology, 2019, 36, 33.	1.2	66
539	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneÂCheckpoint Inhibitors. BioDrugs, 2019, 33, 159-171.	2.2	40

#	Article	IF	Citations
540	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist, 2019, 24, S31-S41.	1.9	239
541	Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. Archivos De Bronconeumologia, 2019, 55, 124-125.	0.4	1
542	ExÂVivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, e299-e308.	1.1	2
543	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896.	0.6	78
544	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterology, 2019, 10, 364-371.	0.9	65
545	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics, 2019, 13, 1-6.	2.0	26
546	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute, 2019, 111, 655-663.	3.0	56
547	Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries. Neuro-Oncology Practice, 2019, 6, 402-409.	1.0	43
548	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine, 2019, 41, 711-716.	2.7	142
550	Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials . Cancer Management and Research, 2019, Volume 11, 1623-1629.	0.9	19
551	Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. Immunotherapy, 2019, 11, 457-460.	1.0	5
552	Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opinion on Biological Therapy, 2019, 19, 423-432.	1.4	53
553	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine, 2019, 13, 435-447.	1.0	7
554	Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Immunotherapy, 2019, 11, 543-554.	1.0	11
555	Recent clinical trials of immunotherapy in non-small-cell lung cancer. Immunotherapy, 2019, 11, 461-466.	1.0	5
556	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, Immunotherapy, 2019, 68, 917-926.	2.0	59
557	RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy. Trends in Cancer, 2019, 5, 149-156.	3.8	34
558	Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2019, 37, 529-536.	0.8	8

#	Article	IF	Citations
559	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2019, 37, 834-849.	0.8	66
560	Using clinical genomic sequencing to guide personalized cancer therapy in China. Personalized Medicine, 2019, 16, 287-299.	0.8	2
561	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. Advances in Therapy, 2019, 36, 1497-1508.	1.3	4
562	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology, 2019, 138, 87-103.	2.0	16
563	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer, 2019, 132, 72-78.	0.9	54
564	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. Oncologist, 2019, 24, 1270-1284.	1.9	21
565	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1104-1113.	0.6	205
566	Management of Metastatic Nasopharyngeal Carcinoma. , 2019, , 313-335.		1
567	Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Letters, 2019, 454, 191-203.	3.2	60
568	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
569	Ferrocene-containing amphiphilic polynorbornenes as biocompatible drug carriers. Polymer Chemistry, 2019, 10, 2527-2539.	1.9	30
570	Are we ready to describe response or progression to immunotherapy in lung cancer?. Critical Reviews in Oncology/Hematology, 2019, 138, 112-119.	2.0	10
571	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. Journal of Translational Medicine, 2019, 17, 99.	1.8	52
572	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 195.	1.3	48
573	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 387-401.	5.2	704
574	Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations. Lancet Respiratory Medicine,the, 2019, 7, 366-367.	5.2	5
575	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treatment Reviews, 2019, 75, 39-51.	3.4	124
576	Outcome of Patients with Nonâ€“Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Journal of Thoracic Oncology, 2019, 14, 1244-1254.	0.5	178

#	Article	IF	Citations
577	Metabolic enzymes expressed by cancer cells impact the immune infiltrate. OncoImmunology, 2019, 8, e1571389.	2.1	15
578	Association between depth of response and survival in patients with advancedâ€stage nonâ€“small cell lung cancer treated with firstâ€line chemotherapy. Cancer, 2019, 125, 2394-2399.	2.0	8
579	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	5.8	189
580	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	6.3	2,347
581	Pembrolizumab for all PD-L1-positive NSCLC. Lancet, The, 2019, 393, 1776-1778.	6.3	21
582	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 2019, 37, 537-546.	0.8	1,144
583	Brain metastases: costs for care need to be spend more effectively!. Annals of Palliative Medicine, 2019, 8, 207-209.	0.5	0
584	Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea?. Medical Hypotheses, 2019, 127, 66-70.	0.8	5
585	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1158-1166.	0.8	17
586	Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice. Future Oncology, 2019, 15, 2915-2931.	1.1	30
587	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. Investigational New Drugs, 2019, 37, 531-537.	1.2	3
588	Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Frontiers of Medicine, 2019, 13, 12-23.	1.5	14
589	The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology, 2019, 21, 1060-1068.	0.6	76
590	BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. Journal of Thoracic Oncology, 2019, 14, e57-e59.	0.5	33
591	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 269-276.	0.4	218
592	Artificial intelligence in cancer imaging: Clinical challenges and applications. Ca-A Cancer Journal for Clinicians, 2019, 69, 127-157.	157.7	965
593	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunology, Immunotherapy, 2019, 68, 341-352.	2.0	82
594	Comparative efficacy and safety of firstâ€line treatments for advanced nonâ€small cell lung cancer with immune checkpoint inhibitors: A systematic review and metaâ€analysis. Thoracic Cancer, 2019, 10, 607-623.	0.8	22

#	Article	IF	Citations
595	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology, 2019, 10, 193.	2.2	105
596	Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. Clinical Neurology and Neurosurgery, 2019, 179, 14-18.	0.6	32
597	Nivolumab-refractory patients with advanced non-small-cell lung cancer. Lung Cancer, 2019, 130, 128-134.	0.9	16
598	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clinical and Translational Oncology, 2019, 21, 1270-1279.	1.2	38
599	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. Clinical Drug Investigation, 2019, 39, 341-353.	1.1	28
600	A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). European Journal of Cancer, 2019, 109, 183-191.	1.3	13
601	Turning the corner on therapeutic cancer vaccines. Npj Vaccines, 2019, 4, 7.	2.9	490
602	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150.	12.8	1,657
603	Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Nonâ€“Small Cell Lung Cancer Treated with Pembrolizumab. Journal of Thoracic Oncology, 2019, 14, e55-e57.	0.5	19
604	Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?. Journal of Thoracic Oncology, 2019, 14, 332-335.	0.5	7
605	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. Clinical Cancer Research, 2019, 25, 4211-4223.	3.2	85
606	Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab. Archivos De Bronconeumologia, 2019, 55, 168-169.	0.4	1
607	Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. Pathology, 2019, 51, 240-245.	0.3	25
608	Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. , 2019, , 151-171.		0
609	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patientsâ€™ treatment. Journal of Thoracic Disease, 2019, 11, 35-38.	0.6	28
610	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. Journal of Thoracic Disease, 2019, 11, S25-S36.	0.6	51
611	Lung cancer stigma and depression: Validation of the Lung Cancer Stigma Inventory. Psycho-Oncology, 2019, 28, 1011-1017.	1.0	30
612	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Frontiers in Oncology, 2019, 9, 51.	1.3	117

#	Article	IF	Citations
613	From clinical trials to real-world practice: Immune checkpoint inhibitors in older adults. Journal of Geriatric Oncology, 2019, 10, 384-388.	0.5	9
614	Immunotherapy in extensive small cell lung cancer. Experimental Hematology and Oncology, 2019, 8, 5.	2.0	32
615	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383.	1.1	10
616	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. Cancers, 2019, 11, 201.	1.7	49
617	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. Expert Opinion on Biological Therapy, 2019, 19, 457-467.	1.4	7
618	New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an â€œESMO Open â€“ Cancer Horizonsâ€•Series. ESMO Open, 2019, 4, e000501.	2.0	6
620	Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies. Translational Cancer Research, 2019, 8, E18-E23.	0.4	0
621	Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?. Translational Cancer Research, 2019, 8, S618-S620.	0.4	6
622	Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. Clinical Cancer Research, 2019, 25, 6890-6892.	3.2	0
623	A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group. Journal of Thoracic Disease, 2019, 11, 5635-5642.	0.6	0
624	Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?. Translational Lung Cancer Research, 2019, 8, S327-S330.	1.3	3
625	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, S323-S326.	1.3	6
626	Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis. Annals of Translational Medicine, 2019, 7, S320-S320.	0.7	0
627	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. Translational Cancer Research, 2019, 8, S585-S588.	0.4	1
628	Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. Translational Cancer Research, 2019, 8, S612-S617.	0.4	10
629	Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Translational Lung Cancer Research, 2019, 8, 1078-1085.	1.3	34
630	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist, 2019, 24, 1128-1136.	1.9	156
631	Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis . Cancer Management and Research, 2019, Volume 11, 10767-10775.	0.9	5

#	Article	IF	Citations
632	Traitements de premiÃ¨re ligne dans les CBNPC avancÃ©s, en lâ€™absence dâ€™addiction oncogÃ©nique (incluant) Tj ETQq0 0 0 rgBT 2019, 11, 342-354.	0.0	0
633	Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 920-928.	1.3	1
634	Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer. Translational Cancer Research, 2019, 8, E11-E14.	0.4	0
635	Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. Journal of Immunotherapy, 2019, 42, 215-220.	1.2	47
636	Cutaneous Toxicity After Chemoradiotherapy and PDâ€Ł1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye. Oncologist, 2019, 24, e149-e153.	1.9	5
637	Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open, 2019, 9, e031019.	0.8	16
638	Latest Immunotherapy Methods in Non-small Cell Lung Cancer Treatment. Juntendo Medical Journal, 2019, 65, 444-450.	0.1	1
639	Identification of anticancer peptides based on Random Relevance Vector Machines. , 2019, , .		0
640	Fine-tuning immunotherapy in MMR-D/MSI-H colorectal cancer. Colorectal Cancer, 2019, 8, CRC12.	0.8	1
641	EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 2019, 7, S326-S326.	0.7	0
642	Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: whatâ€™s known and whatâ€™s next. Translational Lung Cancer Research, 2019, 8, S447-S450.	1.3	12
643	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. Precision Cancer Medicine, 2019, 2, 35-35.	1.8	3
644	Intractable Colitis After the Administration of Pembrolizumab That Is Resistant to Anti-TNF-alpha Antibody. Japanese Journal of Lung Cancer, 2019, 59, 395-400.	0.0	1
645	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
646	Effect of platinumâ€‘based chemotherapy on the expression of natural killer groupï¿½2 memberï¿½D ligands, programmed cell deathâ€‘1 ligandï¿½1 and HLA classï¿½I in nonâ€‘small cell lung cancer. Oncology Reports, 2019, 42, 839-848.	1.2	10
647	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. Translational Lung Cancer Research, 2019, 8, S403-S406.	1.3	2
648	First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancerâ€¦finally what threshold of PD-L1 expression on tumor cells?. Translational Lung Cancer Research, 2019, 8, 728-730.	1.3	3
649	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. Medicina (Lithuania), 2019, 55, 743.	0.8	1

#	Article	IF	Citations
650	Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage Iâ€“III Non-small Cell Lung Cancer Patients. Frontiers in Oncology, 2019, 9, 1139.	1.3	28
651	Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomedical Journal, 2019, 42, 299-306.	1.4	62
652	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. Translational Lung Cancer Research, 2019, 8, 723-727.	1.3	4
653	Costâ€“effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in theÂUSA. Immunotherapy, 2019, 11, 1463-1478.	1.0	43
654	Low-dose Computed Tomography Screening: The (Other) Lung Cancer Revolution. Clinical Oncology, 2019, 31, 697-701.	0.6	3
655	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
656	Immune Checkpoint Inhibitorâ€“Related Cardiovascular Toxicity in Lung Cancer. JACC: CardioOncology, 2019, 1, 193-195.	1.7	1
657	Cancer du poumon. Revue Des Maladies Respiratoires Actualites, 2019, 11, S29-S35.	0.0	0
659	ImmunothÃ©rapie pratique, pratique de lâ€™immunothÃ©rapie: de la prise en charge initiale au suivi. Revue Des Maladies Respiratoires Actualites, 2019, 11, S502-S507.	0.0	0
660	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. Medicine (United States), 2019, 98, e18310.	0.4	2
661	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
662	Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. Clinical Cancer Research, 2019, 25, 7243-7255.	3.2	57
663	Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1256.	1.3	10
664	Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies. Frontiers in Oncology, 2019, 9, 1432.	1.3	27
665	Pembrolizumab microgravity crystallization experimentation. Npj Microgravity, 2019, 5, 28.	1.9	19
666	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6623-6632.	3.2	96
667	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102
668	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Cancer, 2019, 10, 6261-6268.	1.2	22

#	Article	IF	Citations
669	Durvalumab for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 1009-1016.	1.1	20
670	Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?. Drugs, 2019, 79, 1937-1945.	4.9	4
672	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591988554.	1.4	25
673	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. Respiratory Research, 2019, 20, 263.	1.4	5
674	Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?. Translational Lung Cancer Research, 2019, 8, 715-722.	1.3	5
675	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation, 2019, 2019, 1-10.	1.4	39
676	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	1.4	28
677	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	2.6	26
678	Promising Immuno-Oncology Treatments Beyond the 2018 Nobel Prize. Acta Medica Portuguesa, 2019, 32, 251.	0.2	2
679	Treatment of oncogene-driven non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, 25, 300-307.	1.2	7
680	Dietetic assessment and intervention in lung cancer. Current Opinion in Supportive and Palliative Care, 2019, 13, 311-315.	0.5	3
681	Linear IgA Disease of the Gingiva Following Nivolumab Therapy. Journal of Immunotherapy, 2019, 42, 345-347.	1.2	6
682	Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 711-716.	0.6	2
683	Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Nonâ€“Small Cell Lung Cancer Based on Mutational Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 837-844.	0.6	4
684	The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients. Medicine (United States), 2019, 98, e16439.	0.4	1
685	Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis. Medicine (United States), 2019, 98, e16834.	0.4	4
686	Biomarker for personalized immunotherapy. Translational Lung Cancer Research, 2019, 8, S308-S317.	1.3	7
687	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 921-930.	1.0	8

#	Article	IF	Citations
689	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. European Respiratory Review, 2019, 28, 190058.	3.0	73
690	Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors. Current Opinion in Oncology, 2019, 31, 439-444.	1.1	3
691	The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?. Translational Lung Cancer Research, 2019, 8, 731-737.	1.3	1
692	Perioperative systemic therapy for bladder cancer. Current Opinion in Urology, 2019, 29, 220-226.	0.9	4
693	Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Review of Anticancer Therapy, 2019, 19, 1061-1075.	1.1	7
694	Maintenance Therapy in Metastatic Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 615-623.	0.6	4
695	Management of Brain Metastases in Nonâ€“Small-Cell Lung Cancer. Journal of Oncology Practice, 2019, 15, 563-570.	2.5	91
696	Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 6851-6857.	0.5	24
697	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research, 2019, 39, 6887-6893.	0.5	27
698	Setting the scene â€“ a future â€˜epidemicâ€™ of immune-related adverse events in association with checkpoint inhibitor therapy. Rheumatology, 2019, 58, vii1-vii6.	0.9	3
699	Management of rheumatic complications of immune checkpoint inhibitor therapy â€“ an oncological perspective. Rheumatology, 2019, 58, vii29-vii39.	0.9	22
701	Approach to stage IV non-small-cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, Publish Ahead of Print, 311-320.	1.2	1
702	Tumor Mutational Burden Is Site Specific in Nonâ€“Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. JCO Precision Oncology, 2019, 3, 1-13.	1.5	13
703	Pulmonary function is implicated in the prognosis of metastatic non-small cell lung cancer but not in extended disease small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 4562-4572.	0.6	12
704	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist, 2019, 24, 735-742.	1.9	43
705	Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. Translational Lung Cancer Research, 2019, 8, 1091-1106.	1.3	27
706	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	1.0	5
707	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy forÂAdvanced Nonsquamous Nonâ€“Small Cell LungÂCancer. Journal of Thoracic Oncology, 2019, 14, 124-129.	0.5	187

#	Article	IF	Citations
708	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0
709	Impact of cytotoxic chemotherapy on PD-L1 expression in patients with nonâ€“small cell lung cancer negative for EGFR mutation and ALK fusion. Lung Cancer, 2019, 127, 59-65.	0.9	36
710	Dynamics of blood neutrophilâ€related indices during nivolumab treatment may be associated with response to salvage chemotherapy for nonâ€small cell lung cancer: A hypothesisâ€generating study. Thoracic Cancer, 2019, 10, 341-346.	0.8	25
711	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced nonâ€“small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer, 2019, 130, 59-66.	0.9	65
712	Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency. Cancer, 2019, 125, 337-339.	2.0	0
713	Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 143-147.	1.1	24
714	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. JAMA Oncology, 2019, 5, 529.	3.4	192
715	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 304-310.	0.5	10
716	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Journal of Thoracic Oncology, 2019, 14, 494-502.	0.5	114
717	Desperately seekingâ€¦Models to find the right partner and the best use for checkpoint inhibitors. British Journal of Cancer, 2019, 120, 139-140.	2.9	2
718	Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer. Clinical Lung Cancer, 2019, 20, 63-65.	1.1	4
719	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	1.8	78
720	Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2019, 111, 719-726.	3.0	82
721	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCOâ€“ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30, 171-210.	0.6	214
722	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
723	A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy. Journal of Thoracic Oncology, 2019, 14, 8-10.	0.5	10
724	Cancer Immunotherapy: Beyond Checkpoint Blockade. Annual Review of Cancer Biology, 2019, 3, 55-75.	2.3	102
725	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clinical and Translational Oncology, 2019, 21, 3-17.	1.2	110

#	Article	IF	Citations
726	Neural regulation of drug resistance in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 20-28.	3.3	8
727	Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer. Cancer Gene Therapy, 2019, 26, 157-165.	2.2	9
728	Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. Current Medical Research and Opinion, 2019, 35, 817-827.	0.9	12
729	Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. European Journal of Cardio-thoracic Surgery, 2019, 55, 691-698.	0.6	12
730	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	0.6	33
731	Evaluation of objective response, disease controlÂand progression-free survival as surrogate end-points for overall survival in antiâ€“programmed death-1 and antiâ€“programmed death ligand 1 trials. European Journal of Cancer, 2019, 106, 1-11.	1.3	37
732	Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opinion on Pharmacotherapy, 2019, 20, 95-102.	0.9	52
733	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 135-140.	0.5	88
734	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clinical Cancer Research, 2019, 25, 2166-2173.	3.2	67
735	Immunotherapy for the First-Line Treatment of Patients with Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2691-2698.	3.2	78
736	Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Current Medical Research and Opinion, 2019, 35, 1241-1256.	0.9	65
737	Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology, 2019, 30, 219-235.	0.6	340
738	A Phase II Study of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clinical Lung Cancer, 2019, 20, 139-141.	1.1	5
739	Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clinical Lung Cancer, 2019, 20, 148-160.e2.	1.1	27
740	Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. Lung Cancer, 2019, 128, 26-32.	0.9	24
741	Complete response of metastatic melanoma in a patient with Crohnâ€™s disease simultaneously receiving anti-Î±4Î²7 and anti-PD1 antibodies. , 2019, 7, 1.		143
742	Determination of human Î³Î´ T cellâ€“mediated cytotoxicity using a non-radioactive assay system. Journal of Immunological Methods, 2019, 466, 32-40.	0.6	4
743	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opinion on Biological Therapy, 2019, 19, 225-232.	1.4	22

#	Article	IF	Citations
744	Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era. Cancer, 2019, 125, 496-498.	2.0	3
745	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417.	1.1	27
746	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research, 2019, 25, 2144-2154.	3.2	134
747	Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Cancers, 2019, 11, 39.	1.7	84
748	Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death and Differentiation, 2019, 26, 115-129.	5.0	74
749	Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. International Journal of Cancer, 2019, 144, 1061-1072.	2.3	22
750	PD-1 Blockade in Early-Stage Lung Cancer. Annual Review of Medicine, 2019, 70, 425-435.	5.0	29
751	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Modern Pathology, 2019, 32, 511-523.	2.9	33
752	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Seminars in Immunopathology, 2019, 41, 21-30.	2.8	49
753	Computerâ€aided drug design in new druggable targets for the next generation of immuneâ€oncology therapies. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1397.	6.2	6
754	Animal model of local tumor recurrence after resection using the murine MBT2 bladder cancer cell line in syngeneic C3H mice. International Journal of Urology, 2019, 26, 300-302.	0.5	2
755	The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 2019, 19, 9-31.	12.8	692
756	A banner year for immunotherapy and targeted therapy. Nature Reviews Clinical Oncology, 2019, 16, 79-80.	12.5	24
757	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. Expert Opinion on Pharmacotherapy, 2019, 20, 357-366.	0.9	9
758	Câ€reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. Cancer, 2019, 125, 779-787.	2.0	19
759	Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. Current Opinion in Oncology, 2019, 31, 8-12.	1.1	7
760	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Nonâ€“Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncology, 2019, 5, 358.	3.4	48
761	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven nonâ€“small cell lung cancer. Cancer, 2019, 125, 1038-1049.	2.0	66

#	Article	IF	Citations
762	Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167.	12.5	1,093
763	To the edge of cell death and back. FEBS Journal, 2019, 286, 430-440.	2.2	67
764	Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624.	23.0	237
765	Treatment of older patients with advanced non-small cell lung cancer: A challenge. Journal of Geriatric Oncology, 2019, 10, 528-533.	0.5	13
766	Multidisciplinary treatment of lung cancer in older patients: A review. Journal of Geriatric Oncology, 2019, 10, 405-410.	0.5	17
767	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	3.3	83
768	Adjuvant Therapy in Patients With Completely Resected Nonâ€“small-cell Lung Cancer: Current Status and Perspectives. Clinical Lung Cancer, 2019, 20, 1-6.	1.1	36
769	Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. Briefings in Functional Genomics, 2019, 18, 147-156.	1.3	12
770	Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial. Future Oncology, 2019, 15, 81-94.	1.1	2
771	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 64-77.	1.9	30
772	The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 75-90.	12.5	260
773	Albuminâ€“globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 74-81.	1.0	25
774	CD44-Targeted Multifunctional Nanomedicines Based on a Single-Component Hyaluronic Acid Conjugate with All-Natural Precursors: Construction and Treatment of Metastatic Breast Tumors in Vivo. Biomacromolecules, 2020, 21, 104-113.	2.6	23
775	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 358-366.	0.7	9
776	Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in Cancer Biology, 2020, 61, 167-179.	4.3	302
777	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. International Journal of Clinical Oncology, 2020, 25, 818-830.	1.0	86
778	Commentary: Not only SMART clinically, but translationally!. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 2094-2095.	0.4	1
779	Novel genetic variants in KIF16B and NEDD4L in the endosomeâ€related genes are associated with nonsmall cell lung cancer survival. International Journal of Cancer, 2020, 147, 392-403.	2.3	6

#	Article	IF	Citations
780	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 184-193.	2.0	32
781	A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstÂline induction chemotherapy in extensiveÂ-stage small cell lung cancer. Investigational New Drugs, 2020, 38, 148-159.	1.2	22
782	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clinical and Translational Oncology, 2020, 22, 759-771.	1.2	11
783	The antibodyâ€based delivery of interleukinâ€12 to solid tumors boosts NK and CD8⁺ T cell activity and synergizes with immune checkpoint inhibitors. International Journal of Cancer, 2020, 146, 2518-2530.	2.3	39
784	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. Clinical Oncology, 2020, 32, e1-e9.	0.6	6
785	The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. Modern Pathology, 2020, 33, 109-117.	2.9	40
786	Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: A single-center experience study. Journal of Oncology Pharmacy Practice, 2020, 26, 612-618.	0.5	1
787	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 708-716.	1.2	6
788	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
789	Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. International Journal of Clinical Oncology, 2020, 25, 67-73.	1.0	6
790	Blood Predictive Biomarkers for Patients With Nonâ€“small-cell Lung Cancer Associated With Clinical Response to Nivolumab. Clinical Lung Cancer, 2020, 21, 75-85.	1.1	34
791	The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced nonâ€smallâ€cell lung cancer: A systematic review and metaâ€analysis. Journal of Cellular Physiology, 2020, 235, 4913-4927.	2.0	48
792	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 989-1003.	1.2	59
793	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. Internal Medicine, 2020, 59, 569-572.	0.3	8
794	Biomarkers for immune checkpoint inhibition in nonâ€“small cell lung cancer (NSCLC). Cancer, 2020, 126, 260-270.	2.0	202
795	First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative orâ€‰<â€‰1% PD-L1-expressing metastatic non-small-cell lung cancers. Journal of Cancer Research and Clinical Oncology, 2020, 146, 441-448.	1.2	8
796	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology, 2020, 38, 115-123.	0.8	327
797	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 274-281.	3.2	75

#	Article	IF	Citations
798	The Immunoscore: Colon Cancer and Beyond. Clinical Cancer Research, 2020, 26, 332-339.	3.2	255
799	Tumorâ€Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology, 2020, 71, 1626-1642.	3.6	20
800	Association of PDâ€Ł1 expression status with the efficacy of PDâ€1/PDâ€Ł1 inhibitors and overall survival in solid tumours: A systematic review and metaâ€analysis. International Journal of Cancer, 2020, 147, 116-127.	2.3	53
801	Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?. Oral Oncology, 2020, 101, 104435.	0.8	2
802	Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e15-e20.	1.1	5
803	Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers. In Vivo, 2020, 34, 389-392.	0.6	4
804	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. Cancers, 2020, 12, 79.	1.7	29
805	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data . Breast Cancer: Targets and Therapy, 2019, Volume 11, 321-328.	1.0	25
806	Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 1063-1074.	0.6	6
807	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. Immunological Medicine, 2020, 43, 10-15.	1.4	3
808	Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800.	1.0	120
809	Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Lung Cancer, 2020, 141, 21-31.	0.9	20
810	In Search of the Long-Desired â€˜Copernican Therapeutic Revolutionâ€™ in Small-Cell Lung Cancer. Drugs, 2020, 80, 241-262.	4.9	12
811	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Letters, 2020, 473, 148-155.	3.2	31
812	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged â‰¥â€‰75Âyears) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 457-466.	1.2	21
813	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: BriefÂReport. Clinical Lung Cancer, 2020, 21, e57-e60.	1.1	5
814	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	39
815	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203

#	Article	IF	Citations
816	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	4.3	9
817	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology, 2020, 6, 375.	3.4	215
818	Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer, 2020, 140, 99-106.	0.9	79
819	Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Current Opinion in Oncology, 2020, 32, 63-67.	1.1	52
820	Efficacy of immune checkpoint inhibitors according to PDâ€Ł1 tumor proportion scores in nonâ€śsmall cell lung cancer. Thoracic Cancer, 2020, 11, 408-414.	0.8	12
821	Twentyâ€five years of Respirology: Advances in lung cancer. Respirology, 2020, 25, 26-31.	1.3	2
822	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine and Pharmacotherapy, 2020, 121, 109625.	2.5	92
823	Precision Medicine in Lung Cancer Treatment. Surgical Oncology Clinics of North America, 2020, 29, 15-21.	0.6	23
824	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarraysâ€™ and cross-validation with resections, in patients with, stage Iâ€“III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Modern Pathology, 2020, 33, 792-801.	2.9	28
825	Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology, 2020, 15, 5.	1.2	28
826	Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Nonâ€“small-cell Lung Cancer: A Systematic Review and Meta-analysis. Clinical Lung Cancer, 2020, 21, 106-113.e5.	1.1	22
827	The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing Î²-catenin activity. Oncogene, 2020, 39, 2377-2390.	2.6	5
828	Frontline immunotherapy for NSCLC â€” the tale of the tail. Nature Reviews Clinical Oncology, 2020, 17, 73-74.	12.5	35
829	A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab. Respiratory Medicine Case Reports, 2020, 29, 100979.	0.2	4
830	Relationship Between Tumor Immune Markers and Fluorine-18-Î±-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer. Molecular Imaging and Biology, 2020, 22, 1078-1086.	1.3	7
831	Immune checkpoint blockade for nonâ€“small cell lung cancer: What is the role in the special populations?. European Journal of Cancer, 2020, 125, 1-11.	1.3	31
832	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncology, 2020, 16, 4359-4368.	1.1	61
833	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 137-147.	1.0	6

#	Article	IF	Citations
834	External quality assessment demonstrates that PDâ€Ł1 22C3 and SP263 assays are systematically different. Journal of Pathology: Clinical Research, 2020, 6, 138-145.	1.3	22
835	Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Review of Anti-Infective Therapy, 2020, 18, 5-15.	2.0	101
836	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic nonâ€śsmall cell lung cancer (NSCLC) compared with chemotherapy (Quijoteâ€ŒCLICaP). Thoracic Cancer, 2020, 11, 353-361.	0.8	36
837	The immunotherapeutic landscape in nonâ€“small cell lung cancer and its surgical horizons. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 1616-1623.	0.4	21
838	Oncogene addiction and tumor mutational burden in nonâ€śsmallâ€ścell lung cancer: Clinical significance and limitations. Thoracic Cancer, 2020, 11, 205-215.	0.8	22
839	Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1168-1182.	3.3	115
840	Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 115-121.	0.6	18
841	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	5.1	303
842	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. Journal of Clinical Pathology, 2020, 73, 423-430.	1.0	14
843	Acquired Resistance in Lung Cancer. Annual Review of Cancer Biology, 2020, 4, 279-297.	2.3	13
844	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. British Journal of Cancer, 2020, 122, 340-347.	2.9	24
845	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
846	The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. Clinical and Translational Oncology, 2020, 22, 1146-1154.	1.2	11
847	Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors. Cancer Chemotherapy and Pharmacology, 2020, 85, 121-131.	1.1	45
848	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer in Clinical Practice. Clinical Lung Cancer, 2020, 21, 255-263.e4.	1.1	28
849	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 249-256.	0.8	28
850	Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced nonâ€“small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Investigational New Drugs, 2020, 38, 211-218.	1.2	31
851	Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 271-280.	0.8	59

#	Article	IF	Citations
852	Nivolumab-Induced Guillain-BarrÃ© Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma. Clinical Lung Cancer, 2020, 21, e65-e73.	1.1	5
853	Impact of PDâ€L1 expression and human papillomavirus status in antiâ€PD1/PDL1 immunotherapy for head and neck squamous cell carcinomaâ€"Systematic review and metaâ€analysis. Head and Neck, 2020, 42, 774-786.	0.9	52
854	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	1.1	26
855	Tumor Board Report: The value of tissue diagnosis. Current Problems in Cancer, 2020, 44, 100530.	1.0	0
856	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€"Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	0.8	28
857	Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 193-202.	0.6	16
858	Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?. Aids, 2020, 34, 167-175.	1.0	25
859	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 67.	1.7	39
860	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 741-749.	1.2	21
861	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 365-372.	2.0	18
862	Peri-CAR T-Cell Management. , 2020, , 29-44.		1
863	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with â€œcurativeâ€•intent. Lung Cancer, 2020, 141, 1-8.	0.9	17
864	Roles of microbiota in response to cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 164-175.	4.3	36
865	Immune checkpoint blockade and biomarkers of clinical response in nonâ€"small cell lung cancer. Scandinavian Journal of Immunology, 2020, 92, e12980.	1.3	14
866	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
867	Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. , 2020, 8, e000889.		29
868	To Continue or Not to Continue? That Is the Question. Journal of Clinical Oncology, 2020, 38, 3830-3832.	0.8	2
869	Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. Immunotherapy, 2020, 12, 1195-1207.	1.0	2

#	Article	IF	Citations
870	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. International Journal of Molecular Sciences, 2020, 21, 7195.	1.8	55
871	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1196-1206.	1.5	9
872	Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy, 2020, 12, 1313-1324.	1.0	5
873	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2013770.	2.8	34
874	The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer. Lung Cancer, 2020, 150, 44-52.	0.9	5
875	Impact of genetic factors on platinum-induced gastrointestinal toxicity. Mutation Research - Reviews in Mutation Research, 2020, 786, 108324.	2.4	3
876	Genetic variants as predictors of toxicity and response in patients with nonâ€small cell lung cancer undergoing firstâ€line platinumâ€based chemotherapy: Design of the multicenter PGxLUNG study. Thoracic Cancer, 2020, 11, 3634-3640.	0.8	5
877	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell, 2020, 38, 788-802.	7.7	273
878	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy - Oncolytics, 2020, 18, 587-601.	2.0	38
879	MicroRNA â€200b is a potential biomarker of the expression of PDâ€L1 in patients with lung cancer. Thoracic Cancer, 2020, 11, 2975-2982.	0.8	12
880	Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer. Translational Lung Cancer Research, 2020, 9, 1599-1605.	1.3	0
881	First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus cl§a change. Translational Lung Cancer Research, 2020, 9, 1591-1594.	1.3	0
882	Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Scientific Reports, 2020, 10, 15567.	1.6	20
883	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Pharmacological Research, 2020, 160, 105194.	3.1	13
884	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. Translational Lung Cancer Research, 2020, 9, 1000-1014.	1.3	9
885	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. Drugs, 2020, 80, 1783-1797.	4.9	12
886	The PD-1/PD-L1-Checkpoint Restrains TÂcell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020, 38, 685-700.e8.	7.7	299
887	SOX2 and squamous cancers. Seminars in Cancer Biology, 2020, 67, 154-167.	4.3	16

#	Article	IF	Citations
888	Alternative splicing of HER2: a novel mediator of EGFR TKI resistance. Translational Lung Cancer Research, 2020, 9, 1606-1612.	1.3	1
889	FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer. Annals of Nuclear Medicine, 2020, 34, 968-974.	1.2	26
890	Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nature Communications, 2020, 11, 5228.	5.8	149
891	TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Scientific Reports, 2020, 10, 17284.	1.6	13
892	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. Chinese Medical Journal, 2020, 133, 2466-2475.	0.9	4
893	Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient. Thoracic Cancer, 2020, 11, 3605-3608.	0.8	6
894	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
895	Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer, 2020, 20, 1004.	1.1	16
896	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. Biomarkers in Medicine, 2020, 14, 1383-1392.	0.6	16
897	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
898	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. Chinese Medical Journal, 2020, 133, 2444-2455.	0.9	7
899	Efficacy and safety of combination PDâ€1/PDâ€L1 checkpoint inhibitors for malignant solid tumours: A systematic review. Journal of Cellular and Molecular Medicine, 2020, 24, 13494-13506.	1.6	4
900	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers, 2020, 12, 2983.	1.7	56
901	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. International Journal of Molecular Sciences, 2020, 21, 7621.	1.8	12
902	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. Cancer Science, 2020, 111, 3739-3746.	1.7	20
903	Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. , 2020, 8, e001358.		44
904	The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature. Current Treatment Options in Oncology, 2020, 21, 95.	1.3	15
905	Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. , 2020, 8, e000974.		49

#	Article	IF	Citations
907	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. Medicine (United States), 2020, 99, e22567.	0.4	5
908	Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 572853.	1.3	15
909	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. Cell, 2020, 183, 303-304.	13.5	4
910	Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response. Scientific Reports, 2020, 10, 16945.	1.6	16
911	The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059.	1.3	47
912	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. European Journal of Cancer, 2020, 140, 28-36.	1.3	17
913	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opinion on Investigational Drugs, 2020, 29, 1355-1364.	1.9	39
914	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. Translational Lung Cancer Research, 2020, 9, 811-815.	1.3	3
916	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. Cancer Medicine, 2020, 9, 8406-8411.	1.3	31
917	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. Oncologist, 2020, 25, e1930-e1955.	1.9	20
920	Les CBNPC de stades avancÃ©s hors addiction oncogÃ©nique : les traitements systÃ©miques de deuxiÃ¨me ligne. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S185-2S194.	0.0	0
922	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell, 2020, 183, 363-376.e13.	13.5	206
923	Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced nonâ€“small cell lung cancer: IFCT-1201 MODEL trial. European Journal of Cancer, 2020, 138, 193-201.	1.3	4
924	PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. Scientific Reports, 2020, 10, 16150.	1.6	2
925	Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers, 2020, 12, 1905.	1.7	14
926	Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer. Cancer Investigation, 2020, 38, 424-430.	0.6	1
927	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Research, 2020, 30, 364-375.	0.6	42
928	Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiation Oncology, 2020, 15, 167.	1.2	29

#	Article	IF	Citations
929	Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 2782-2797.	0.8	201
930	Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report. Annals of Palliative Medicine, 2020, 9, 2341-2346.	0.5	5
931	Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?. Journal of Thoracic Disease, 2020, 12, 3287-3295.	0.6	9
932	Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. Frontiers in Immunology, 2020, 11, 1479.	2.2	30
933	Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Advanced Drug Delivery Reviews, 2020, 154-155, 142-150.	6.6	28
934	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. Biomedicine and Pharmacotherapy, 2020, 129, 110504.	2.5	26
935	Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093790.	1.4	49
936	The changing landscape of stage III lung cancer: a literature review. Expert Review of Anticancer Therapy, 2020, 20, 675-686.	1.1	3
937	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093688.	1.4	17
938	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Translational Lung Cancer Research, 2020, 9, 617-628.	1.3	8
939	Pembrolizumabâ€”the â€œKEYâ€•to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2020, 9, 824-827.	1.3	0
940	Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e250-e254.	1.1	4
941	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resistance Updates, 2020, 53, 100718.	6.5	103
942	Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 1098.	1.3	29
943	Immune Checkpoint Inhibitors for Patients Agedâ€‰â‰¥â€‰75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. Drugs and Aging, 2020, 37, 747-754.	1.3	24
944	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. Journal of Clinical Rheumatology and Immunology, 2020, 20, 25-34.	0.4	0
945	Efficacy and safety of immune checkpoint inhibitors in patients with advanced nonâ€“small cell lung cancer (NSCLC): a systematic literature review. OncoImmunology, 2020, 9, 1774314.	2.1	34
946	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Frontiers in Oncology, 2020, 10, 568279.	1.3	11

#	Article	IF	Citations
947	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
948	The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Research, 2020, 9, 1770-1784.	1.3	26
949	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challengeâ€"a narrative review. Translational Lung Cancer Research, 2020, 9, 2120-2136.	1.3	16
950	The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2184-2187.	1.3	2
951	Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancerâ€. Cancer Investigation, 2020, 38, 608-617.	0.6	1
952	An Innovative Immune Score-Based Prognostic Nomogram for Patients with Cervical Cancer. BioMed Research International, 2020, 2020, 1-9.	0.9	4
953	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. Translational Lung Cancer Research, 2020, 9, 2059-2073.	1.3	9
954	Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology, 2020, 15, e189-e191.	0.5	0
955	Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 572172.	2.2	21
956	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392.		27
957	Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review. BMJ Open, 2020, 10, e034010.	0.8	6
958	New insights into the interaction of the immune system with non-small cell lung carcinomas. Translational Lung Cancer Research, 2020, 9, 2199-2213.	1.3	11
959	Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report. Annals of Medicine and Surgery, 2020, 60, 31-35.	0.5	2
960	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	0.7	1
961	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. Medical Oncology, 2020, 37, 111.	1.2	13
962	Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. OncoImmunology, 2020, 9, 1836766.	2.1	15
963	Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy. Medicine (United States), 2020, 99, e22933.	0.4	3
964	Imperfect Predictors for Lung Cancer Immunotherapyâ€"A Field for Further Research. Frontiers in Oncology, 2020, 10, 568174.	1.3	14

#	Article	IF	Citations
965	Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 3881.	1.0	14
966	Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Communications Biology, 2020, 3, 720.	2.0	82
967	Immune Checkpoint Inhibitor-Related Pneumonitis. Respiration, 2020, 99, 932-942.	1.2	30
968	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer, 2020, 20, 1185.	1.1	75
969	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3574.	1.7	42
970	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers, 2020, 12, 3625.	1.7	27
971	PremiÃ¨re ligne des CBNPC avancÃ©s sans addiction oncogÃ©nique : quel traitement pour quel patient ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S329-2S338.	0.0	0
972	TolÃ©rance de lâ€™immunothÃ©rapie en combinaison dans le cancer bronchique non Ã petites cellules. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S344-2S351.	0.0	0
973	Cancers bronchiques non Ã petites cellules (CBNPC) rÃ©sÃ©cables et immunothÃ©rapie : Ã©tat des lieux et perspectives. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S352-2S358.	0.0	0
974	Immunotherapy for extensive stage small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6212-6224.	0.6	3
975	Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer. Journal of Thoracic Disease, 2020, 12, 7048-7056.	0.6	9
976	A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes, 2020, 11, 1453.	1.0	2
977	Treatment of epithelial ovarian cancer. BMJ, The, 2020, 371, m3773.	3.0	359
978	Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. , 2020, 8, e001240.		95
979	Functional and clinical significance of ROR1 in lung adenocarcinoma. BMC Cancer, 2020, 20, 1085.	1.1	10
980	First line Immunotherapy for Non-Small Cell Lung Cancer. Pharmaceuticals, 2020, 13, 373.	1.7	49
981	Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11). Journal of Thoracic Oncology, 2020, 15, e191-e192.	0.5	13
982	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095299.	1.4	23

#	Article	IF	Citations
983	Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 570080.	1.3	5
984	Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiation Oncology, 2020, 15, 185.	1.2	18
985	Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. Cells Tissues Organs, 2022, 211, 91-109.	1.3	12
986	First-line immune-chemotherapy combination for squamous NSCLC is already a reality. Translational Lung Cancer Research, 2020, 9, 819-823.	1.3	1
987	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis. International Immunopharmacology, 2020, 87, 106852.	1.7	3
988	Treatment of muscleâ€invasive and advanced bladder cancer in 2020. Ca-A Cancer Journal for Clinicians, 2020, 70, 404-423.	157.7	507
989	Studying Lineage Plasticity One Cell at a Time. Cancer Cell, 2020, 38, 150-152.	7.7	6
990	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	28
991	Emerging Therapies in Thoracic Malignanciesâ€”Immunotherapy, Targeted Therapy, and T-Cell Therapy in Nonâ€“Small Cell Lung Cancer. Surgical Oncology Clinics of North America, 2020, 29, 555-569.	0.6	6
992	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 1243-1250.	1.6	154
993	Atezolizumab in a <u>C</u>o<u>H</u>ort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyp<u>E</u>s (CHANCE trial). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091598.	1.4	5
994	Current management of RET rearranged non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092863.	1.4	31
995	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094092.	1.4	11
996	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. Journal of Autoimmunity, 2020, 114, 102514.	3.0	37
997	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respiratory Investigation, 2020, 58, 305-319.	0.9	11
998	Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with nonâ€small cell lung cancer (<scp>ABâ€CLICaP</scp>). Thoracic Cancer, 2020, 11, 2552-2560.	0.8	12
999	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. Cancer Treatment Reviews, 2020, 89, 102085.	3.4	41
1000	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. International Immunopharmacology, 2020, 87, 106770.	1.7	7

#	Article	IF	Citations
1001	IMpower 131: The Exception to the Rule. Journal of Thoracic Oncology, 2020, 15, 1258-1260.	0.5	1
1002	Multidisciplinary Approach of Immune Checkpoint Inhibitorâ€“Related Pneumonitis: A Key to Address Knowledge and Management Gaps. Journal of Thoracic Oncology, 2020, 15, 1261-1264.	0.5	6
1003	Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. Expert Opinion on Emerging Drugs, 2020, 25, 353-366.	1.0	5
1004	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 672.	1.8	205
1005	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Frontiers in Immunology, 2020, 11, 1612.	2.2	21
1006	A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III nonâ€“small cell lung cancer: Hoosier Cancer Research Network LUN 14â€179. Cancer, 2020, 126, 4353-4361.	2.0	100
1007	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	7.7	210
1008	Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. British Journal of Cancer, 2020, 123, 874-884.	2.9	15
1009	The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Frontiers in Oncology, 2020, 10, 1256.	1.3	33
1010	Do Elderly Lung Cancer Patients Aged â‰¥75 Years Benefit from Immune Checkpoint Inhibitors?. Cancers, 2020, 12, 1995.	1.7	8
1011	Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper. Current Oncology Reports, 2020, 22, 98.	1.8	3
1012	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2020, 21, 69.	1.3	20
1013	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. Journal of Hematology and Oncology, 2020, 13, 105.	6.9	73
1014	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. Oncology Research, 2020, 28, 237-248.	0.6	8
1015	PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death. Angewandte Chemie, 2020, 132, 19232-19240.	1.6	13
1016	A brief report on combination chemotherapy and antiâ€“programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?. European Journal of Cancer, 2020, 137, 40-44.	1.3	5
1017	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. Lung Cancer, 2020, 147, 229-236.	0.9	9
1018	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nature Reviews Cancer, 2020, 20, 662-680.	12.8	860

#	Article	IF	Citations
1019	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) nonâ€“small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
1020	Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?. Annals of Translational Medicine, 2020, 8, 778-778.	0.7	1
1021	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context . OncoTargets and Therapy, 2020, Volume 13, 6885-6896.	1.0	1
1022	Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer. Journal of Cancer, 2020, 11, 5503-5510.	1.2	32
1023	Association of BTLA rs1982809 polymorphism with lung cancer risk in Tunisian population. International Journal of Immunogenetics, 2020, 47, 554-562.	0.8	13
1024	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	1.8	8
1025	Predicting the Role of DNA Polymerase Î² Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2438.	1.0	2
1026	Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy. Cancer, 2020, 126, 4572-4583.	2.0	13
1027	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs and Aging, 2020, 37, 677-689.	1.3	1
1028	B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma. Pathology Research and Practice, 2020, 216, 153134.	1.0	15
1029	Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies. Biomarkers, 2020, 25, 441-448.	0.9	1
1030	Programmed cell death 1 (PDâ€1)/PDâ€ligand 1(PDâ€L1) inhibitorsâ€related pneumonitis in patients with advanced nonâ€“small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 299-304.	0.7	10
1031	An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies. Journal of Thoracic Oncology, 2020, 15, 686-688.	0.5	0
1032	Selenium-Containing Nanomaterials for Cancer Treatment. Cell Reports Physical Science, 2020, 1, 100111.	2.8	46
1033	Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncology, 2020, 16, 1707-1713.	1.1	11
1034	PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death. Angewandte Chemie - International Edition, 2020, 59, 19070-19078.	7.2	79
1035	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Lung Cancer, 2020, 147, 259-268.	0.9	31
1036	Multimodal â€œsynergisticâ€•treatment based on tumour immunological contexture for advanced nonâ€driver nonâ€small cell lung cancer: A myth or reality?. European Journal of Cancer Care, 2020, 29, e13291.	0.7	1

#	Article	IF	Citations
1037	Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer. BMJ Open, 2020, 10, e037746.	0.8	1
1038	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. Journal of Hematology and Oncology, 2020, 13, 110.	6.9	698
1039	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Experimental Hematology and Oncology, 2020, 9, 17.	2.0	21
1040	Immuno-oncology for esophageal cancer. Future Oncology, 2020, 16, 2673-2681.	1.1	16
1041	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Management, 2020, 9, LMT36.	1.5	19
1042	Targeting the immune milieu in gastrointestinal cancers. Journal of Gastroenterology, 2020, 55, 909-926.	2.3	7
1043	A case of durvalumab-treated double primary cancers of the colon and lung. Annals of Palliative Medicine, 2020, 9, 3614-3622.	0.5	4
1044	Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report. Cancer Reports, 2020, 3, e1272.	0.6	1
1045	Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine and Pharmacotherapy, 2020, 130, 110626.	2.5	25
1046	Adverse impact of bone metastases on clinical outcomes of patients with advanced nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2020, 11, 2812-2819.	0.8	23
1047	Perioperative considerations for neoadjuvant immunotherapy in nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1376-1382.	0.4	18
1048	Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer, 2020, 20, 760.	1.1	43
1049	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers, 2020, 12, 2234.	1.7	31
1050	Immune Oncology Biomarkers in Lung Cancer: an Overview. Current Oncology Reports, 2020, 22, 107.	1.8	8
1051	Medical management of brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa015.	0.4	15
1052	Independent drug action and its statistical implications for development of combination therapies. Contemporary Clinical Trials, 2020, 98, 106126.	0.8	9
1053	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. Frontiers in Pharmacology, 2020, 11, 578091.	1.6	51
1054	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. Journal of Bone Oncology, 2020, 25, 100332.	1.0	19

#	Article	IF	Citations
1055	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. ESMO Open, 2020, 5, e000748.	2.0	2
1056	Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma. Journal of Immunology Research, 2020, 2020, 1-12.	0.9	16
1057	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. Frontiers in Oncology, 2020, 10, 556275.	1.3	6
1058	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. Frontiers in Oncology, 2020, 10, 568939.	1.3	15
1059	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3112.	1.7	23
1060	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. Cancers, 2020, 12, 3129.	1.7	29
1061	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers, 2020, 12, 3169.	1.7	10
1062	Impact of PET/CT for Assessing Response to Immunotherapyâ€”A Clinical Perspective. Journal of Clinical Medicine, 2020, 9, 3483.	1.0	26
1063	Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma. Medical Oncology, 2020, 37, 106.	1.2	4
1064	Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. PLoS ONE, 2020, 15, e0236503.	1.1	25
1065	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâ˜1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048.	1.7	37
1066	Efficacy and safety of immune checkpoint blockade in selfâ€identified Black patients with advanced nonâ€“small cell lung cancer. Cancer, 2020, 126, 5040-5049.	2.0	12
1067	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Respiratory Medicine and Research, 2020, 78, 100788.	0.4	2
1068	Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open, 2020, 5, e000631.	2.0	8
1069	Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. , 2020, 8, e001170.		28
1070	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research, 2020, 8, 34.	2.8	266
1071	Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 2185-2194.	0.9	1
1072	Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. PLoS ONE, 2020, 15, e0238536.	1.1	34

#	Article	IF	Citations
1073	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. Journal of Clinical Medicine, 2020, 9, 2775.	1.0	10
1074	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 1447-1453.	0.6	14
1075	The application of artificial intelligence and radiomics in lung cancer. Precision Clinical Medicine, 2020, 3, 214-227.	1.3	25
1076	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. Molecules, 2020, 25, 3987.	1.7	14
1077	STK11Â(LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS ONE, 2020, 15, e0238358.	1.1	44
1078	Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV nonâ€small cell lung cancer. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 866-872.	0.9	3
1079	Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. Translational Lung Cancer Research, 2020, 9, 1302-1323.	1.3	16
1080	Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients. Translational Lung Cancer Research, 2020, 9, 1407-1421.	1.3	17
1081	A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians. Translational Lung Cancer Research, 2020, 9, 1124-1137.	1.3	6
1082	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. Cancers, 2020, 12, 2637.	1.7	40
1083	Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2020, 9, 1053-1066.	1.3	7
1084	Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy. Translational Lung Cancer Research, 2020, 9, 1015-1028.	1.3	15
1085	Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 1671.	1.3	25
1086	Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 1556-1558.	0.5	5
1087	Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 576314.	1.3	17
1088	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 2691.	1.7	39
1089	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	1.7	13
1090	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1413-1422.	5.1	475

#	Article	IF	Citations
1091	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. Lung Cancer, 2020, 148, 159-165.	0.9	17
1092	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage <scp>III</scp> nonâ€small cell lung cancer: Chinese multicenter report and literature review. Thoracic Cancer, 2020, 11, 2916-2923.	0.8	7
1093	Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer, 2020, 20, 806.	1.1	12
1094	An update on the immune landscape in lung and head and neck cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 505-517.	157.7	93
1095	Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. Current Treatment Options in Oncology, 2020, 21, 86.	1.3	6
1096	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncology, The, 2020, 21, 1213-1223.	5.1	109
1097	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patientâ€™s Suitability for Immune Checkpoint Inhibition . Cancer Management and Research, 2020, Volume 12, 7881-7890.	0.9	6
1098	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced nonâ€“small cell lung cancer without tumor PDâ€L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer, 2020, 126, 4867-4877.	2.0	69
1099	Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1Ââ‰¥Â50%. Scientific Reports, 2020, 10, 14990.	1.6	23
1100	A novel scoring method based on RNAâ€Seq immunograms describing individual cancerâ€immunity interactions. Cancer Science, 2020, 111, 4031-4040.	1.7	32
1101	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 497-505.	1.1	7
1103	PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2020, 2020, 1-5.	0.2	1
1104	ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. Frontiers in Oncology, 2020, 10, 1706.	1.3	17
1105	FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p). Cells, 2020, 9, 2083.	1.8	14
1106	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 554313.	1.3	32
1107	Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted. In Vivo, 2020, 34, 2687-2691.	0.6	1
1108	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clinical Medicine Insights: Oncology, 2020, 14, 117955492095135.	0.6	24
1109	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Frontiers in Oncology, 2020, 10, 1677.	1.3	32

#	Article	IF	Citations
1110	Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Advances, 2020, 4, 4256-4266.	2.5	12
1111	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495.	1.7	12
1112	Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression. Cancers, 2020, 12, 2496.	1.7	11
1113	World Lung Day: what, why, and where to?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L527-L533.	1.3	6
1114	Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	2.0	80
1115	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16
1116	Radiation-induced lung toxicity â€“ cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiation Oncology, 2020, 15, 214.	1.2	103
1117	A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies . Cancer Management and Research, 2020, Volume 12, 6493-6509.	0.9	19
1118	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2012534.	2.8	72
1119	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. Current Oncology Reports, 2020, 22, 109.	1.8	10
1120	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 5774.	1.8	23
1121	Targeting phosphatidylserine for Cancer therapy: prospects and challenges. Theranostics, 2020, 10, 9214-9229.	4.6	69
1122	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. Journal of Thoracic Disease, 2020, 12, 3796-3803.	0.6	19
1124	Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clinical Cancer Research, 2020, 26, 6453-6463.	3.2	92
1125	Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunology Research, 2020, 8, 1300-1310.	1.6	39
1126	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Current HIV/AIDS Reports, 2020, 17, 547-556.	1.1	21
1127	Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. Anticancer Research, 2020, 40, 4245-4251.	0.5	4
1128	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 2020, 12, 2319.	1.7	52

#	Article	IF	Citations
1129	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5918.	1.8	15
1130	Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Research, 2020, 30, 966-979.	5.7	349
1131	The current treatment landscape in the UK for stage III NSCLC. British Journal of Cancer, 2020, 123, 3-9.	2.9	55
1132	DRACP: a novel method for identification of anticancer peptides. BMC Bioinformatics, 2020, 21, 559.	1.2	9
1133	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 595655.	2.2	8
1134	Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.. Cancer Treatment and Research Communications, 2020, 25, 100265.	0.7	3
1135	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a â€˜Real-Lifeâ€™ Setting. Cancers, 2020, 12, 3707.	1.7	12
1136	Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers, 2020, 12, 3729.	1.7	55
1137	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Disease Markers, 2020, 2020, 1-14.	0.6	13
1138	A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma. Respiratory Medicine Case Reports, 2020, 31, 101266.	0.2	7
1139	Immune Escape in Prostate Cancer. Urologic Clinics of North America, 2020, 47, e9-e16.	0.8	7
1140	What Is the Standard First-Line Treatment for Advanced Nonâ€“Small Cell Lung Cancer?. Cancer Journal (Sudbury, Mass), 2020, 26, 485-495.	1.0	5
1141	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
1142	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095480.	1.4	9
1143	Changing paradigm in advanced and metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6992-7001.	0.6	3
1144	Radiation and immunotherapy: emerging mechanisms of synergy. Journal of Thoracic Disease, 2020, 12, 7011-7023.	0.6	28
1145	Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date . OncoTargets and Therapy, 2020, Volume 13, 12301-12316.	1.0	22
1146	A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS â‰¥1% Metastatic NSCLC. Cancers, 2020, 12, 3648.	1.7	14

#	Article	IF	Citations
1147	Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines, 2020, 8, 730.	2.1	6
1148	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (ImfinziÂ®â–¼, AstraZeneca UK) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	13
1149	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 517-524.	1.0	18
1150	Opioids impair nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. BMJ Supportive and Palliative Care, 2023, 13, e185-e189.	0.8	10
1151	Durable Remission of Human Papillomavirusâ€“Positive JAK2/PDL1/PDL2â€“Amplified Urethral Squamous Carcinoma With Sequential Chemotherapy and Immune Checkpoint Inhibitor Therapy. JCO Precision Oncology, 2020, 4, 860-864.	1.5	0
1152	Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 575472.	1.3	43
1153	PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. Analytical Cellular Pathology, 2020, 2020, 1-7.	0.7	3
1154	Biomimetic Diselenideâ€Bridged Mesoporous Organosilica Nanoparticles as an Xâ€rayâ€Responsive Biodegradable Carrier for Chemoâ€Immunotherapy. Advanced Materials, 2020, 32, e2004385.	11.1	122
1155	Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma. Medicine (United States), 2020, 99, e23172.	0.4	15
1156	Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced nonâ€small cell lung cancer. Cancer Science, 2020, 111, 4442-4452.	1.7	25
1157	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease, 2020, 12, 5096-5103.	0.6	0
1158	Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. Frontiers in Cell and Developmental Biology, 2020, 8, 582370.	1.8	48
1159	Immune Checkpoint Inhibitors and Perioperative Considerations. Journal of Perianesthesia Nursing, 2020, 35, 687-691.	0.3	1
1160	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer, 2020, 150, 159-163.	0.9	33
1161	De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology, 2020, 3, 645.	2.0	30
1162	PrÃzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. Karger Kompass Pneumologie, 2020, 8, 300-317.	0.0	1
1163	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095.	0.6	29
1164	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. Journal of Clinical Medicine, 2020, 9, 3543.	1.0	28

#	Article	IF	Citations
1165	Radiomics of ¹⁸F Fluorodeoxyglucose PET/CT Images Predicts Severe Immune-related Adverse Events in Patients with NSCLC. Radiology: Artificial Intelligence, 2020, 2, e190063.	3.0	24
1166	Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer. Bladder Cancer, 2020, 6, 1-8.	0.2	3
1167	Update 2020: Management of Non-Small Cell Lung Cancer. Lung, 2020, 198, 897-907.	1.4	270
1168	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Network Open, 2020, 3, e2017675.	2.8	20
1169	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
1170	Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study. Lung Cancer, 2020, 150, 172-177.	0.9	9
1171	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 2020, 26, 4186-4197.	3.2	44
1172	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 2020, 8, 203.	2.1	38
1173	Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 653-659.	1.0	7
1174	First-line combination immunotherapy for metastatic non-small cell lung cancer. Journal of the Chinese Medical Association, 2020, 83, 433-441.	0.6	2
1175	Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 258-267.	0.4	11
1176	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. Journal of Thoracic Oncology, 2020, 15, 1472-1483.	0.5	32
1177	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	3.2	95
1178	Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. , 2020, 8, e000461.		26
1179	Genomics models in radiotherapy: From mechanistic to machine learning. Medical Physics, 2020, 47, e203-e217.	1.6	17
1180	Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV. Lung Cancer, 2020, 145, 71-75.	0.9	10
1181	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. Annals of Translational Medicine, 2020, 8, 555-555.	0.7	8
1182	Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. International Journal of Cardiology, 2020, 313, 67-75.	0.8	19

#	Article	IF	Citations
1183	Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis. Translational Lung Cancer Research, 2020, 9, 188-203.	1.3	16
1184	Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. Cancer Immunology, Immunotherapy, 2020, 69, 2041-2051.	2.0	13
1185	Switching administration of <scp>antiâ€PD</scp>â€1 and <scp>antiâ€PDâ€L1</scp> antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced nonâ€small cell lung cancer: Case series and literature review. Thoracic Cancer, 2020, 11, 1927-1933.	0.8	47
1186	A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer. Case Reports in Oncology, 2020, 13, 212-218.	0.3	0
1187	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092203.	1.4	26
1188	Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?. Translational Lung Cancer Research, 2020, 9, 401-405.	1.3	1
1189	Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells. Anticancer Research, 2020, 40, 1451-1458.	0.5	7
1190	Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs, 2020, 80, 883-892.	4.9	5
1191	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. Clinical Cancer Research, 2020, 26, 5068-5077.	3.2	34
1192	The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer. Translational Lung Cancer Research, 2020, 9, 410-413.	1.3	0
1193	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. Cancer Medicine, 2020, 9, 4991-5007.	1.3	14
1194	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 2020, 12, 1125.	1.7	43
1195	Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 786-795.	5.1	419
1196	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung Cancer, 2020, 144, 76-84.	0.9	29
1197	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. British Journal of Clinical Pharmacology, 2020, 86, 1736-1752.	1.1	10
1198	Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Nonâ€“Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 480.	1.3	28
1199	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. Journal of Clinical Medicine, 2020, 9, 1362.	1.0	102
1200	Adult immuno-oncology: using past failures to inform the future. Neuro-Oncology, 2020, 22, 1249-1261.	0.6	19

#	Article	IF	Citations
1201	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e89-e106.	1.8	17
1202	Keynote 42: Pembrolizumab, PD-L1, and where to draw the line. Annals of Translational Medicine, 2020, 8, 517-517.	0.7	2
1203	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2020, 40, 2981-2987.	0.5	4
1204	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs, 2020, 34, 463-476.	2.2	49
1205	Immune checkpoint inhibition in urothelial carcinoma. Lancet, The, 2020, 395, 1522-1523.	6.3	2
1206	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. JCO Precision Oncology, 2020, 4, 486-491.	1.5	9
1207	The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. Oncology, 2020, 98, 661-668.	0.9	7
1208	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	2.0	60
1209	Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2699-2707.	1.2	9
1210	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Frontiers in Pharmacology, 2020, 11, 722.	1.6	65
1211	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
1212	Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy, 2020, 12, 587-603.	1.0	21
1213	Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. Investigational New Drugs, 2020, 38, 1901-1905.	1.2	4
1214	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncology Practice, 2020, 16, e933-e942.	1.4	33
1215	Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review . OncoTargets and Therapy, 2020, Volume 13, 3319-3324.	1.0	15
1216	Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Frontiers in Oncology, 2020, 10, 507.	1.3	6
1217	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 472-476.	1.1	12
1218	Tuberculosis associated with Triplet therapy for lung cancer. Thorax, 2020, 75, 609-610.	2.7	4

#	Article	IF	Citations
1219	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Current Oncology Reports, 2020, 22, 54.	1.8	20
1220	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer. Chest, 2020, 158, 1230-1239.	0.4	27
1221	A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer. International Immunopharmacology, 2020, 83, 106537.	1.7	10
1222	Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. Lung Cancer, 2020, 144, 71-75.	0.9	21
1223	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opinion on Drug Safety, 2020, 19, 775-783.	1.0	2
1224	Immune checkpoint inhibitorâ€“related dermatologic adverse events. Journal of the American Academy of Dermatology, 2020, 83, 1255-1268.	0.6	221
1225	Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198.	0.4	19
1226	Current Landscape of Personalized Therapy. Thoracic Surgery Clinics, 2020, 30, 121-125.	0.4	2
1227	Immuno-Oncologyâ€”The New Paradigm of Lung Cancer Treatment. Current Oncology, 2020, 27, 78-86.	0.9	18
1229	Effects of folic acid withdrawal on transcriptomic profiles in murine triple-negative breast cancer cell lines. Biochimie, 2020, 173, 114-122.	1.3	7
1230	Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. Thoracic Cancer, 2020, 11, 1911-1917.	0.8	13
1231	The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases. Scandinavian Journal of Immunology, 2020, 92, e12893.	1.3	6
1232	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. BioMed Research International, 2020, 2020, 1-10.	0.9	8
1233	Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2957-2966.	1.2	14
1234	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cellular Oncology (Dordrecht), 2020, 43, 681-694.	2.1	7
1235	The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature. Journal of Endocrinological Investigation, 2020, 43, 1531-1542.	1.8	18
1236	Anaplastic Lymphoma Kinase Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 137-146.	0.4	8
1237	Tepotinib in Nonâ€“Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 2020, 383, 931-943.	13.9	500

#	Article	IF	Citations
1238	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. Expert Opinion on Drug Safety, 2020, 19, 927-934.	1.0	5
1239	Immunotherapy as secondâ€line treatment and beyond for nonâ€small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a realâ€world retrospective analysis. Thoracic Cancer, 2020, 11, 1955-1962.	0.8	16
1240	Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2530-2542.	0.8	47
1241	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. Journal of Clinical Oncology, 2020, 38, 2369-2379.	0.8	410
1242	Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer. PLoS ONE, 2020, 15, e0233768.	1.1	6
1243	Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors. Frontiers in Oncology, 2020, 10, 570.	1.3	127
1244	Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology, 2020, 27, 106-114.	0.9	17
1245	Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer, 2020, 146, 42-49.	0.9	25
1246	Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay. , 2020, 8, e000152.		0
1247	Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. International Journal of Clinical Pharmacy, 2020, 42, 1175-1183.	1.0	31
1248	Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell, 2020, 78, 1002-1018.	4.5	95
1249	The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 4465-4471.	1.0	8
1250	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
1251	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093033.	1.4	25
1252	Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells, 2020, 9, 1474.	1.8	37
1253	The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. Archivos De Bronconeumologia, 2020, 56, 380-389.	0.4	1
1254	Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology, 2020, 152, 102983.	2.0	11
1255	Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respiratory Medicine and Research, 2020, 78, 100769.	0.4	11

#	Article	IF	Citations
1256	Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. Pharmacogenomics, 2020, 21, 705-720.	0.6	9
1257	Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1295.	2.2	58
1258	IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. Immunogenetics, 2020, 72, 295-304.	1.2	4
1259	Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. Internal Medicine, 2020, 59, 2003-2008.	0.3	10
1260	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 2020, 27, 146-155.	0.9	14
1261	Treatment of Non-Small-Cell Lung Cancer after Progression on Nivolumab or Pembrolizumab. Current Oncology, 2020, 27, 76-82.	0.9	7
1262	Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors. Molecular Oncology, 2020, 14, 2096-2110.	2.1	21
1263	Immunotherapy in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 400-408.	0.8	4
1264	Association of CD8 T cell apoptosis and EGFR mutation in nonâ€small lung cancer patients. Thoracic Cancer, 2020, 11, 2130-2136.	0.8	12
1265	Advances in the Treatment of Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 237-247.	0.8	50
1266	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	0.8	11
1267	Management of Oligometastatic Disease in Advanced Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 249-258.	0.8	6
1268	Pulmonary Complications of Immunotherapy. Clinics in Chest Medicine, 2020, 41, 295-305.	0.8	1
1269	Lung cancer in India: The rewards of REWERDS (REal World Evidence from Retrospective Data) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.0	5
1270	Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer, 2020, 146, 30-35.	0.9	20
1271	The State of the Science in Patient-Reported Outcomes for Patients with Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 377-385.	0.8	8
1272	Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Molecular Cancer Therapeutics, 2020, 19, 1575-1588.	1.9	35
1273	Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Future Oncology, 2020, 16, 749-762.	1.1	0

#	Article	IF	Citations
1274	From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. Cell Death Discovery, 2020, 6, 48.	2.0	18
1275	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports, 2020, 5, 1139-1148.	0.4	71
1276	Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer, 2020, 146, 86-96.	0.9	14
1277	Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta OncolÃ³gica, 2020, 59, 1051-1057.	0.8	5
1278	Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. Journal of Clinical Oncology, 2020, 38, 2926-2936.	0.8	107
1279	Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery) Tj ETQq1 1 0.784314 rgBT /Overloc	1.1	3
1280	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	1.0	16
1281	Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer. Scientific Reports, 2020, 10, 9805.	1.6	17
1282	Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Investigation, 2020, 38, 365-371.	0.6	8
1283	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	0.9	8
1284	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancerâ€"A Stimulating Partnership. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 360-368.	0.8	2
1285	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4814-4822.	3.2	82
1286	Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids andÂantibiotics. Future Oncology, 2020, 16, 1683-1690.	1.1	4
1287	PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 83-87.	0.9	7
1288	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Nonâ€"Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e207205.	2.8	19
1289	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Frontiers in Immunology, 2020, 11, 1088.	2.2	61
1290	Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2020, 76, 1345-1354.	0.8	16
1291	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Current Oncology Reports, 2020, 22, 70.	1.8	11

#	Article	IF	Citations
1292	Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology, 2020, 85, 106677.	1.7	61
1293	Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma. BMC Cancer, 2020, 20, 571.	1.1	7
1294	Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 1604.	1.7	63
1295	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂâ‰¥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	1.1	50
1296	Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. Journal of Thoracic Oncology, 2020, 15, 1281-1297.	0.5	109
1297	Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged â‰¥75 years with squamous-cell lung cancer: TORG1322. Lung Cancer, 2020, 146, 182-188.	0.9	1
1298	Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clinical Infectious Diseases, 2021, 73, e2697-e2704.	2.9	12
1299	Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma. Journal of Dermatology, 2020, 47, 907-910.	0.6	9
1300	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncology, 2020, 16, 1751-1766.	1.1	20
1301	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e196828.	3.4	48
1302	The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 261.	1.3	11
1303	Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 666.	1.7	24
1304	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Hematology, 2020, 13, 435-445.	1.0	5
1305	Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Thoracic Cancer, 2020, 11, 1350-1353.	0.8	14
1306	Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Nonâ€“Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. Clinical Lung Cancer, 2020, 21, e265-e269.	1.1	7
1307	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 1505-1517.	0.8	710
1308	Immunotherapy, Inflammation and Colorectal Cancer. Cells, 2020, 9, 618.	1.8	167
1309	Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, 210, 107522.		56

#	Article	IF	Citations
1310	Î±₃Î²₁ Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment. ACS Applied Materials & Interfaces, 2020, 12, 14905-14913.	4.0	26
1311	Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1229-1236.	2.0	18
1312	Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. American Journal of Cardiology, 2020, 125, 1920-1926.	0.7	50
1313	Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration. Journal of Palliative Medicine, 2020, 23, 1038-1044.	0.6	9
1314	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceutical Medicine, 2020, 34, 83-91.	1.0	9
1315	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii.	0.4	0
1316	Icotinib: efficacy in different solid tumors and gene mutations. Anti-Cancer Drugs, 2020, 31, 205-210.	0.7	3
1317	Patterns of response in metastatic NSCLC during PDâ€1 or PDâ€L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thoracic Cancer, 2020, 11, 1068-1075.	0.8	15
1318	Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a twoâ€year period using continuous bronchoscopy: A case report. Thoracic Cancer, 2020, 11, 1339-1343.	0.8	3
1319	Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer. Biological and Pharmaceutical Bulletin, 2020, 43, 399-403.	0.6	10
1320	Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study . Cancer Management and Research, 2020, Volume 12, 1339-1346.	0.9	12
1321	Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?. International Journal of Molecular Sciences, 2020, 21, 1658.	1.8	22
1322	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine, 2020, 9, 675.	1.0	57
1323	Combining Immunotherapy and Chemotherapy for Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 199-206.	0.4	30
1324	Treatment options after first-line immunotherapy in metastatic NSCLC. Expert Review of Anticancer Therapy, 2020, 20, 221-228.	1.1	8
1325	Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101411.	2.2	16
1326	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. European Journal of Cancer, 2020, 129, 97-106.	1.3	48
1327	A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates. Nature Chemistry, 2020, 12, 381-390.	6.6	122

#	Article	IF	Citations
1328	PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer. Npj Precision Oncology, 2020, 4, 6.	2.3	32
1329	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapyâ€associated hepatitis in Japan. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1782-1788.	1.4	22
1330	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 197.	1.3	9
1331	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi.	0.4	0
1332	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 895-904.	5.2	111
1333	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
1334	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 761-771.	1.1	32
1335	Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort. Lung Cancer, 2020, 143, 36-39.	0.9	22
1336	Conquering lung cancer: current status and prospects for the future. Pulmonology, 2020, 26, 283-290.	1.0	51
1337	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Frontiers in Medicine, 2020, 7, 90.	1.2	31
1338	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
1339	KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 148-153.	1.3	5
1340	Immunotherapy in lung cancer: effective for patients with poor performance status?. Lancet Respiratory Medicine,the, 2020, 8, 838-839.	5.2	5
1341	Costâ€Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. Oncology Research, 2020, 28, 117-125.	0.6	24
1342	Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. British Journal of Cancer, 2020, 122, 1535-1543.	2.9	37
1343	First-line pembrolizumab in advanced nonâ€“small cell lung cancer patients with poor performance status. European Journal of Cancer, 2020, 130, 155-167.	1.3	98
1344	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
1345	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 655-663.	5.1	335

#	Article	IF	Citations
1346	Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer. Surgery Today, 2020, 50, 1049-1055.	0.7	9
1347	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	0.5	119
1348	Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanomaâ€”A Retrospective Study. Frontiers in Oncology, 2020, 10, 70.	1.3	28
1349	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 546.	1.7	177
1350	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
1351	Performance status and endâ€ofâ€life care among adults with nonâ€“small cell lung cancer receiving immune checkpoint inhibitors. Cancer, 2020, 126, 2288-2295.	2.0	49
1352	Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy. Immunotherapy, 2020, 12, 697-703.	1.0	5
1353	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€“ A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035.	2.0	5
1354	Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Nonâ€“Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2020, 154, 517-524.	0.4	4
1355	Regorafenib Versus Nivolumab After Sorafenib Failure: Realâ€World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications, 2020, 4, 1073-1086.	2.0	28
1357	Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Current Treatment Options in Oncology, 2020, 21, 64.	1.3	22
1358	Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers, 2020, 12, 1685.	1.7	10
1359	The plasticity of DNA replication forks in response to clinically relevant genotoxic stress. Nature Reviews Molecular Cell Biology, 2020, 21, 633-651.	16.1	198
1360	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. OncoImmunology, 2020, 9, 1748982.	2.1	23
1361	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35
1362	Rechallenge Strategy in Cancer Therapy. Oncology, 2020, 98, 669-679.	0.9	9
1363	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€“Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precision Oncology, 2020, 4, 780-784.	1.5	2
1364	Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects . OncoTargets and Therapy, 2020, Volume 13, 5093-5112.	1.0	8

#	Article	IF	Citations
1365	Do systemic treatments delivered after Nivolumab result in better outcomes? A bicentric case-control study. Respiratory Medicine and Research, 2020, 77, 100-105.	0.4	1
1366	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
1367	Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23.	2.8	47
1368	Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review . Cancer Management and Research, 2020, Volume 12, 4503-4518.	0.9	5
1369	Clinical Application of Iodine-125 Seed Brachytherapy Combined with Antiâ€“PD-1 Antibodies in the Treatment of Lung Cancer. Clinical Therapeutics, 2020, 42, 1612-1616.	1.1	4
1370	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treatment Reviews, 2020, 89, 102067.	3.4	48
1371	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 â€œEPNECâ€•study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093797.	1.4	19
1372	Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice. BMC Geriatrics, 2020, 20, 231.	1.1	36
1373	Immunotherapy in Prostate Cancer. Cancers, 2020, 12, 1752.	1.7	58
1374	Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target. CNS Neuroscience and Therapeutics, 2020, 26, 804-814.	1.9	15
1375	Clinical Outcomes of Anti-programmed Death-1 Antibodyâ€“Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Comprehensive Clinical Medicine, 2020, 2, 570-578.	0.3	8
1376	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. Cancer Treatment and Research Communications, 2020, 25, 100179.	0.7	4
1377	Spondylodiscitis and spinal epidural abscess related to longâ€term placement of an airway stent for malignant central airway obstruction. Thoracic Cancer, 2020, 11, 2343-2346.	0.8	1
1378	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e435-e444.	1.1	46
1379	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. , 2020, 8, e000527.		24
1380	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
1381	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. Frontiers in Immunology, 2020, 11, 1036.	2.2	10
1382	Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations. Current Treatment Options in Oncology, 2020, 21, 60.	1.3	6

#	Article	IF	Citations
1383	Successful continuous nivolumab therapy for metastatic <scp>nonâ€small</scp> cell lung cancer after local treatment of oligometastatic lesions. Thoracic Cancer, 2020, 11, 2357-2360.	0.8	8
1384	Anti-PDL1 effect in squamous non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 406-409.	1.3	2
1385	Organoid technology and applications in cancer immunotherapy and precision medicine. Current Opinion in Biotechnology, 2020, 65, 242-247.	3.3	23
1386	Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomarker Research, 2020, 8, 22.	2.8	37
1387	Immunotherapy combinations for the treatment of patients with solid tumors. Future Oncology, 2020, 16, 1715-1736.	1.1	6
1388	The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77.	2.6	89
1389	Identification of Biomarkers for Nonâ€“small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. Anticancer Research, 2020, 40, 3889-3896.	0.5	12
1390	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57.	4.3	104
1391	Pembrolizumab for the treatment of esophageal cancer. Expert Opinion on Biological Therapy, 2020, 20, 1143-1150.	1.4	14
1392	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 2020, 20, 319-326.	1.4	12
1393	PET/CT and the Response to Immunotherapy in Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 177-184.	0.3	17
1394	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 387-397.	5.1	119
1395	Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment. Journal of Cellular Biochemistry, 2020, 121, 4569-4579.	1.2	13
1396	Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. International Journal of Radiation Oncology Biology Physics, 2020, 108, 304-313.	0.4	42
1397	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 2083.	1.6	124
1398	Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. European Respiratory Journal, 2020, 55, 1901907.	3.1	27
1399	Advancing the systemic therapy of lung cancer: quality or quantity?. Lancet Oncology, The, 2020, 21, 322-324.	5.1	2
1400	Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. Oncologist, 2020, 25, e536-e544.	1.9	39

#	Article	IF	Citations
1401	Immunotherapy in lung cancer: the chemotherapy conundrum. Chinese Clinical Oncology, 2020, 9, 59-59.	0.4	15
1402	The emerging development of tumor mutational burden in patients with NSCLC. Future Oncology, 2020, 16, 469-481.	1.1	2
1403	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary. JCO Oncology Practice, 2020, 16, e844-e848.	1.4	18
1404	Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer . OncoTargets and Therapy, 2020, Volume 13, 667-683.	1.0	24
1405	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology, 2020, 31, 599-608.	0.6	183
1406	Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. Lung Cancer, 2020, 142, 106-113.	0.9	28
1407	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer, 2020, 142, 70-79.	0.9	17
1408	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Japanese Journal of Clinical Oncology, 2020, 50, 800-809.	0.6	12
1409	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2354-2361.	3.2	70
1411	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. Journal of Drug Targeting, 2020, 28, 861-872.	2.1	11
1412	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. OncoImmunology, 2020, 9, 1708065.	2.1	41
1413	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert Opinion on Biological Therapy, 2020, 20, 635-652.	1.4	36
1414	Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Research, 2020, 80, 1615-1623.	0.4	120
1415	Intratumoral Immunotherapy for Early-stage Solid Tumors. Clinical Cancer Research, 2020, 26, 3091-3099.	3.2	88
1416	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,Âand heavy smokers with non-small-cell lung cancer and PD-L1 expression â‰¥50%. Annals of Oncology, 2020, 31, 404-411.	0.6	79
1417	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences, 2019, 6, 160.	1.6	596
1418	Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 848.	3.4	89
1419	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	0.5	94

#	Article	IF	Citations
1420	Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. Lung Cancer, 2020, 142, 63-69.	0.9	12
1421	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€'Positive, Advanced Nonâ€'Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590.	0.8	189
1422	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. Anticancer Research, 2020, 40, 901-913.	0.5	1
1423	Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma. Lancet Oncology, The, 2020, 21, e126.	5.1	0
1424	Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Nonâ€"Small-Cell Lung Cancer and High PD-L1 Tumor Expression. Clinical Lung Cancer, 2020, 21, e366-e379.	1.1	26
1425	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer, 2020, 143, 1-11.	0.9	19
1426	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	1.9	10
1428	Immunotherapeutic approaches for small-cell lung cancer. Nature Reviews Clinical Oncology, 2020, 17, 300-312.	12.5	212
1429	Current status and progress of concurrent chemoradiotherapy in patients with locally advanced nonâ€small cell lung cancer prior to the approval of durvalumab. Thoracic Cancer, 2020, 11, 1005-1014.	0.8	10
1430	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310
1431	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xlii.	0.4	1
1432	Current multidisciplinary management of brain metastases. Cancer, 2020, 126, 1390-1406.	2.0	70
1433	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical Cancer Research, 2020, 26, 1796-1802.	3.2	8
1434	Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discovery, 2020, 10, 185-197.	7.7	68
1435	Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecologic Oncology, 2020, 157, 222-233.	0.6	31
1436	Immune checkpoint inhibitors in advanced nonâ€"small cell lung cancer: A metacentric experience from India. Current Problems in Cancer, 2020, 44, 100549.	1.0	4
1437	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 87-96.	1.5	5
1438	Costâ€effectiveness analysis of pembrolizumab plus chemotherapy with PDâ€L1 test for the firstâ€line treatment of NSCLC. Cancer Medicine, 2020, 9, 1683-1693.	1.3	41

#	Article	IF	Citations
1439	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences, 2020, 21, 556.	1.8	21
1440	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	1.3	52
1441	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. Cancer Investigation, 2020, 38, 130-138.	0.6	14
1442	Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy inÂvivo. Drug Delivery, 2020, 27, 180-190.	2.5	55
1443	Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. Annual Review of Medicine, 2020, 71, 117-136.	5.0	101
1444	Radiological Monitoring of Modern Immunotherapy: AÂNovelÂChallenge for Interdisciplinary Patient Care. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 235-245.	0.7	7
1445	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2020, 38, 1608-1632.	0.8	301
1446	Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. PLoS ONE, 2020, 15, e0228288.	1.1	12
1447	Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. Current Cancer Drug Targets, 2020, 20, 3-18.	0.8	43
1448	Patterns of care for older patients with stage IV nonâ€small cell lung cancer in the immunotherapy era. Cancer Medicine, 2020, 9, 2019-2029.	1.3	17
1449	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518.	2.3	44
1450	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Molecular Therapy, 2020, 28, 794-804.	3.7	42
1451	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. Clinical Cancer Research, 2020, 26, 2176-2187.	3.2	54
1452	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World Journal of Surgical Oncology, 2020, 18, 15.	0.8	58
1453	PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFÎ² Inhibitors. Clinical Cancer Research, 2020, 26, 1644-1655.	3.2	25
1454	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. The Cochrane Library, 2020, 2020, CD009256.	1.5	28
1455	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54.	6.6	127
1456	Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35.	6.6	1,177

#	Article	IF	Citations
1457	Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. Lung Cancer, 2020, 141, 64-71.	0.9	14
1458	Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments. ACS Nano, 2020, 14, 1033-1044.	7.3	161
1459	Optimizing Patient Outcomes with PDâ€1/PDâ€L1 Immune Checkpoint Inhibitors for the Firstâ€Line Treatment of Advanced Nonâ€“Small Cell Lung Cancer. Pharmacotherapy, 2020, 40, 239-255.	1.2	14
1460	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii.	0.4	0
1461	Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e286-e293.	1.1	22
1462	Cytology for PD-L1 testing: A systematic review. Lung Cancer, 2020, 141, 101-106.	0.9	42
1463	Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity. Frontiers in Oncology, 2020, 9, 1521.	1.3	11
1464	Clinical Features and Outcomes of Immune Checkpoint Inhibitorâ€“Associated AKI: A Multicenter Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 435-446.	3.0	247
1465	Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab. BMC Cancer, 2020, 20, 93.	1.1	15
1466	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
1467	Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition. Cancer Immunology, Immunotherapy, 2020, 69, 629-640.	2.0	11
1468	The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Critical Reviews in Oncology/Hematology, 2020, 147, 102893.	2.0	33
1469	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Cancer Treatment Reviews, 2020, 85, 101979.	3.4	21
1470	Pulmonary small cell carcinoma: Review, common and uncommon differentials, genomics and management. Diagnostic Cytopathology, 2020, 48, 790-803.	0.5	4
1471	Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers, 2020, 12, 1046.	1.7	47
1472	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. Frontiers in Oncology, 2020, 10, 492.	1.3	33
1473	Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 1268.	1.0	42
1474	Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy. Molecules, 2020, 25, 1994.	1.7	9

#	Article	IF	Citations
1475	COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy, 2020, 12, 545-548.	1.0	20
1476	Adjuvant and Neoadjuvant Immunotherapy in Nonâ€“small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 215-220.	0.4	78
1477	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 2020, 12, 738.	1.7	826
1479	Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncology, The, 2020, 21, 607-608.	5.1	9
1480	In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening. Journal of Translational Medicine, 2020, 18, 163.	1.8	11
1481	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 661.	3.4	446
1482	The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy. JAMA Oncology, 2020, 6, 674.	3.4	7
1483	Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 856.	3.4	103
1484	Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. International Journal of Clinical Oncology, 2020, 25, 1270-1277.	1.0	12
1485	Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell, 2020, 37, 443-455.	7.7	444
1486	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonâ€“small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European Journal of Cancer, 2020, 131, 27-36.	1.3	44
1487	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. European Journal of Cancer, 2020, 131, 40-50.	1.3	143
1488	NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2020, 15, 1147-1159.	0.5	88
1489	Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients. Lung Cancer, 2020, 144, 1-9.	0.9	10
1490	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma. British Journal of Cancer, 2020, 122, 1686-1694.	2.9	38
1492	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid, 2020, 30, 1458-1469.	2.4	44
1493	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. International Immunology, 2020, 32, 547-557.	1.8	18
1494	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patientsâ€™ Age: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 95-103.	1.2	7

#	Article	IF	Citations
1495	Programmed Death Ligand 1 Testing of Endobronchial Ultrasoundâ€“guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Nonâ€“Small Cell Lung Cancer. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 50-57.	0.8	19
1496	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open, 2020, 5, e000567.	2.0	7
1497	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2â^'negative endocrine-refractory metastatic breast cancer. , 2020, 8, e000173.		62
1498	Propensity scoreâ€“weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with nonâ€“small cell lung cancer (WJOG10217L). , 2020, 8, e000350.		42
1499	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines, 2020, 8, 191.	2.1	10
1500	Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation. Oncogene, 2020, 39, 4344-4357.	2.6	22
1501	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. BMC Cancer, 2020, 20, 352.	1.1	24
1502	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. Science China Life Sciences, 2020, 63, 1499-1514.	2.3	20
1503	Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer, 2020, 143, 40-46.	0.9	38
1504	Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. Diagnostic Cytopathology, 2020, 48, 759-764.	0.5	3
1505	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. Advances in Experimental Medicine and Biology, 2020, 1244, 69-92.	0.8	15
1506	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1505-1517.	2.0	58
1507	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	2.0	21
1508	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2153-2160.	1.2	8
1509	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Nonâ€“small Cell Lung Cancer. Current Oncology Reports, 2020, 22, 41.	1.8	20
1510	An immune gene expression signature distinguishes central nervous system metastases from primary tumours in nonâ€“small-cell lung cancer. European Journal of Cancer, 2020, 132, 24-34.	1.3	14
1511	Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. Lung Cancer, 2020, 143, 47-54.	0.9	6
1512	Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Review of Clinical Pharmacology, 2020, 13, 403-421.	1.3	7

#	Article	IF	Citations
1513	Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. OncoImmunology, 2020, 9, 1746112.	2.1	26
1514	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. Neurosurgery, 2020, 87, E281-E288.	0.6	22
1515	Clinical characteristics and prognosis of pulmonary large cell carcinoma: A populationâ€based retrospective study using <scp>SEER</scp> data. Thoracic Cancer, 2020, 11, 1522-1532.	0.8	12
1516	Mechanismâ€based treatment of cancer with immune checkpoint inhibitor therapies. British Journal of Clinical Pharmacology, 2020, 86, 1690-1702.	1.1	26
1517	Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer Science, 2020, 111, 1910-1920.	1.7	21
1518	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials, 2020, 21, 352.	0.7	7
1519	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e159-e170.	1.8	7
1520	Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Research, 2020, 80, 3101-3115.	0.4	77
1521	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
1522	Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations. Oncology Research and Treatment, 2020, 43, 289-298.	0.8	22
1523	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
1524	Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 1079-1084.	0.6	5
1525	Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 3039-3044.	1.0	1
1526	Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?. Lung Cancer Management, 2020, 9, LMT22.	1.5	15
1527	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers, 2020, 12, 832.	1.7	27
1528	Toxicity of Carlina Oxideâ€"A Natural Polyacetylene from the Carlina acaulis Rootsâ€"In Vitro and in Vivo Study. Toxins, 2020, 12, 239.	1.5	15
1529	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. Current Oncology, 2020, 27, 52-60.	0.9	13
1530	Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Annals of Oncology, 2020, 31, 959-961.	0.6	30

#	Article	IF	Citations
1531	Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e511-e515.	1.1	10
1532	Lung Cancer in Israel. Journal of Thoracic Oncology, 2020, 15, 493-498.	0.5	2
1533	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.5	153
1534	Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. Clinical and Translational Oncology, 2021, 23, 418-423.	1.2	31
1535	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038240.	2.9	34
1536	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. Clinical and Translational Oncology, 2021, 23, 434-449.	1.2	6
1537	Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. Supportive Care in Cancer, 2021, 29, 117-125.	1.0	2
1538	Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014. PharmacoEconomics - Open, 2021, 5, 121-127.	0.9	2
1539	Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). Clinical Lung Cancer, 2021, 22, e336-e341.	1.1	2
1540	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	1.1	10
1541	The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. Chinese Clinical Oncology, 2021, 10, 30-30.	0.4	1
1542	Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases. Journal of Neuro-Oncology, 2021, 151, 75-84.	1.4	19
1543	Glucocorticoids and immune checkpoint inhibitors in glioblastoma. Journal of Neuro-Oncology, 2021, 151, 13-20.	1.4	15
1544	PDâ€Ł1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	1.4	14
1545	Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. International Journal of Clinical Oncology, 2021, 26, 507-514.	1.0	1
1546	Phase III study of selpercatinib versus chemotherapy Â±Âpembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncology, 2021, 17, 763-773.	1.1	30
1547	Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. , 2021, 217, 107662.		18
1548	Nanoparticles as immunomodulators and translational agents in brain tumors. Journal of Neuro-Oncology, 2021, 151, 29-39.	1.4	6

#	Article	IF	Citations
1549	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced nonâ€smallâ€cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e125-e131.	0.7	3
1550	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. International Immunology, 2021, 33, 39-48.	1.8	4
1551	Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunology, Immunotherapy, 2021, 70, 323-336.	2.0	25
1552	Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunology, Immunotherapy, 2021, 70, 619-631.	2.0	80
1553	Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1227-1237.	1.2	3
1554	What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer?. Clinical Lung Cancer, 2021, 22, 242-251.e5.	1.1	9
1555	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. British Journal of Cancer, 2021, 124, 281-289.	2.9	22
1556	Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 93-107.	0.9	12
1557	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
1558	Nonâ€“small cell lung cancer in never- and ever-smokers: Is it the same disease?. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1903-1917.e9.	0.4	12
1559	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	3.2	50
1560	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist, 2021, 26, 49-55.	1.9	18
1561	Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunology, Immunotherapy, 2021, 70, 857-868.	2.0	22
1562	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 162-168.	0.5	90
1563	Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. International Journal of Cardiology, 2021, 322, 177-182.	0.8	18
1564	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. Cellular and Molecular Immunology, 2021, 18, 829-841.	4.8	21
1565	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Nonâ€“Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Clinical Lung Cancer, 2021, 22, 147-151.	1.1	16
1566	A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clinical Lung Cancer, 2021, 22, 142-146.	1.1	10

#	Article	IF	Citations
1567	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood, 2021, 137, 1669-1678.	0.6	123
1568	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respiratory Medicine,the, 2021, 9, 467-475.	5.2	277
1569	Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2021, 27, 405-413.	0.5	2
1570	Integration of multiomic annotation data to prioritize and characterize inflammation and immuneâ€related risk variants in squamous cell lung cancer. Genetic Epidemiology, 2021, 45, 99-114.	0.6	7
1571	Acute Leukemias. Hematologic Malignancies, 2021, , .	0.2	2
1572	When Constrained by Constraints: Thinking Outside of the Box in Both Technology and Biology. International Journal of Radiation Oncology Biology Physics, 2021, 110, 266-267.	0.4	5
1573	Recent advances in the management of cutaneous malignant melanoma: our case cohort. British Journal of Oral and Maxillofacial Surgery, 2021, 59, 534-545.	0.4	5
1574	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Antiâ€“PD-(L)1 Therapy. Clinical Cancer Research, 2021, 27, 1019-1028.	3.2	58
1575	Does the Waiting Period for Genetic Tests Affect the Prognosis in Chemotherapy-Treated de novo Metastatic Non-Small Cell Lung Cancer Patients without a Driver Mutation?. Oncology Research and Treatment, 2021, 44, 12-19.	0.8	2
1576	PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Lung Cancer, 2021, 151, 76-83.	0.9	10
1577	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. Critical Reviews in Oncology/Hematology, 2021, 157, 103169.	2.0	14
1578	Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncology, 2021, 17, 877-892.	1.1	29
1579	Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 671-690.	1.2	30
1580	Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Letters, 2021, 500, 163-171.	3.2	55
1581	Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. Expert Review of Anticancer Therapy, 2021, 21, 315-323.	1.1	7
1582	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer, 2021, 151, 30-38.	0.9	30
1583	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clinical Lung Cancer, 2021, 22, e180-e192.	1.1	15
1584	Radiomics features as predictive and prognostic biomarkers in NSCLC. Expert Review of Anticancer Therapy, 2021, 21, 257-266.	1.1	17

#	Article	IF	Citations
1585	Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. AAPS Journal, 2021, 23, 5.	2.2	22
1586	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. Cancer Medicine, 2021, 10, 3-14.	1.3	28
1587	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory â€œFoRECATTâ€• study. Cancer Immunology, Immunotherapy, 2021, 70, 1583-1592.	2.0	12
1588	Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. Molecular Therapy, 2021, 29, 658-670.	3.7	8
1589	The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cellular and Molecular Immunology, 2021, 18, 279-293.	4.8	102
1590	Outcome and risk factor of immuneâ€related adverse events and pneumonitis in patients with advanced or postoperative recurrent nonâ€small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 2021, 12, 153-164.	0.8	28
1591	The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology, 2021, 23, 1117-1127.	1.2	3
1592	Radiotherapy and Immunotherapy Combinations for Lung Cancer. Current Oncology Reports, 2021, 23, 4.	1.8	11
1593	Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discovery, 2021, 11, 293-307.	7.7	139
1594	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	1.9	17
1595	Outcomes in Patients With Nonâ€“small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer, 2021, 22, 58-66.e3.	1.1	19
1596	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. European Journal of Cancer, 2021, 144, 41-48.	1.3	64
1597	Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Lung Cancer, 2021, 151, 25-29.	0.9	4
1598	Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. Oncogene, 2021, 40, 885-898.	2.6	10
1599	Immunotherapy combinations in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2021, 33, 73-79.	1.1	5
1600	Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Nonâ€“small-cell Lung Cancer Brain Metastases. Clinical Lung Cancer, 2021, 22, 110-119.	1.1	27
1601	Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. Cytokine, 2021, 138, 155363.	1.4	20
1602	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 2021, 16, 653-664.	0.5	251

#	Article	IF	Citations
1603	Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?. Current Opinion in Oncology, 2021, 33, 64-72.	1.1	3
1604	Pembrolizumab for advanced cervical cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2021, 21, 221-228.	1.1	17
1605	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunology, Immunotherapy, 2021, 70, 1667-1678.	2.0	27
1606	Expanding the nanotherapeutic toolbox for non-small-cell lung cancer. Annals of Oncology, 2021, 32, 9-11.	0.6	8
1607	Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacologica Sinica, 2021, 42, 1516-1523.	2.8	23
1608	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. Journal of Cancer, 2021, 12, 1133-1143.	1.2	14
1609	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. BioDrugs, 2021, 35, 61-73.	2.2	1
1610	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 305-314.	5.2	277
1611	Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States. Current Medical Research and Opinion, 2021, 37, 469-476.	0.9	1
1612	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clinical Cancer Research, 2021, 27, 1631-1640.	3.2	70
1613	Nanomaterialâ€mediated platinum drugâ€based combinatorial cancer therapy. View, 2021, 2, 20200030.	2.7	28
1614	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer Reports, 2021, 4, e1322.	0.6	4
1615	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	0.5	48
1616	Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced nonâ€“small cell lung cancer: A network metaâ€analysis of randomized trials. Cancer, 2021, 127, 709-719.	2.0	16
1617	Immuneâ€related adverse events of a PDâ€L1 inhibitor plus chemotherapy versus a PDâ€L1 inhibitor alone in firstâ€line treatment for advanced nonâ€“small cell lung cancer: A metaâ€analysis of randomized control trials. Cancer, 2021, 127, 777-786.	2.0	21
1618	The rediscovery of platinum-based cancer therapy. Nature Reviews Cancer, 2021, 21, 37-50.	12.8	452
1619	Predictors of survival among Japanese patients receiving firstâ€line chemoimmunotherapy for advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 97-105.	0.8	20
1620	Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunology, Immunotherapy, 2021, 70, 1177-1188.	2.0	60

#	Article	IF	Citations
1621	Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Nonâ€“Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. Clinical Lung Cancer, 2021, 22, 6-15.e4.	1.1	8
1622	Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS â‰¥ 50%) NSCLC. Clinical Lung Cancer, 2021, 22, 127-133.e3.	1.1	9
1623	Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model. Cancer Letters, 2021, 498, 111-120.	3.2	5
1624	Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Annals of Oncology, 2021, 32, 85-96.	0.6	37
1625	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research, 2021, 13, 248-258.	0.6	6
1626	Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A realâ€world evidence. International Journal of Cancer, 2021, 148, 1183-1191.	2.3	1
1627	Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opinion on Drug Delivery, 2021, 18, 187-203.	2.4	66
1628	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
1629	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opinion on Biological Therapy, 2021, 21, 311-322.	1.4	10
1630	PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. Clinical Lung Cancer, 2021, 22, e51-e53.	1.1	6
1631	Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 881-891.	1.2	13
1632	Current status and future perspectives of immunotherapy in bladder cancer treatment. Science China Life Sciences, 2021, 64, 512-533.	2.3	21
1633	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 2021, 124, 359-367.	2.9	590
1634	Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 589-595.	2.0	17
1635	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clinical Cancer Research, 2021, 27, 665-679.	3.2	69
1636	Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. Pharmaceutical Statistics, 2021, 20, 129-145.	0.7	14
1637	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. Expert Review of Clinical Pharmacology, 2021, 14, 9-23.	1.3	5
1638	Immune checkpoint: The novel target for antitumor therapy. Genes and Diseases, 2021, 8, 25-37.	1.5	27

#	Article	IF	Citations
1639	Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus â€œat progressionâ€•cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	2
1640	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	1.4	12
1641	Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer. Frontiers in Medicine, 2020, 7, 621838.	1.2	6
1642	LDH-doped electrospun short fibers enable dual drug loading and multistage release for chemotherapy of drug-resistant cancer cells. New Journal of Chemistry, 2021, 45, 13421-13428.	1.4	15
1643	Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma. Internal Medicine, 2021, , .	0.3	0
1644	Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas. Cancer Treatment and Research Communications, 2021, 27, 100353.	0.7	10
1645	Tumors: Non-small Cell Lung Cancer. , 2021, , 1-10.		0
1646	Tumor Î²â€‘catenin expression is associated with immune evasion in nonâ€‘small cell lung cancer with high tumor mutation burden. Oncology Letters, 2021, 21, 203.	0.8	13
1647	Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma. Journal of Pathology Informatics, 2021, 12, 28.	0.8	7
1648	The Clinical Impact of Capmatinib in the Treatment of Advanced Nonâ€“Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Cancer Research and Treatment, 2021, 53, 1024-1032.	1.3	8
1649	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 31-44.	1.4	23
1650	Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors. Cancer Management and Research, 2021, Volume 13, 765-771.	0.9	21
1651	Realâ€world efficacy of atezolizumab in nonâ€small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of antiâ€•PD â€‘1 antibody. Thoracic Cancer, 2021, 12, 613-618.	0.8	16
1652	Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. Investigational New Drugs, 2021, 39, 1150-1158.	1.2	14
1653	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. Pharmaceuticals, 2021, 14, 89.	1.7	9
1654	Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 869-876.	0.5	19
1655	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. JNCI Cancer Spectrum, 2021, 5, pkab012.	1.4	16
1656	Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110011.	1.4	5

#	Article	IF	Citations
1657	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. OncoImmunology, 2021, 10, 1950411.	2.1	22
1659	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell Death and Disease, 2021, 12, 106.	2.7	16
1660	Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Journal of Thoracic Disease, 2021, 13, 220-231.	0.6	9
1661	An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. Cancer Control, 2021, 28, 107327482110171.	0.7	3
1662	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€•(December 4thâ€“5th,) Tj ETQq0 0 0 rgBT /Over	1.8	3
1663	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	1.3	29
1664	Induction therapy with Erlotinib (E) and Gemcitabine/Platinum (GP) in stage III NSCLC. Journal of Pulmonology and Respiratory Research, 2021, 5, 001-018.	0.0	0
1665	Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 203-215.	0.7	3
1666	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. OncoImmunology, 2021, 10, 1957603.	2.1	10
1668	Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2020, 10, 574752.	1.3	11
1669	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. Cancer Immunology, Immunotherapy, 2021, 70, 2389-2400.	2.0	11
1670	The Impact of Priming Effect of Immune Checkpoint Inhibitor Therapy for Advanced Stage Non-Small Cell Lung Cancer: A Meta-Epidemiological Study. SSRN Electronic Journal, 0, , .	0.4	0
1671	The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors. , 2021, , 339-339.		0
1672	Systemic Chemotherapy for Unresectable Pleural Mesothelioma from Front Line to Salvage Treatment: How Can We Treat the Patients Failed to PD-1/PD-L1 Inhibitors?. Respiratory Disease Series, 2021, , 253-266.	0.1	0
1673	Neoantigen landscape in metastatic nasopharyngeal carcinoma. Theranostics, 2021, 11, 6427-6444.	4.6	14
1674	Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Internal Medicine, 2021, 60, 3941-3945.	0.3	3
1675	Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. Frontiers in Immunology, 2020, 11, 607416.	2.2	2
1676	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0

#	Article	IF	Citations
1677	Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology, 2021, 152, 125-134.	1.4	7
1678	Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC). Journal of Cancer, 2021, 12, 584-594.	1.2	9
1679	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	3.3	90
1680	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 93-102.	1.5	31
1681	The ROC of Cox proportional hazards cure models with application in cancer studies. Lifetime Data Analysis, 2021, 27, 195-215.	0.4	5
1682	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110244.	1.4	8
1683	Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Annals of Translational Medicine, 2021, 9, 34-34.	0.7	22
1684	Induction treatment in patients with stage III non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 539-554.	1.3	8
1685	Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. SAGE Open Medicine, 2021, 9, 205031212110437.	0.7	1
1686	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: MÃ¶gliche Implikationen fÃ¼r den Erfolg von CAR-T-Zell-Therapien. Karger Kompass Onkologie, 2021, 8, 116-127.	0.0	0
1687	The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of Medical Economics, 2021, 24, 447-457.	1.0	3
1689	Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with nonâ€small cell lung cancer. Aging Medicine (Milton (N S W)), 2021, 4, 42-46.	0.9	4
1690	Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors. In Vivo, 2021, 35, 1687-1692.	0.6	2
1691	A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. Cancer Treatment and Research Communications, 2021, 27, 100330.	0.7	16
1692	The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen. Technology in Cancer Research and Treatment, 2021, 20, 153303382110194.	0.8	9
1693	Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Translational Lung Cancer Research, 2021, 10, 355-367.	1.3	26
1694	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer Treatment and Research Communications, 2021, 28, 100416.	0.7	0
1695	The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2313-2321.	2.0	35

#	Article	IF	Citations
1696	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 563-580.	1.3	14
1697	Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treatment and Research Communications, 2021, 26, 100298.	0.7	10
1698	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investigational New Drugs, 2021, 39, 860-870.	1.2	12
1699	Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110473.	1.1	1
1700	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. OncoImmunology, 2021, 10, 1878599.	2.1	11
1701	Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 2983-2994.	5.7	115
1702	Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11.	0.0	0
1703	Management of Brain Metastases. Current Cancer Research, 2021, , 115-137.	0.2	0
1704	Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. Journal of Cancer, 2021, 12, 2960-2967.	1.2	25
1705	Cost-Effectiveness of Pembrolizumab in Combination with Platinum-Based Chemotherapy in First-Line for Squamous and Nonsquamous Non Small-Cell Lung Cancer. Far from Economic Sustainability. Eurasian Journal of Medicine and Oncology, 2021, , .	1.0	0
1706	An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. Oncology, 2021, 99, 389-396.	0.9	4
1707	Activation of NF-Î¹B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	47
1708	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research, 2021, 27, 2571-2583.	3.2	22
1709	Dendritic Cell-Based Immunotherapy in Lung Cancer. Frontiers in Immunology, 2020, 11, 620374.	2.2	31
1710	Carcinoma de pulmÃ³n no microcÃ¡tico. Medicine, 2021, 13, 1377-1387.	0.0	2
1711	Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. Oncologist, 2021, 26, 269-273.	1.9	22
1712	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 544339.	1.3	18
1713	Immunotherapy in non-small cell lung cancer: advancements and challenges. Chinese Medical Journal, 2021, 134, 1135-1137.	0.9	4

#	Article	IF	Citations
1714	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics, 2020, 11, 617174.	1.1	12
1715	Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial. BMJ Supportive and Palliative Care, 2023, 13, e213-e219.	0.8	6
1716	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 198-211.	5.1	773
1717	Single-arm, open label prospective trial to assess prediction of the role ofÂERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open, 2021, 6, 100034.	2.0	0
1718	Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. BioMed Research International, 2021, 2021, 1-10.	0.9	4
1719	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 776-789.	1.3	6
1720	Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469.	1.2	3
1721	<scp>Antiâ€PD1</scp> versus <scp>antiâ€PDâ€L1</scp> immunotherapy in firstâ€line therapy for advanced nonâ€small cell lung cancer: A systematic review and metaâ€analysis. Thoracic Cancer, 2021, 12, 1058-1066.	0.8	18
1722	IMpower132: Atezolizumab plus platinumâ€based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Science, 2021, 112, 1534-1544.	1.7	24
1723	Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations. JNCI Cancer Spectrum, 2021, 5, pkab014.	1.4	0
1724	Remarkable response to pembrolizumab with platinumâ€doublet in PDâ€L1â€low pulmonary sarcomatoid carcinoma: A case report. Thoracic Cancer, 2021, 12, 1126-1130.	0.8	11
1725	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	3.2	65
1726	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, The, 2021, 397, 592-604.	6.3	441
1727	C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. PLoS ONE, 2021, 16, e0246486.	1.1	6
1728	Impact of Antiretroviral Therapy on Cancer Treatment Outcomes among People Living with HIV in Low- and Middle-Income Countries: a Systematic Review. Current HIV/AIDS Reports, 2021, 18, 105-116.	1.1	9
1729	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Nonâ€“small Cell Lung Cancer, A Collaborative Project Orbis Review. Clinical Cancer Research, 2021, 27, 3522-3527.	3.2	32
1730	Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 239-252.	0.4	3
1731	Immune checkpoint inhibitors: Significant advancements in nonâ€“small cell lung cancer treatment. American Journal of Health-System Pharmacy, 2021, 78, 769-780.	0.5	11

#	Article	IF	Citations
1732	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 109-118.	0.9	14
1733	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
1734	Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, , .	0.4	23
1735	Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review. Oncology and Therapy, 2021, 9, 41-53.	1.0	2
1736	Overall Survival With Second-Line Pembrolizumab in Patients With Nonâ€“Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data. JCO Clinical Cancer Informatics, 2021, 5, 56-65.	1.0	12
1737	Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction â€“ A case report. International Journal of Surgery Case Reports, 2021, 79, 131-134.	0.2	5
1738	Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinumâ€based doublet chemotherapy and immunotherapy (SPACE study). Thoracic Cancer, 2021, 12, 1264-1268.	0.8	1
1739	Effectiveness of a Reverse Manual for Immune-related Adverse Events. Japanese Journal of Lung Cancer, 2021, 61, 17-23.	0.0	0
1740	nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). Frontiers in Oncology, 2020, 10, 569715.	1.3	3
1741	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. International Immunopharmacology, 2021, 91, 107296.	1.7	20
1742	CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer. Lancet Oncology, The, 2021, 22, 157-159.	5.1	10
1743	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. ESMO Open, 2021, 6, 100013.	2.0	2
1744	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. , 2021, 9, e001999.		26
1745	Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Supportive Care in Cancer, 2021, 29, 4763-4772.	1.0	23
1747	Guillain-BarrÃ© Syndrome Developed as a Neurological Immune-related Adverse Event After Response to Combination Chemo-immunotherapy. Japanese Journal of Lung Cancer, 2021, 61, 24-29.	0.0	1
1748	Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. Future Oncology, 2021, 17, 597-609.	1.1	3
1749	Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	0.8	30
1750	Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer. Bioscience Reports, 2021, 41, .	1.1	19

#	Article	IF	Citations
1751	Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced nonâ€squamous nonâ€small cell lung cancer: A singleâ€arm, openâ€label, multicenter, phase II study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 486-494.	0.7	1
1752	Coâ€delivery of cisplatin and oleanolic acid by silica nanoparticlesâ€enhanced apoptosis and reverse multidrug resistance in lung cancer. Kaohsiung Journal of Medical Sciences, 2021, 37, 505-512.	0.8	9
1753	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Frontiers in Immunology, 2020, 11, 629722.	2.2	75
1754	Cancer recognition of artificial intelligence. Artificial Intelligence in Cancer, 2021, 2, 1-6.	1.1	0
1755	Incidence risk of PD-1/PD-L1â€"related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2021, 77, 1079-1088.	0.8	9
1756	Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma. Annals of Translational Medicine, 2021, 9, 339-339.	0.7	12
1757	Blood T cell diversity associated with the prognosis of advanced nonâ€small cell lung carcinoma treated with firstâ€line pemetrexed based chemotherapy. Thoracic Cancer, 2021, 12, 997-1005.	0.8	1
1758	The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma. Frontiers in Genetics, 2020, 11, 609405.	1.1	13
1759	A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol. Clinical Lung Cancer, 2021, 22, e921-e924.	1.1	3
1761	PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). Journal of Clinical Pathology, 2021, 74, 735-740.	1.0	54
1762	Establishment and validation of an eight-gene metabolicâ€"related prognostic signature model for lung adenocarcinoma. Aging, 2021, 13, 8688-8705.	1.4	6
1763	Immunotherapy in lung cancer. Journal of Surgical Oncology, 2021, 123, 718-729.	0.8	7
1764	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunology, Immunotherapy, 2021, 70, 2517-2528.	2.0	34
1765	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer, 2021, 152, 165-173.	0.9	23
1766	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Molecular Cancer, 2021, 20, 27.	7.9	54
1767	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 27-33.	0.9	35
1768	A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. European Journal of Health Economics, 2021, 22, 669-677.	1.4	15
1769	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. Cancers, 2021, 13, 1065.	1.7	5

#	Article	IF	Citations
1770	Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Frontiers in Oncology, 2021, 11, 640690.	1.3	6
1771	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. JTO Clinical and Research Reports, 2021, 2, 100142.	0.6	1
1772	Is major pathologic response sufficient to predict survival in resectable nonsmallâ€cell lung cancer patients receiving neoadjuvant chemotherapy?. Thoracic Cancer, 2021, 12, 1336-1346.	0.8	3
1774	A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers in Pharmacology, 2021, 12, 599598.	1.6	10
1775	Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia â€“ A case-based review of clinical management. Thrombosis Research, 2021, 199, 38-42.	0.8	6
1776	Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. International Journal of Clinical Oncology, 2021, 26, 1065-1072.	1.0	3
1777	Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation. Medicine (United States), 2021, 100, e19713.	0.4	5
1778	Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. Cancer Immunology, Immunotherapy, 2021, 70, 2819-2833.	2.0	8
1779	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics, 2021, 20, 975-985.	1.9	79
1780	Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review. Human Vaccines and Immunotherapeutics, 2021, 17, 2626-2629.	1.4	3
1781	Lowâ€dose pembrolizumab in the treatment of advanced nonâ€small cell lung cancer. International Journal of Cancer, 2021, 149, 169-176.	2.3	24
1782	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423.	0.7	6
1783	Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 510-522.	1.1	5
1784	Impact of PTV margin reduction (2â€¯mm to 0â€¯mm) on pseudoprogression in stereotactic radiotherapy of solitary brain metastases. Technical Innovations and Patient Support in Radiation Oncology, 2021, 17, 40-47.	0.6	3
1785	Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 625578.	1.3	8
1786	Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in nonâ€‘small cell lung cancer. Oncology Letters, 2021, 21, 365.	0.8	5
1787	Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer. Cancers, 2021, 13, 1024.	1.7	6
1788	Effect of corticosteroids on the outcome of patients with advanced nonâ€“small cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Cancer, 2021, 145, 245-254.	1.3	52

#	Article	IF	Citations
1789	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. European Urology Oncology, 2021, 4, 943-947.	2.6	11
1790	The histological diagnosis and molecular testing of lung cancer by surgical biopsy for intrathoracic lesions. General Thoracic and Cardiovascular Surgery, 2021, 69, 1185-1191.	0.4	0
1791	Neoadjuvant immunotherapy for nonâ€“small cell lung cancer: State of the art. Cancer Communications, 2021, 41, 287-302.	3.7	74
1792	Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 615967.	1.3	6
1793	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 641469.	1.8	76
1794	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	1.9	18
1795	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert Opinion on Drug Safety, 2021, 20, 537-547.	1.0	9
1798	Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy. Biomaterials, 2021, 270, 120690.	5.7	21
1799	Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/â˜L1 directed immune checkpoint inhibition.. Journal of Immunological Methods, 2021, 490, 112956.	0.6	5
1800	A Case of Stevens-Johnson Syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab. Current Problems in Cancer Case Reports, 2021, 3, 100048.	0.1	3
1801	The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors. Frontiers in Nanotechnology, 2021, 3, .	2.4	5
1803	Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. European Journal of Cancer, 2021, 145, 234-244.	1.3	9
1804	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). Anticancer Research, 2021, 41, 1123-1141.	0.5	6
1805	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine, 2021, 10, 1005.	1.0	23
1806	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. Expert Review of Anticancer Therapy, 2021, 21, 705-713.	1.1	4
1807	Rational nanocarrier design towards clinical translation of cancer nanotherapy. Biomedical Materials (Bristol), 2021, 16, 032005.	1.7	14
1808	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. JACC: CardioOncology, 2021, 3, 35-47.	1.7	80
1809	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 723-733.	0.8	329

#	Article	IF	Citations
1810	Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints. Trends in Cell Biology, 2021, 31, 224-235.	3.6	16
1811	Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. , 2021, 9, e001966.		78
1813	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 3025.	1.8	5
1814	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. Cancers, 2021, 13, 1562.	1.7	10
1815	Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers, 2021, 13, 1464.	1.7	7
1816	A combination of PDâ€'1/PDâ€'L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Molecular Medicine Reports, 2021, 23, .	1.1	16
1817	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	3.2	42
1818	Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL). BMJ Open, 2021, 11, e043234.	0.8	3
1819	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cellular Oncology (Dordrecht), 2021, 44, 261-278.	2.1	16
1820	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist, 2021, 26, 523-532.	1.9	4
1821	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for <scp>NSCLC</scp>. Cancer Reports, 2021, 4, e1368.	0.6	14
1822	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. International Journal of Clinical Oncology, 2021, 26, 1057-1064.	1.0	2
1823	Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Network Open, 2021, 4, e211136.	2.8	43
1824	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. European Journal of Medicinal Chemistry, 2021, 214, 113218.	2.6	65
1825	NCCN Guidelines Insights: Nonâ€"Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 254-266.	2.3	628
1826	The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer. Medicine (United States), 2021, 100, e25145.	0.4	3
1827	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers, 2021, 13, 1052.	1.7	5
1828	The role of immunotherapy in fusion-driven lung cancer. Expert Review of Anticancer Therapy, 2021, 21, 461-464.	1.1	3

#	Article	IF	Citations
1829	Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 2021, 11, 1353-1367.	7.7	197
1830	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3749-3755.	1.2	6
1832	DNA methylation as predictive marker of response to immunotherapy?. Memo - Magazine of European Medical Oncology, 2021, 14, 150-153.	0.3	3
1833	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 653358.	2.2	19
1834	Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer. Molecular Imaging and Biology, 2021, 23, 714-723.	1.3	16
1835	Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report. Clinical Case Reports (discontinued), 2021, 9, e03973.	0.2	2
1836	Populationâ€level changes in outcomes and Medicare cost following the introduction of new cancer therapies. Health Services Research, 2021, 56, 486-496.	1.0	3
1837	CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2021, 22, 71-73.	1.1	4
1839	Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer: Targets and Therapy, 2021, Volume 12, 21-34.	1.3	10
1840	KRAS G12C inhibition and innate immune targeting. Expert Opinion on Therapeutic Targets, 2021, 25, 1-8.	1.5	6
1841	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precision Oncology, 2021, 5, 510-524.	1.5	36
1842	Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancerâ€"A Clinicopathological Series. Frontiers in Oncology, 2021, 11, 621050.	1.3	7
1843	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Nonâ€"Small-Cell Lung Cancer After Previous Systemic Treatment Failureâ€"A Retrospective Study. Frontiers in Oncology, 2021, 11, 628124.	1.3	39
1844	Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy. Current Problems in Cancer Case Reports, 2021, 3, 100060.	0.1	0
1845	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2021, 20, 651-667.	1.0	4
1846	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 630136.	1.3	17
1847	Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report. Annals of Translational Medicine, 2021, 9, 424-424.	0.7	2
1848	Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports. Anticancer Research, 2021, 41, 1693-1699.	0.5	9

#	Article	IF	Citations
1849	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
1850	The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. BioMed Research International, 2021, 2021, 1-13.	0.9	15
1851	Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series. Frontiers in Oncology, 2021, 11, 633522.	1.3	8
1852	First-line Immunotherapy for Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2021, 61, 88-94.	0.0	0
1853	Suitability of endobronchial ultrasoundâ€guided transbronchial needle aspiration samples for programmed death ligandâ€1 testing in nonâ€small cell lung cancer, the Bristol experience. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	1
1854	Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of AdvancedÂNon-Small Cell Lung Cancer. Pakistan Journal of Medical Sciences, 2021, 37, 1036-1041.	0.3	2
1855	A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards. Statistical Methods in Medical Research, 2021, 30, 1211-1234.	0.7	3
1856	Cytomegalovirus pneumonia complicating immune checkpoint inhibitorsâ€induced pneumonitis: A case report. Molecular and Clinical Oncology, 2021, 14, 120.	0.4	3
1857	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. Frontiers in Oncology, 2021, 11, 572740.	1.3	4
1858	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 562315.	1.3	38
1859	Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 643-652.	0.5	123
1860	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. Immunotherapy, 2021, 13, 419-432.	1.0	9
1861	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. Cancer Letters, 2021, 502, 166-179.	3.2	16
1862	The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. Frontiers in Immunology, 2021, 12, 665147.	2.2	11
1863	Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial. Frontiers in Oncology, 2021, 11, 657024.	1.3	17
1864	Personalized and targeted therapies. ChemistrySelect, 2023, 8, 2103-2126.	0.7	0
1865	Malignant Pleural Effusionsâ€"A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747.	1.3	9
1867	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12

#	Article	IF	Citations
1868	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4618.	1.8	30
1869	Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer. ESMO Open, 2021, 6, 100094.	2.0	8
1870	From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy eraâ€"chemo-free or chemo-reform?. Translational Lung Cancer Research, 2021, 10, 1924-1927.	1.3	7
1871	Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. Seminars in Oncology, 2021, 48, 57-68.	0.8	5
1872	Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report. Annals of Translational Medicine, 2021, 9, 724-724.	0.7	1
1873	Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. Journal of Nanobiotechnology, 2021, 19, 110.	4.2	16
1874	Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery, 2021, 11, 1368-1397.	7.7	130
1875	Impact of Reninâ€"angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients. Anticancer Research, 2021, 41, 2093-2100.	0.5	12
1876	IMpower 132: Loses Power at the Finish Line. Journal of Thoracic Oncology, 2021, 16, 512-514.	0.5	0
1877	Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Molecular Cancer, 2021, 20, 62.	7.9	76
1878	Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax, 2021, 76, 1150-1153.	2.7	4
1879	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. Annals of Translational Medicine, 2021, 9, 648-648.	0.7	2
1880	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Nonâ€"Small Cell Lung Cancer. Cancer Research, 2021, 81, 3295-3308.	0.4	51
1881	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	0.5	13
1882	Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it. ESMO Open, 2021, 6, 100095.	2.0	8
1883	Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nature Communications, 2021, 12, 2425.	5.8	75
1884	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression â‰¥ 50%: Selecting the best strategy. Critical Reviews in Oncology/Hematology, 2021, 160, 103302.	2.0	18
1885	PD-L1 â‰¥Â50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination. Immunotherapy, 2021, 13, 363-369.	1.0	3

#	Article	IF	Citations
1886	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy, 2021, 13, 509-525.	1.0	3
1887	Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 149-154.	1.0	1
1888	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. JTO Clinical and Research Reports, 2021, 2, 100150.	0.6	2
1889	Tracking Cancer Evolution through the Disease Course. Cancer Discovery, 2021, 11, 916-932.	7.7	77
1890	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 2429-2438.	2.0	10
1891	Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Pathology and Oncology Research, 2021, 27, 597499.	0.9	2
1892	Targeting rare and non-canonical driver variants in NSCLC â€“ An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	0.9	8
1893	"Present and future of immunotherapy in Neuroendocrine Tumors". Reviews in Endocrine and Metabolic Disorders, 2021, 22, 615-636.	2.6	21
1894	The Next Decade of Immune Checkpoint Therapy. Cancer Discovery, 2021, 11, 838-857.	7.7	363
1895	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery, 2021, 11, 874-899.	7.7	107
1896	Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Translational Lung Cancer Research, 2021, 10, 1642-1652.	1.3	11
1897	Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. Scientific Reports, 2021, 11, 9222.	1.6	35
1898	Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study. Annals of Translational Medicine, 2021, 9, 685-685.	0.7	10
1899	Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2141.	1.7	11
1900	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. British Journal of Cancer, 2021, 125, 313-323.	2.9	29
1901	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 271-280.	0.4	0
1902	Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Reports, 2021, 3, 100224.	2.6	12
1903	Factors affecting survival after palliative radiotherapy in patients with lung cancer. Reports of Practical Oncology and Radiotherapy, 2021, 26, 674-682.	0.3	0

#	Article	IF	Citations
1904	Synergistic Chemo-thermal Therapy of Cancer by DNA-Templated Silver Nanoclusters and Polydopamine Nanoparticles. ACS Applied Materials & Interfaces, 2021, 13, 21653-21660.	4.0	29
1905	Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy. Nuclear Medicine Communications, 2021, 42, 1017-1023.	0.5	3
1906	Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature, 2021, 592, 629-633.	13.7	115
1907	A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies. Expert Opinion on Biological Therapy, 2021, 21, 1237-1251.	1.4	3
1908	Immune-checkpoint inhibitor toxicity during a pandemic: Overcoming patient fears to provide care. A case report. Journal of Oncology Pharmacy Practice, 2021, , 107815522110127.	0.5	4
1909	Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy. International Journal of Neuroscience, 2023, 133, 186-193.	0.8	6
1910	Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 645352.	1.3	2
1911	A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer, 2021, 21, 441.	1.1	25
1912	Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis. Cancers, 2021, 13, 2046.	1.7	13
1913	What a general practitioner should know about bronchogenic carcinoma. MedicÃna Pro Praxi, 2021, 18, 63-67.	0.0	0
1914	A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy. Translational Lung Cancer Research, 2021, 10, 1690-1699.	1.3	2
1915	Resistance mechanisms to checkpoint inhibitors. Current Opinion in Immunology, 2021, 69, 47-55.	2.4	19
1916	Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. Oncologist, 2021, 26, 694-700.	1.9	5
1917	Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439.	1.1	17
1918	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer, 2021, 154, 151-160.	0.9	25
1919	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. Lancet Oncology, The, 2021, 22, 415-417.	5.1	3
1920	Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 670313.	1.3	9
1921	Cancer neoantigens as potential targets for immunotherapy. Clinical and Experimental Metastasis, 2022, 39, 51-60.	1.7	24

#	Article	IF	Citations
1922	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. Cancers, 2021, 13, 2225.	1.7	21
1923	Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis. Journal of Thoracic Disease, 2021, 13, 2959-2967.	0.6	2
1924	Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapy. Journal of Oncology Pharmacy Practice, 2021, 27, 2057-2060.	0.5	1
1925	Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. Cancers, 2021, 13, 2365.	1.7	11
1926	PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori, 2022, 108, 47-55.	0.6	8
1927	Association of Dynamic Changes inÂPeripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 672271.	2.2	21
1928	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2021, 7, 709.	3.4	185
1929	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol. The Cochrane Library, 0, , .	1.5	0
1930	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut, 2022, 71, 734-745.	6.1	177
1931	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncology, The, 2021, 22, 824-835.	5.1	191
1932	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Frontiers in Oncology, 2021, 11, 621639.	1.3	12
1933	Current advances in the treatment of lung cancer with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 333-341.	0.1	0
1934	Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report. JTO Clinical and Research Reports, 2021, 2, 100156.	0.6	6
1935	Mast Cells: A New Frontier for Cancer Immunotherapy. Cells, 2021, 10, 1270.	1.8	59
1936	Toxicities of Immunotherapy for Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 603658.	1.3	6
1937	Clinical Insights Into Novel Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 681320.	1.6	76
1938	Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases. Translational Cancer Research, 2021, 10, 2527-2536.	0.4	1
1939	Tâ€cell response to phytohemagglutinin in the interferonâ€Î³ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1726-1734.	0.8	5

#	Article	IF	Citations
1940	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2111113.	2.8	17
1941	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
1942	Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications. Frontiers in Oncology, 2021, 11, 648687.	1.3	29
1943	Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy. Journal of the American Chemical Society, 2021, 143, 8391-8401.	6.6	64
1944	The prognostic value of weight and body composition changes in patients with nonâ€smallâ€cell lung cancer treated with nivolumab. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 657-664.	2.9	18
1945	Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nature Communications, 2021, 12, 2540.	5.8	295
1946	Beyond PACIFIC: Uncharted Waters. Journal of Thoracic Oncology, 2021, 16, 715-718.	0.5	0
1947	Sarcoidâ€like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab. Thoracic Cancer, 2021, 12, 2122-2125.	0.8	6
1949	Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study. Frontiers in Oncology, 2021, 11, 652312.	1.3	9
1950	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targeted Oncology, 2021, 16, 425-434.	1.7	16
1951	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)â€"insights of people affected by cancer and healthcare professionals: a qualitative study protocol. BMJ Open, 2021, 11, e043750.	0.8	3
1952	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Frontiers in Immunology, 2021, 12, 663986.	2.2	50
1953	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	1.7	2
1954	Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. Advances in Oncology, 2021, 1, 73-84.	0.1	0
1955	Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Translational Lung Cancer Research, 2021, 10, 2148-2162.	1.3	19
1956	Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2352.	1.7	15
1957	Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment. Cancer Management and Research, 2021, Volume 13, 4041-4053.	0.9	11
1958	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Frontiers in Oncology, 2021, 11, 635007.	1.3	76

#	Article	IF	Citations
1959	Role of immunotherapy in oligometastatic nonsmall cell lung cancer. BMJ Case Reports, 2021, 14, e241070.	0.2	1
1960	PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. Anticancer Research, 2021, 41, 2501-2509.	0.5	1
1961	Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. Anticancer Research, 2021, 41, 2597-2603.	0.5	0
1962	Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report. Medicina (Lithuania), 2021, 57, 547.	0.8	0
1963	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	1
1964	Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis. Aging, 2021, 13, 12691-12709.	1.4	1
1965	IMpower 132: Is the Second Exception to the Rule No Longer an Exception?. Journal of Thoracic Oncology, 2021, 16, e29-e30.	0.5	2
1966	Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 904-909.	1.5	1
1967	A brand new era of cancer immunotherapy: breakthroughs and challenges. Chinese Medical Journal, 2021, 134, 1267-1275.	0.9	15
1968	Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. JTO Clinical and Research Reports, 2021, 2, 100147.	0.6	3
1969	Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 3315-3322.	0.6	11
1970	Nanoparticle-based approaches to target the lymphatic system for antitumor treatment. Cellular and Molecular Life Sciences, 2021, 78, 5139-5161.	2.4	17
1971	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Lung Cancer, 2021, 155, 53-60.	0.9	8
1972	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrology Dialysis Transplantation, 2021, , .	0.4	1
1973	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2021, 155, 28-33.	0.9	18
1974	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers, 2021, 13, 2638.	1.7	32
1975	A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 662302.	1.3	10
1976	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology, 2021, 18, 558-576.	12.5	202

#	Article	IF	Citations
1977	Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/â^'bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison. Lung Cancer, 2021, 155, 175-182.	0.9	11
1978	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist, 2021, 26, e1226-e1239.	1.9	17
1979	Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Seminars in Ultrasound, CT and MRI, 2021, 42, 552-562.	0.7	0
1980	Harnessing Genomic Stress for Antitumor Immunity. Antioxidants and Redox Signaling, 2021, 34, 1128-1150.	2.5	5
1981	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology, 2021, 96-97, 101-111.	0.3	10
1982	Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Journal of Thoracic Disease, 2021, 13, 2824-2832.	0.6	9
1983	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
1984	Multiplex immune protein profiling of fineâ€needle aspirates from patients with nonâ€smallâ€cell lung cancer reveals signatures associated with PDâ€L1 expression and tumor stage. Molecular Oncology, 2021, 15, 2941-2957.	2.1	8
1985	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. European Journal of Cancer, 2021, 149, 49-60.	1.3	1
1986	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectrum, 2021, 5, pkab048.	1.4	23
1987	Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , .		0
1988	Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101.	2.0	8
1989	Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2021, 156, 59-67.	0.9	7
1990	Classification of Non-Small Cell Lung Cancerâ€™s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers, 2021, 13, 2924.	1.7	18
1991	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	3.4	31
1992	Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 387-398.	2.0	16
1993	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer, 2021, 21, 731.	1.1	4
1994	Post-immunotherapy imaging in lung cancer. Clinical Radiology, 2022, 77, 44-57.	0.5	3

#	Article	IF	Citations
1995	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers, 2021, 13, 2935.	1.7	13
1996	Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. , 2021, 9, e002118.		75
1997	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers, 2021, 13, 3083.	1.7	9
1998	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
1999	Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. Translational Lung Cancer Research, 2021, 10, 2509-2522.	1.3	13
2000	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2021, 113, 1761-1769.	3.0	27
2001	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naÃ¯ve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. European Journal of Cancer, 2021, 150, 63-72.	1.3	20
2002	Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges. Cancer Communications, 2021, 41, 830-850.	3.7	42
2003	Pembrolizumab plus pemetrexedâ€platinum for metastatic nonsquamous nonâ€“smallâ€cell lung cancer: KEYNOTEâ€189 Japan Study. Cancer Science, 2021, 112, 3255-3265.	1.7	26
2004	Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. Lung Cancer Management, 2021, 10, LMT44.	1.5	3
2005	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Critical Reviews in Oncology/Hematology, 2021, 162, 103351.	2.0	24
2006	Association of immuneâ€related pneumonitis with clinical benefit of antiâ€programmed cell deathâ€1 monotherapy in advanced nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 4796-4804.	1.3	13
2007	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. Drugs, 2021, 81, 971-984.	4.9	5
2008	Precise medicine of programmed cell death-1/programmed cell death 1 ligand 1 inhibitor immunotherapy combined radiotherapy for inoperable advanced lung cancer. Medicine (United States), 2021, 100, e26367.	0.4	0
2009	Sociodemographic disparities in the management of advanced lung cancer: a narrative review. Journal of Thoracic Disease, 2021, 13, 3772-3800.	0.6	14
2010	B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Immunology, 2021, 164, 507-523.	2.0	30
2011	Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?. Translational Lung Cancer Research, 2021, 10, 2868-2875.	1.3	1
2012	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. Translational Lung Cancer Research, 2021, 10, 2441-2451.	1.3	19

#	Article	IF	Citations
2013	The dark side of immunotherapy. Annals of Translational Medicine, 2021, 9, 1041-1041.	0.7	12
2014	The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Annals of Translational Medicine, 2021, 9, 1034-1034.	0.7	21
2015	Barriers to antibody therapy in solid tumors, and their solutions. Cancer Science, 2021, 112, 2939-2947.	1.7	13
2016	High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Science, 2021, 112, 3314-3323.	1.7	15
2017	Advances in Immunotherapy and Implications for Current Practice in Nonâ€“Small-Cell Lung Cancer. JCO Oncology Practice, 2021, 17, 662-668.	1.4	14
2018	Crizotinib in Patients With MET-Amplified NSCLC. Journal of Thoracic Oncology, 2021, 16, 1017-1029.	0.5	84
2019	Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine, 2021, 384, 2371-2381.	13.9	833
2020	PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. Frontiers in Oncology, 2021, 11, 648068.	1.3	13
2021	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics, 2021, 13, 912.	2.0	2
2022	Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient. Thoracic Cancer, 2021, 12, 2217-2220.	0.8	4
2023	When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine, 2022, 27, 151-152.	1.7	1
2024	Immunotherapy for Advanced Nonâ€“Small Cell Lung Cancer: A Decade of Progress. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e105-e127.	1.8	67
2025	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging, 2021, 13, 15413-15432.	1.4	9
2026	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS ONE, 2021, 16, e0252537.	1.1	20
2027	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. Frontiers in Oncology, 2021, 11, 690093.	1.3	5
2028	Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. BMC Cancer, 2021, 21, 689.	1.1	2
2029	Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. Frontiers in Oncology, 2021, 11, 634920.	1.3	7
2030	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 2021, 28, 2173-2179.	0.9	14

#	Article	IF	Citations
2031	Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients. Journal of Molecular Pathology, 2021, 2, 197-206.	0.5	2
2032	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 639745.	1.3	9
2033	Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 â‰¥50%: Results of a Retrospective Study. Frontiers in Oncology, 2021, 11, 691519.	1.3	4
2034	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Translational Lung Cancer Research, 2021, 10, 2970-2987.	1.3	11
2035	Pleural effusions associated with squamous cell lung carcinoma have a low diagnostic yield and a poor prognosis. Translational Lung Cancer Research, 2021, 10, 2500-2508.	1.3	4
2036	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2937-2954.	1.3	19
2037	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 703893.	1.3	33
2038	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open, 2021, 6, 100124.	2.0	75
2039	Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy, 2021, Volume 12, 51-60.	1.3	8
2040	Real-world outcomes of immunotherapyâ€“based regimens in first-line advanced non-small cell lung cancer. Lung Cancer, 2021, 156, 41-49.	0.9	66
2041	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers, 2021, 13, 3164.	1.7	35
2042	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 2021, 13, 727-734.	1.0	11
2043	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology, Immunotherapy, 2022, 71, 267-276.	2.0	2
2045	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. European Journal of Cancer, 2021, 150, 168-178.	1.3	11
2046	Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. Journal of Cancer Policy, 2021, 28, 100279.	0.6	3
2047	Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. BMC Medical Informatics and Decision Making, 2021, 21, 205.	1.5	15
2048	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chinese Medical Journal, 2021, 134, 1780-1788.	0.9	7
2049	Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2022, 23, 95-107.	1.1	18

#	Article	IF	Citations
2050	First-Line Treatment Options for PD-L1â€“Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 657545.	1.3	6
2051	Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine, 2021, 9, 1040-1040.	0.7	3
2052	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778.	1.3	9
2053	Lung cancer and the immune systemâ€”current controversies and future opportunities. Translational Lung Cancer Research, 2021, 10, 2733-2735.	1.3	0
2054	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. Translational Lung Cancer Research, 2021, 10, 2917-2936.	1.3	18
2055	ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunology, Immunotherapy, 2022, 71, 219-228.	2.0	5
2056	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy, 2021, 70, 3337-3348.	2.0	16
2057	Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer. Disease Markers, 2021, 2021, 1-10.	0.6	13
2058	Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 3949-3958.	1.0	0
2059	Introductory Chapter: Recent Progress in Lung Cancer Treatment - The Value of Multiple Perspectives. , 0, , .		0
2060	DNA Nanotechnologyâ€Based Biosensors and Therapeutics. Advanced Healthcare Materials, 2021, 10, e2002205.	3.9	51
2061	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews Clinical Oncology, 2021, 18, 625-644.	12.5	148
2062	Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 662731.	1.3	10
2063	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. Cancers, 2021, 13, 2950.	1.7	12
2064	Clinical outcomes of nonâ€“small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer, 2021, 150, 23-30.	1.3	11
2065	Interrelations between Patientsâ€™ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Cancers, 2021, 13, 3249.	1.7	9
2066	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	2.1	9
2067	The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Nonâ€“Small Cell Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 702924.	1.3	6

#	Article	IF	Citations
2068	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. The Lancet Regional Health - Western Pacific, 2021, 11, 100151.	1.3	13
2069	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. Frontiers in Oncology, 2021, 11, 679331.	1.3	4
2070	Coordination and Redox Dualâ€Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy. Small, 2021, 17, e2100006.	5.2	40
2071	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
2072	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2021, 22, 72.	1.3	9
2073	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 3014-3028.	1.3	9
2074	A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD). Cancer Cell International, 2021, 21, 294.	1.8	18
2075	Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future Science OA, 2021, 7, FSO691.	0.9	4
2076	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. Cancers, 2021, 13, 3020.	1.7	11
2077	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 4566-4573.	3.2	13
2078	Exploring the immune-checkpoint inhibitorsâ€™ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease. Translational Lung Cancer Research, 2021, 10, 2876-2889.	1.3	2
2079	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics, 2021, 11, 1195.	1.3	9
2080	Integrated transcriptionalâ€phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Clinical and Translational Medicine, 2021, 11, e434.	1.7	3
2081	Identification of an immune signature to predict poor clinical outcome in cervical cancer. Epigenomics, 2021, 13, 891-907.	1.0	2
2082	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 69.	1.3	16
2083	Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced nonâ€“small cell lung cancer treated with first-line pembrolizumab. European Journal of Cancer, 2021, 150, 99-107.	1.3	36
2084	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	3.5	3
2086	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1â€“Selected NSCLC. Journal of Thoracic Oncology, 2021, 16, 1872-1882.	0.5	85

#	Article	IF	Citations
2087	The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study. Frontiers in Oncology, 2021, 11, 671127.	1.3	2
2088	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncology, 2021, 17, 3965-3976.	1.1	6
2089	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer, 2021, 157, 21-29.	0.9	8
2090	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. European Journal of Cancer, 2021, 151, 211-220.	1.3	24
2091	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415.	1.7	15
2092	Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies. Cancers, 2021, 13, 3819.	1.7	23
2093	Local Ablative Therapy in Oligometastatic NSCLC. Seminars in Radiation Oncology, 2021, 31, 235-241.	1.0	1
2094	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Annals of Oncology, 2021, 32, 881-895.	0.6	213
2095	IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 1909-1924.	0.5	212
2096	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology, 2021, 39, 2327-2338.	0.8	146
2097	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targeted Oncology, 2021, 16, 553-568.	1.7	13
2098	Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel. Immunotherapy, 2021, 13, 851-861.	1.0	2
2099	Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction. Clinical Lung Cancer, 2021, , .	1.1	4
2100	Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy. Current Treatment Options in Oncology, 2021, 22, 77.	1.3	6
2101	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. Clinical Lung Cancer, 2021, 22, 483-499.	1.1	11
2102	Neoadjuvant immunochemotherapy in surgically resectable non-small-cell lung cancer: surgical expertise required. European Journal of Cardio-thoracic Surgery, 2021, 60, 88-90.	0.6	2
2103	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 707198.	1.8	17
2104	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology, 2021, 14, 101102.	1.7	8

#	Article	IF	Citations
2105	A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 268-273.	1.1	16
2106	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	1.3	23
2107	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR). Translational Lung Cancer Research, 2021, 10, 3059-3070.	1.3	2
2108	Combination of pembrolizumab with radiotherapy can change treatment paradigm in metastatic â€œnonâ€driverâ€•nonâ€smallâ€•cell lung cancer: Assembling a path. Clinical Respiratory Journal, 2021, 15, 1139-1144.	0.6	1
2109	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers, 2021, 13, 3633.	1.7	10
2111	Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy. Seminars in Cancer Biology, 2022, 86, 732-742.	4.3	23
2112	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3351-3368.	1.3	1
2113	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2021, 10, 3420-3431.	1.3	5
2114	Immunotherapy in Older Adults With Cancer. Journal of Clinical Oncology, 2021, 39, 2115-2127.	0.8	33
2115	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Frontiers in Pharmacology, 2021, 12, 640099.	1.6	3
2116	Feasibility and reliability of evaluate PDâ€L1 expression determination using small biopsy specimens in nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 2339-2344.	0.8	6
2117	ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight, 2021, 6, .	2.3	4
2118	Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Seminars in Radiation Oncology, 2021, 31, 217-226.	1.0	2
2119	Immunotherapy in ovarian cancer: we are not there yet. Lancet Oncology, The, 2021, 22, 903-905.	5.1	16
2120	First-in-Humans Evaluation of a PD-L1â€“Binding Peptide PET Radiotracer in Nonâ€“Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 536-542.	2.8	56
2121	Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMABÂ® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. Molecular Imaging and Biology, 2021, 23, 914-928.	1.3	3
2122	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. Journal of Thoracic Oncology, 2021, 16, 1883-1892.	0.5	93
2123	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cellular and Molecular Immunology, 2022, 19, 46-58.	4.8	39

#	Article	IF	Citations
2124	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncology, 2021, 17, 2593-2603.	1.1	14
2125	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	0.6	11
2126	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus, 2021, 13, e16266.	0.2	4
2127	Hypoxia in Lung Cancer Management: A Translational Approach. Cancers, 2021, 13, 3421.	1.7	17
2128	Role of NRF2 in Lung Cancer. Cells, 2021, 10, 1879.	1.8	35
2129	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2021, 16, 1086-1098.	0.5	53
2130	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	48
2131	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
2132	Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology. Clinical Lung Cancer, 2021, , .	1.1	10
2133	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Scientific Reports, 2021, 11, 15312.	1.6	15
2134	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. International Immunopharmacology, 2021, 96, 107594.	1.7	11
2135	Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 7154.	1.8	5
2136	Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report. Case Reports in Oncology, 2021, 14, 1124-1133.	0.3	3
2137	Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Nonâ€“Small Cell Lung Cancer: Results From a Phase 1b Trial. Clinical Lung Cancer, 2022, 23, 273-281.	1.1	6
2138	Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. Translational Lung Cancer Research, 2021, 10, 3191-3202.	1.3	10
2139	Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. Frontiers in Oncology, 2021, 11, 685320.	1.3	3
2140	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. Frontiers in Oncology, 2021, 11, 676732.	1.3	14
2141	The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 667650.	1.3	8

#	Article	IF	Citations
2142	The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade. PLoS ONE, 2021, 16, e0253864.	1.1	3
2144	Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development. Contemporary Clinical Trials, 2021, 106, 106434.	0.8	7
2145	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2â˜' negative breast cancer. Breast Cancer Research and Treatment, 2021, 189, 1-13.	1.1	3
2146	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death and Disease, 2021, 12, 713.	2.7	29
2147	Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 1034-1046.	5.1	171
2148	Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. British Journal of Cancer, 2021, 125, 948-954.	2.9	11
2149	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Nonâ€“Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score â‰¥ 50%. Journal of Clinical Oncology, 2021, 39, 2339-2349.	0.8	468
2150	Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533.	0.8	0
2151	Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer. Food Science and Technology, 0, 42, .	0.8	0
2152	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. Journal of Thoracic Oncology, 2021, 16, 1952-1958.	0.5	32
2153	Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers, 2021, 13, 3797.	1.7	2
2154	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	1.3	22
2155	Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer. Cancer Immunology, Immunotherapy, 2022, 71, 637-644.	2.0	23
2156	Local ablative therapies in oligometastatic NSCLC-upfront or outback?â€"a narrative review. Translational Lung Cancer Research, 2021, 10, 3446-3456.	1.3	7
2157	Update on recent key publications in lung oncology: picking up speed. European Respiratory Review, 2021, 30, 200300.	3.0	1
2158	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. Clinical Lung Cancer, 2021, 22, 282-291.e6.	1.1	12
2159	Inhibitors of immune checkpointsâ€"PD-1, PD-L1, CTLA-4â€"new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer and Metastasis Reviews, 2021, 40, 949-982.	2.7	72
2160	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist, 2021, 26, e1786-e1799.	1.9	52

#	Article	IF	Citations
2161	Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vsÂHistological Specimens. Chest, 2021, 160, 743-753.	0.4	10
2162	Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients. Radiologia Medica, 2021, 126, 1425-1433.	4.7	34
2163	Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 627016.	1.3	7
2164	Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer. Clinical and Translational Oncology, 2022, 24, 379-387.	1.2	8
2165	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. Current Oncology Reports, 2021, 23, 119.	1.8	4
2166	Immune Checkpoint Inhibitors in the Aged. Current Oncology Reports, 2021, 23, 115.	1.8	3
2167	The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100990.	3.2	34
2168	Effects of LncRNA MEG3 on immunity and autophagy of non-small cell lung carcinoma through IDO signaling pathway. World Journal of Surgical Oncology, 2021, 19, 244.	0.8	12
2169	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Scientific Reports, 2021, 11, 16122.	1.6	13
2170	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology, 2021, 32, 1332-1347.	0.6	227
2171	Lung cancer. Lancet, The, 2021, 398, 535-554.	6.3	896
2172	The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell International, 2021, 21, 454.	1.8	19
2173	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2021, 398, 759-771.	6.3	642
2174	Prognostic significance of programmed cell deathâ€ligand 1 expression on circulating tumor cells in various cancers: A systematic review and metaâ€analysis. Cancer Medicine, 2021, 10, 7021-7039.	1.3	13
2175	Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Nonâ€“Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 915-921.	2.3	27
2176	Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. Future Oncology, 2021, 17, 2940-2949.	1.1	11
2177	Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. Chinese Medical Journal, 2021, 134, 1908-1919.	0.9	2
2178	Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine, 2021, 27, 1345-1356.	15.2	338

#	Article	IF	Citations
2179	Phase 1, pharmacogenomic, doseâ€expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1â€deficient nonâ€squamous nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 6642-6652.	1.3	11
2180	Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 672233.	1.6	9
2181	Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 685047.	1.3	2
2182	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. Diagnostics, 2021, 11, 1452.	1.3	5
2183	Immunotherapy for Metastatic Nonâ€Small Cell Lung Cancer: Realâ€World Data from an Academic Central and Eastern European Center. Oncologist, 2021, 26, e2143-e2150.	1.9	12
2184	Expression of immune checkpoint PDâ€1 in nonâ€small cell lung cancer is associated with tumor cell DNAâ€dependent protein kinase. Molecular and Clinical Oncology, 2021, 15, 211.	0.4	6
2185	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	12.8	150
2186	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Scientific Reports, 2021, 11, 17324.	1.6	24
2187	Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. Oncologist, 2021, 26, e2090-e2093.	1.9	5
2188	Estrogen Receptor ÃŸ in Cancer: To ÃŸ(e) or not to ÃŸ(e)?. Endocrinology, 2021, 162, .	1.4	8
2189	Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 731546.	2.2	13
2190	Tumorâ€associated macrophages (<scp>TAMs</scp>)â€derived osteopontin (<scp>OPN</scp>) upregulates <scp>PDâ€L1</scp> expression and predicts poor prognosis in nonâ€small cell lung cancer (<scp>NSCLC</scp>). Thoracic Cancer, 2021, 12, 2698-2709.	0.8	20
2191	The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1721-1735.	1.2	3
2192	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 4035.	1.7	18
2193	Immunotherapy in elderly patients. Meditsinskiy Sovet, 2021, , 26-32.	0.1	0
2195	A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 512-518.	0.6	1
2196	PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis. Future Oncology, 2021, 17, 4415-4424.	1.1	6
2197	Real-world treatment patterns and outcomes in PD-L1-positive non-smallÂcell lung cancer. Immunotherapy, 2021, 13, 1521-1533.	1.0	7

#	Article	IF	Citations
2198	Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	1
2199	Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA nonâ€“small-cell lung cancer: a case report. Anti-Cancer Drugs, 2022, 33, e784-e788.	0.7	2
2200	Concurrent use of nivolumab and radiotherapy for patients with metastatic nonâ€‘small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. Molecular and Clinical Oncology, 2021, 15, 214.	0.4	1
2201	Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer. Immunotherapy, 2021, 13, 893-904.	1.0	19
2202	Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Annals of Oncology, 2021, 32, 1391-1399.	0.6	32
2203	Does denosumab offer survival benefits? â€"Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. Journal of Thoracic Disease, 2021, 13, 4668-4677.	0.6	8
2204	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. Journal of Clinical Medicine, 2021, 10, 3744.	1.0	11
2205	Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Critical Reviews in Oncology/Hematology, 2021, 164, 103417.	2.0	18
2206	Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 2139-2143.	0.5	15
2208	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Cancer Discovery, 2022, 12, 47-61.	7.7	58
2209	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	5
2210	Determining the optimal PDâ€1/PDâ€L1 inhibitors for the firstâ€line treatment of nonâ€smallâ€cell lung cancer with highâ€level PDâ€L1 expression in China. Cancer Medicine, 2021, 10, 6344-6353.	1.3	9
2211	Predictive Role of Prior Radiotherapy and Immunotherapy-Related Adverse Effects in Advanced NSCLC Patients Receiving Anti-PD-1/L1 Therapy. Journal of Clinical Medicine, 2021, 10, 3719.	1.0	2
2212	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. Pharmacoeconomics, 2021, 39, 1429-1442.	1.7	10
2213	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
2214	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451.	0.8	97
2215	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Journal of Thoracic Oncology, 2021, 16, 2109-2120.	0.5	75
2216	Predicted outcomes of subdividing M1-stage metastatic lung cancer based on the prognosis and the response to local consolidative therapy. Annals of Translational Medicine, 2021, 9, 1293-1293.	0.7	0

#	Article	IF	Citations
2217	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. Lung Cancer, 2021, 158, 74-84.	0.9	8
2218	Efficacy of immunotherapy inKRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy, 2021, 13, 941-952.	1.0	14
2219	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843.	1.1	5
2220	Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1. ESMO Open, 2021, 6, 100198.	2.0	6
2221	Initial rapidity of tumor growth as a prognostic factor for the therapeutic effect of immune-checkpoint inhibitors in patients with non-small cell lung cancer: evaluation for linear and non-linear correlation. Journal of Thoracic Disease, 2021, 13, 4903-4914.	0.6	0
2222	Immunotherapy for locally advanced non-small cell lung cancer: current evidence and future perspectives. Current Challenges in Thoracic Surgery, 0, 3, 25-25.	0.2	0
2223	Viral Infection and Lung Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 577514.	1.3	1
2224	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Immunotherapy, 2021, 13, 1031-1051.	1.0	14
2225	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression â‰¥50%. Future Oncology, 2021, 17, 3007-3016.	1.1	6
2226	Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 703143.	1.3	23
2227	The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. BMC Cancer, 2021, 21, 968.	1.1	12
2228	The best regimens for chemo-naÃ¯ve incurable non-squamous non- small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1â€“49%: a network meta-analysis. Translational Lung Cancer Research, 2021, 10, 3550-3566.	1.3	4
2229	Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab. CEN Case Reports, 2021, , 1.	0.5	2
2230	Challenges of Immunotherapy in Stage IV Nonâ€“Small-Cell Lung Cancer. JCO Oncology Practice, 2021, 17, 465-471.	1.4	6
2231	Clinical cases of pembrolisumab immunotherapy treatment in patients with non-small lung cancer with high level of PD-L1 expression in fist line therapy. Medical Alphabet, 2021, , 8-11.	0.0	0
2232	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. Frontiers in Oncology, 2021, 11, 704336.	1.3	29
2233	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
2234	Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2021, 22, 91.	1.3	10

#	Article	IF	Citations
2235	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Science Translational Medicine, 2021, 13, .	5.8	44
2236	Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Biomarkers in Medicine, 2021, 15, 1123-1130.	0.6	6
2237	Perforated appendicitis induced by pembrolizumab. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	5
2238	Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. Journal of Geriatric Oncology, 2021, 12, 1104-1106.	0.5	0
2239	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1597-1607.	0.6	47
2240	Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Patients With Colon Cancer and to Assist in Immunotherapy. Frontiers in Genetics, 2021, 12, 726387.	1.1	5
2242	The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 732214.	1.3	11
2243	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2437-2446.	1.2	4
2244	Immune checkpoint inhibitors for firstâ€line treatment of advanced nonâ€smallâ€cell lung cancer: A systematic review and network metaâ€analysis. Thoracic Cancer, 2021, 12, 2873-2885.	0.8	10
2245	Perspectives on the Treatment of Malignant Pleural Mesothelioma. New England Journal of Medicine, 2021, 385, 1207-1218.	13.9	71
2246	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 361-375.	0.4	22
2247	Etomidate inhibits cell proliferation and induces apoptosis in A549 nonâ€‘small cell lung cancer cells via downregulating WWP2. Experimental and Therapeutic Medicine, 2021, 22, 1254.	0.8	12
2248	Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor. Molecular Oncology, 2021, 15, 2958-2968.	2.1	5
2249	Firstâ€line chemotherapy or in combination with programmed cell death proteinâ€1 antibody in patients with metastatic or recurrent biliary tract cancer. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	2
2251	PDâ€L1 heterogeneity in patients with nonâ€“small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	2
2252	Characterization of KRAS Mutation Subtypes in Nonâ€“small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 2577-2584.	1.9	66
2254	Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression. Frontiers in Oncology, 2021, 11, 643503.	1.3	2
2255	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. Nature Medicine, 2021, 27, 1512-1513.	15.2	5

#	Article	IF	Citations
2256	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1â€"Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. Journal of Personalized Medicine, 2021, 11, 914.	1.1	2
2257	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer, 2021, 159, 45-55.	0.9	23
2258	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology, 2022, 237, 346-372.	2.0	13
2259	Therapeutic Rigid Bronchoscopy Intervention for Malignant Central Airway Obstruction Improves Performance Status to Allow Systemic Treatment. Journal of Bronchology and Interventional Pulmonology, 2022, 29, 93-98.	0.8	2
2260	Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients. Translational Lung Cancer Research, 2021, 10, 3807-3822.	1.3	11
2261	A Phase 1â€"2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 1559-1569.	0.5	41
2262	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers, 2021, 13, 4705.	1.7	86
2263	Palm Pustules Induced by Pemetrexed. Journal of Thoracic Oncology, 2021, 16, 1589-1591.	0.5	1
2264	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037895.	2.9	24
2265	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life, 2021, 11, 1029.	1.1	8
2266	Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features. Histopathology, 2021, 79, 1051-1060.	1.6	4
2267	TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 716710.	2.2	11
2268	Metabolic Modifications, Inflammation, and Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 703681.	1.3	8
2269	PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Advances, 2021, 5, 5086-5097.	2.5	16
2270	Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report. Clinical Lung Cancer, 2021, 22, e708-e711.	1.1	0
2271	Biomarkers of Immune Checkpoint Inhibitors in Nonâ€"Small Cell Lung Cancer: Beyond PD-L1. Clinical Lung Cancer, 2021, 22, 381-389.	1.1	4
2272	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1523-1532.	0.5	57
2273	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. JAMA Oncology, 2021, 7, 1368.	3.4	57

#	Article	IF	Citations
2274	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. , 0, , .		10
2275	Camrelizumab plus oxaliplatinâ€based chemotherapy as firstâ€line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer, 2021, 149, 1944-1954.	2.3	32
2276	Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future. Annals of Oncology, 2021, 32, 1075-1076.	0.6	2
2277	Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report. Clinical Lung Cancer, 2021, 22, e734-e737.	1.1	0
2278	PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Nonâ€“small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2021, 22, 423-431.	1.1	34
2279	Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review. Advances in Medical Sciences, 2021, 66, 381-387.	0.9	5
2280	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
2281	Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy. Internal Medicine, 2021, 60, 3009-3013.	0.3	1
2282	Sintilimab plus Bronchial Arterial Infusion Chemotherapy/Drug-Eluting Embolic Chemoembolization for Advanced Nonâ€“Small Cell Lung Cancer: A Preliminary Study of 10 Patients. Journal of Vascular and Interventional Radiology, 2021, 32, 1679-1687.	0.2	8
2283	Winds From the ORIENT: New Data to Inform RATIONAL Choice?. Journal of Thoracic Oncology, 2021, 16, 1434-1436.	0.5	0
2284	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Scientific Reports, 2021, 11, 18174.	1.6	15
2285	CauchyCP: A powerful test under non-proportional hazards using Cauchy combination of change-point Cox regressions. Statistical Methods in Medical Research, 2021, 30, 096228022110370.	0.7	1
2286	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma. JAMA - Journal of the American Medical Association, 2021, 326, 916.	3.8	310
2287	Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon, 2021, 7, e07916.	1.4	4
2288	Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations. Frontiers in Oncology, 2021, 11, 752545.	1.3	3
2289	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10
2290	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	1.7	6
2291	Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1137-1147.	0.6	94

#	Article	IF	Citations
2292	The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression. Clinical Lung Cancer, 2021, 22, 432-440.	1.1	16
2293	Gold Compounds and the Anticancer Immune Response. Frontiers in Pharmacology, 2021, 12, 739481.	1.6	7
2294	Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1512-1522.	0.5	127
2295	Risk factors for immuneâ€related adverse events from <scp>antiâ€PD</scp>â€1 or antiâ€<scp>PDâ€L1</scp> treatment in an Asian cohort of nonsmall cell lung cancer patients. International Journal of Cancer, 2022, 150, 636-644.	2.3	20
2296	Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 156.	6.9	202
2297	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	1.3	12
2298	Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stageÂsmall-cell lung cancer: a single-center experience. Cancer Immunology, Immunotherapy, 2022, 71, 1093-1101.	2.0	23
2299	Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy. Frontiers in Oncology, 2021, 11, 693704.	1.3	4
2300	Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Nonâ€'Small-Cell Lung Cancer in KEYNOTE-407. JTO Clinical and Research Reports, 2021, 2, 100225.	0.6	13
2301	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. Supportive Care in Cancer, 2022, 30, 1633-1641.	1.0	6
2302	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Molecular Oncology, 2021, 15, 2910-2922.	2.1	23
2303	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta OncolÃ³gica, 2021, 60, 1597-1603.	0.8	13
2304	Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2021, 159, 128-134.	0.9	13
2305	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. JTO Clinical and Research Reports, 2021, 2, 100214.	0.6	3
2306	Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic nonâ€smallâ€cell lung cancer treated with pembrolizumab. Molecular Oncology, 2021, 15, 2923-2940.	2.1	17
2307	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1275-1289.	5.1	118
2308	Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?. Translational Lung Cancer Research, 2021, 10, 3705-3708.	1.3	0
2309	Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 6610-6617.	1.3	8

#	Article	IF	Citations
2310	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2021, 7, 1351.	3.4	113
2311	Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. Biology, 2021, 10, 890.	1.3	4
2312	Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Frontiers in Oncology, 2021, 11, 696512.	1.3	22
2313	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 732125.	2.2	10
2314	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€“IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet, The, 2021, 398, 1344-1357.	6.3	689
2315	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 2021, 16, 1501-1511.	0.5	158
2316	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open, 2021, 6, 100254.	2.0	35
2317	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 166, 103460.	2.0	3
2318	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732.	0.5	141
2319	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer, 2021, 160, 50-58.	0.9	14
2320	The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials. International Immunopharmacology, 2021, 99, 108011.	1.7	4
2321	Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapyÂor palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option. European Journal of Cancer, 2021, 156, 175-186.	1.3	3
2322	Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer. Frontiers in Nutrition, 2021, 8, 734735.	1.6	16
2323	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection. Scientific Reports, 2021, 11, 19555.	1.6	8
2324	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. Journal of Experimental and Clinical Cancer Research, 2021, 40, 311.	3.5	26
2325	An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam University Journal of Medicine, 2021, 38, 308-317.	0.7	1
2326	Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report. Yeungnam University Journal of Medicine, 2021, 38, 366-370.	0.7	5
2327	Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review. Life, 2021, 11, 1036.	1.1	7

#	Article	IF	Citations
2328	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. European Journal of Pharmacology, 2021, 909, 174404.	1.7	18
2329	The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine, 2021, 41, 101134.	3.2	147
2330	Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol. Respiratory Medicine and Research, 2021, 80, 100845.	0.4	3
2331	STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?. European Journal of Cancer, 2021, 157, 108-113.	1.3	49
2332	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 100, 102280.	3.4	10
2333	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer, 2021, 161, 26-33.	0.9	31
2334	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. Lung Cancer, 2021, 161, 180-188.	0.9	14
2335	Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188585.	3.3	48
2336	Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma. Current Problems in Cancer Case Reports, 2021, 4, 100105.	0.1	0
2337	Multitarget therapy for pembrolizumab-induced refractory hemophagocytic lympho histiocytosis. Current Problems in Cancer Case Reports, 2021, 4, 100120.	0.1	0
2338	Management of Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC). , 2022, , 825-843.		0
2339	Management of Advanced Disease in NSCLC. , 2022, , 912-920.		0
2340	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 153-162.	1.5	4
2341	Immunotherapy in non-small cell lung cancer: update and new insights. Journal of Clinical and Translational Research, 0, , .	0.3	23
2342	Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging, 2021, 21, 11.	1.2	21
2343	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Scientific Reports, 2021, 11, 1324.	1.6	38
2344	Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary, 2021, 24, 359-373.	1.6	12
2345	TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 611444.	1.8	24

#	Article	IF	Citations
2346	Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel. Internal Medicine, 2021, 60, 3273-3277.	0.3	2
2347	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. Current Challenges in Thoracic Surgery, 0, .	0.2	2
2348	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	1.4	1
2349	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1745-1753.	2.0	1
2350	Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	2
2351	Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. Respiratory Medicine Case Reports, 2021, 34, 101498.	0.2	2
2352	Immune Therapy: What Can We Learn From Acquired Resistance?. Current Cancer Research, 2021, , 75-114.	0.2	0
2353	Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. Cancer Treatment and Research Communications, 2021, 29, 100458.	0.7	4
2354	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. Current Cancer Research, 2021, , 27-54.	0.2	0
2355	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Current Cancer Research, 2021, , 139-173.	0.2	0
2356	Immunotherapy response modeling by ex-vivo organ culture for lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2223-2234.	2.0	9
2358	A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. PharmacoEconomics - Open, 2021, 5, 365-383.	0.9	9
2359	Comparing organâ€specific immuneâ€related adverse events for immune checkpoint inhibitors: A Bayesian network metaâ€analysis. Clinical and Translational Medicine, 2021, 11, e291.	1.7	6
2361	Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer. Internal Medicine, 2021, 60, 3459-3462.	0.3	10
2362	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
2363	Research progress in immune checkpoint inhibitors for lung cancer in China. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110298.	1.4	17
2364	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) â‰¥50%: real-world data. OncoImmunology, 2021, 10, 1865653.	2.1	24
2365	Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug Delivery, 2021, 28, 767-775.	2.5	8

#	Article	IF	Citations
2366	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. International Journal of Clinical Oncology, 2021, 26, 659-669.	1.0	1
2367	Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. Scientific Reports, 2021, 11, 750.	1.6	16
2368	Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110047.	1.0	20
2369	The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199296.	1.4	40
2370	Immune Resistance in Lung Adenocarcinoma. Cancers, 2021, 13, 384.	1.7	82
2371	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a <i>ROS1</i> p.L1950F Mutation: Case Report. Oncology Research and Treatment, 2021, 44, 495-502.	0.8	5
2372	Small cell lung cancer transformation during antitumor therapies: A systematic review. Open Medicine (Poland), 2021, 16, 1160-1167.	0.6	6
2373	A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab. Journal of Immunotherapy, 2021, 44, 175-178.	1.2	6
2374	Association between CD47 expression, clinical characteristics and prognosis in patients with advanced nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 2390-2402.	1.3	40
2375	Tumor mutational burden on cytological samples: A pilot study. Cancer Cytopathology, 2021, 129, 460-467.	1.4	34
2376	EGFR Mutation Analysis in Non-small Cell Lung Carcinoma from Tissue Samples Using the Fully Automated Idyllaâ„¢ qPCR System. Methods in Molecular Biology, 2019, 2054, 147-155.	0.4	5
2377	Neurological Complications of Immune-Based Therapies. , 2020, , 365-372.		2
2378	Healthcare Perspective. , 2020, , 1-12.		1
2379	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. Cancer Treatment and Research, 2020, 180, 251-279.	0.2	15
2380	Mechanisms of Resistance to Checkpoint Blockade Therapy. Advances in Experimental Medicine and Biology, 2020, 1248, 83-117.	0.8	22
2382	The role of molecularly targeted therapies and immunotherapy in head and neck cancer. , 2020, , 33-47.		1
2383	Importancia de la imagen en la valoraciÃ³n de la respuesta al tratamiento con inmunoterapia del cÃ¡ncer de pulmÃ³n. Archivos De Bronconeumologia, 2020, 56, 380-389.	0.4	4
2384	Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura. Annals of Thoracic Surgery, 2020, 112, 1862-1869.	0.7	1

#	Article	IF	Citations
2385	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 2020, 124, 251-260.	1.5	35
2386	A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clinical Lung Cancer, 2020, 21, 421-427.e2.	1.1	30
2387	Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 151, 102974.	2.0	17
2388	Double immune checkpoint blockade in advanced NSCLC. Critical Reviews in Oncology/Hematology, 2020, 152, 102980.	2.0	12
2389	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. Cancer Treatment Reviews, 2020, 87, 102031.	3.4	82
2390	The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. International Immunopharmacology, 2020, 80, 106247.	1.7	28
2391	Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. International Immunopharmacology, 2020, 85, 106599.	1.7	17
2392	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Oral Oncology, 2020, 107, 104754.	0.8	7
2394	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews Clinical Oncology, 2019, 16, 341-355.	12.5	347
2395	Checkpoint inhibitor immunotherapy in kidney cancer. Nature Reviews Urology, 2020, 17, 137-150.	1.9	162
2396	Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 308-347.	0.8	14
2397	Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Bioscience Reports, 2020, 40, .	1.1	29
2398	KRASG12C inhibitor: combing for combination. Biochemical Society Transactions, 2020, 48, 2691-2701.	1.6	10
2399	Atezolizumab for First-Line Treatment of PD-L1â€“Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339.	13.9	959
2400	Durvalumab for the treatment of PD-L1 non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 95-105.	0.4	1
2401	Computational modelling of modern cancer immunotherapy. Physics in Medicine and Biology, 2020, 65, 24TR01.	1.6	14
2402	A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study). Japanese Journal of Clinical Oncology, 2020, 50, 821-825.	0.6	15
2403	Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. Oxford Medical Case Reports, 2020, 2020, omaa116.	0.2	2

#	Article	IF	Citations
2404	Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. Journal of Immunotherapy, 2021, 44, 41-48.	1.2	13
2405	Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Nonâ€“Small Cell Lung Cancer in a Routine Hospital Setting. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 49-55.	0.6	4
2406	The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 76-81.	0.6	7
2407	Overview of Lung Cancer Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 473-484.	1.0	6
2408	Moving Immunotherapy Into Early-Stage Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 543-547.	1.0	5
2409	Optimising patient fitness: strategies to reduce the effects of cancer cachexia in patients with advanced lung cancer. Current Opinion in Supportive and Palliative Care, 2020, 14, 304-308.	0.5	2
2417	Fiveâ€year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced nonâ€smallâ€cell lung cancer. Cancer Science, 2020, 111, 1933-1942.	1.7	13
2418	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Cancer Science, 2020, 111, 1969-1978.	1.7	13
2419	Supplementation of <scp>l</scp>â€arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy. Cancer Science, 2020, 111, 2248-2258.	1.7	31
2420	Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous nonâ€“small-cell lung cancer in China. European Journal of Hospital Pharmacy, 2022, 29, 139-144.	0.5	17
2421	Personalized therapy for lung cancer: Striking a moving target. JCI Insight, 2018, 3, .	2.3	114
2422	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 2019, 4, .	2.3	42
2423	Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight, 2019, 4, .	2.3	113
2424	Clinical implications of monitoring nivolumab immunokinetics in nonâ€“small cell lung cancer patients. JCI Insight, 2018, 3, .	2.3	156
2425	DNA repair defects and implications for immunotherapy. Journal of Clinical Investigation, 2018, 128, 4236-4242.	3.9	59
2426	PARP inhibition enhances tumor cellâ€“intrinsic immunity in ERCC1-deficient nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	3.9	222
2427	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
2428	Pembrolizumab plus allogeneic NK cells in advanced nonâ€“small cell lung cancer patients. Journal of Clinical Investigation, 2020, 130, 2560-2569.	3.9	77

#	Article	IF	Citations
2429	EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Medicine, 2021, 19, 26.	2.3	27
2430	Imaging of tumour response to immunotherapy. European Radiology Experimental, 2020, 4, 2.	1.7	65
2431	Management of Pneumonitis and Neuropathy in Patients Receiving PD-1â€“Based Therapy for Nonâ€“Small-Cell Lung Cancer. JCO Oncology Practice, 2020, 16, 4s-9s.	1.4	3
2432	Pembrolizumab in the Treatment of Microsatellite Instabilityâ€“High Sebaceous Carcinoma: A Case Report With Review of the Literature. JCO Precision Oncology, 2020, 4, 61-65.	1.5	6
2433	Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report. World Journal of Clinical Cases, 2020, 8, 97-102.	0.3	8
2434	Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World Journal of Clinical Cases, 2020, 8, 2876-2884.	0.3	6
2435	The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors. Endocrine-Related Cancer, 2020, 27, R329-R343.	1.6	13
2436	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. Cell Stress, 2019, 3, 284-294.	1.4	40
2437	Advanced non-small cell lung cancer â€“ Treatment with Pembrolizumab. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2019, 65, 1423-1432.	0.3	4
2438	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
2439	Clinical characteristics of colitis induced by taxane-based chemotherapy. Annals of Gastroenterology, 2019, 33, 59-67.	0.4	12
2440	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	1.4	95
2441	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biology and Medicine, 2020, 17, 599-611.	1.4	45
2442	VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?. Annals of Translational Medicine, 2018, 6, 446-446.	0.7	10
2443	Systemic therapy of elderly patients with advanced non-small cell lung cancerâ€”individualized treatment is key. Annals of Translational Medicine, 2019, 7, S48-S48.	0.7	3
2444	Pembrolizumab monotherapy for PD-L1 â‰¥50% non-small cell lung cancer, undisputed first choice?. Annals of Translational Medicine, 2019, 7, S140-S140.	0.7	11
2445	Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?. Annals of Translational Medicine, 2019, 7, S212-S212.	0.7	5
2446	Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer. Translational Cancer Research, 2018, 8, S55-S63.	0.4	12

#	Article	IF	Citations
2447	Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?. Translational Cancer Research, 2019, 8, S103-S105.	0.4	2
2448	CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer. Translational Cancer Research, 2020, 9, 2168-2170.	0.4	3
2449	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2020, 9, 2656-2673.	1.3	16
2450	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2696-2715.	1.3	43
2451	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 448-466.	0.7	6
2452	A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy. Future Science OA, 2020, 6, FSO608.	0.9	23
2453	Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study . Lung Cancer: Targets and Therapy, 2020, Volume 11, 113-121.	1.3	7
2454	PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases . OncoTargets and Therapy, 2020, Volume 13, 12777-12786.	1.0	7
2455	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
2458	Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy. Immunotherapy, 2020, 12, 431-437.	1.0	4
2459	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 162-174.	0.4	38
2460	Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience, 2019, 13, 936.	0.6	3
2461	Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience, 2020, 14, 1148.	0.6	11
2462	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
2463	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 97.	1.7	6
2464	Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab. Onkologie (Czech Republic), 2020, 14, 17-20.	0.0	1
2468	Value of TTFâ€‘1 expression in nonâ€‘squamous nonâ€‘smallâ€‘cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. Molecular and Clinical Oncology, 2020, 13, 9.	0.4	6
2469	Biomarkers of immunotherapy in nonâ€‘small cell lung cancer (Review). Oncology Letters, 2020, 20, 1-1.	0.8	8

#	Article	IF	Citations
2470	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 50-59.	0.7	14
2471	PD-L1 expression in regional lymph nodes and predictable roles in anti-cancer immune responses. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 113-116.	0.3	7
2472	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. Tuberculosis and Respiratory Diseases, 2020, 83, 14.	0.7	19
2473	Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm. Oncology Reviews, 2020, 14, 490.	0.8	36
2474	Low doses in immunotherapy: Are they effective?. Cancer Research Statistics and Treatment, 2019, 2, 54.	0.1	12
2475	Cancer Immunotherapy: An Impossible Dream for the Common Man?. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 312-316.	0.1	1
2476	Immunotherapy in breast cancer. Journal of Carcinogenesis, 2019, 18, 2.	2.5	56
2477	Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2019, 15, 1629.	0.3	23
2478	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. South Asian Journal of Cancer, 2019, 08, 65-68.	0.2	4
2479	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 1086-1097.	1.3	59
2480	Immunotherapy â€“ new perspective in lung cancer. World Journal of Clinical Oncology, 2020, 11, 250-259.	0.9	10
2481	Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 469-477.	2.3	16
2482	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1464-1472.	2.3	556
2483	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1287-1290.	2.3	5
2484	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs in Context, 2020, 9, 1-11.	1.0	34
2485	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. Cureus, 2019, 11, e5997.	0.2	5
2486	Application of Chimeric Antigen Receptor-T Cell (CAR-T) in Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2021, 11, 4373-4377.	0.0	0
2487	Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. Briefings in Bioinformatics, 2022, 23, .	3.2	10

#	Article	IF	Citations
2488	Immunotherapy in head and neck squamous cell carcinoma: a narrative review. Frontiers of Oral and Maxillofacial Medicine, 0, 4, 28-28.	0.1	4
2489	Costs of Extended Use of the Immune Check Point Inhibitors in 1st-line Non-Small Cell Lung Cancer. Journal of Clinical and Medical Research, 0, , .	0.0	0
2490	JASPER: Phase 2 trial of firstâ€line niraparib plus pembrolizumab in patients with advanced nonâ€“small cell lung cancer. Cancer, 2022, 128, 65-74.	2.0	36
2491	Essais contrÃ1Ã©s randomisÃ©s : quelques clÃ©s mÃ©thodologiques pour comprendre. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S55-2S62.	0.0	0
2492	Demographic and Clinical Outcomes of Brazilian Patients With Stage III or IV Nonâ€“Small-Cell Lung Cancer: Real-World Evidence Study on the Basis of Deterministic Linkage Approach. JCO Global Oncology, 2021, 7, 1454-1461.	0.8	6
2494	Algorithme thÃ©rapeutique des CBNPC sans anomalie molÃ©culaire actionnable. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S121-2S134.	0.0	0
2495	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 2022, 17, 289-308.	0.5	173
2496	Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small-cell lung cancer. Immunotherapy, 2021, 13, 1453-1456.	1.0	2
2497	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapyâ€‰Â±â€‰immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1407-1416.	3.3	5
2498	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Frontiers in Pharmacology, 2021, 12, 686876.	1.6	9
2499	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Nonâ€“Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clinical Lung Cancer, 2022, 23, e285-e288.	1.1	12
2500	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulmonary Medicine, 2021, 21, 309.	0.8	2
2501	Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 684070.	1.3	12
2502	Pembrolizumab in endometrial cancer: Where we stand now (Review). Oncology Letters, 2021, 22, 821.	0.8	10
2503	Dramatic, significant metabolic response to a oneâ€time pembrolizumab treatment following a relapse of preâ€existing organizing pneumonia in a patient with advanced nonâ€small cell lung cancer: A case report. Thoracic Cancer, 2021, 12, 3076-3079.	0.8	3
2504	First-line treatment options for advanced non-small cell lung cancer patients with PD-L1â€‰â‰¥â€‰50%: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 2022, 71, 1345-1355.	2.0	5
2505	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 89-102.	0.5	16
2507	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open, 2021, 6, 100273.	2.0	91

#	Article	IF	Citations
2508	Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters. Journal of Pathology and Translational Medicine, 2021, 55, 398-405.	0.4	1
2509	Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 360-367.	3.2	14
2510	Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancerâ€”A Prospective Longitudinal Assessment. Diagnostics, 2021, 11, 1968.	1.3	5
2511	PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. Clinical Lung Cancer, 2022, 23, e252-e256.	1.1	10
2513	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2021, 5, 1611-1624.	1.5	7
2514	Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched caseâ€“control study. Cancer Chemotherapy and Pharmacology, 2022, 89, 21-30.	1.1	7
2515	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. World Neurosurgery, 2021, 158, e87-e87.	0.7	2
2516	Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Nonâ€“Small Cell Lung Cancer After Nivolumab Therapy. Journal of Immunotherapy, 2022, 45, 125-131.	1.2	17
2517	The role of immunotherapy in treating lung cancer: current status and future perspective. Future Drug Discovery, 0, , .	0.8	1
2518	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer, 2021, 21, 1121.	1.1	3
2519	The injury response to DNA damage in live tumor cells promotes antitumor immunity. Science Signaling, 2021, 14, eabc4764.	1.6	32
2521	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 1355-1370.	1.1	6
2522	The <scp>RNA</scp>â€binding protein La/<scp>SSB</scp> associates with radiationâ€induced <scp>DNA</scp> doubleâ€strand breaks in lung cancer cell lines. Cancer Reports, 2022, 5, e1543.	0.6	3
2523	Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors. Frontiers in Oncology, 2021, 11, 752918.	1.3	6
2524	Body composition and inflammation impact in non-small-cell lung cancer patients treated by first-line immunotherapy. Immunotherapy, 2021, 13, 1501-1519.	1.0	5
2525	Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. Journal of the American Geriatrics Society, 2022, 70, 136-149.	1.3	10
2526	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor TÂcell immunity. Immunity, 2021, 54, 2354-2371.e8.	6.6	34
2527	Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Communications, 2021, 41, 1100-1115.	3.7	71

#	Article	IF	Citations
2528	Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer. Journal of Medical Economics, 2021, 24, 1185-1193.	1.0	1
2529	Realâ€world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot. Clinical Pharmacology and Therapeutics, 2022, 111, 444-454.	2.3	12
2530	Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer: Realâ€world data from 86â€‰173 patients. Thoracic Cancer, 2021, 12, 2943-2948.	0.8	7
2531	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 2021, 6, .	2.3	2
2532	Firstâ€line nab â€paclitaxel plus carboplatin for patients with advanced nonâ€small cell lung cancer: Results of the NEPTUN study. Cancer Medicine, 2021, 10, 8127-8137.	1.3	1
2533	Dynamic changes in the radiologic manifestation of a recurrent checkpoint inhibitor related pneumonitis in a non-small cell lung cancer patient: A case report. World Journal of Clinical Cases, 2021, 9, 9108-9113.	0.3	4
2534	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment. Advanced Pharmaceutical Bulletin, 2021, , .	0.6	3
2535	Safety of thoracic radiotherapy after PDâ€(L)1 inhibitor treatment in patients with lung cancer. Cancer Medicine, 2021, 10, 8518-8529.	1.3	3
2536	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Scientific Reports, 2021, 11, 20059.	1.6	53
2537	Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 647-654.	0.7	6
2538	PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	1
2539	Immunotherapeutic Advances for NSCLC. Biologics: Targets and Therapy, 2021, Volume 15, 399-417.	3.0	9
2540	Tumour burden and efficacy of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2022, 19, 75-90.	12.5	111
2541	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. Current Opinion in Neurology, 2021, Publish Ahead of Print, 834-839.	1.8	0
2542	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. Thoracic Surgery Clinics, 2021, 31, 399-406.	0.4	1
2543	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer, 2021, 158, 47-62.	1.3	32
2544	Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. Pathology Research and Practice, 2021, 227, 153651.	1.0	1
2545	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188636.	3.3	27

#	Article	IF	Citations
2546	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews, 2021, 101, 102300.	3.4	8
2548	Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer. Oncology & Hematology Review, 2018, 14, 67.	0.2	0
2549	CongrÃ¨s de lâ€™association amÃ©ricaine de recherche contre le cancer â€" AACR 2018. Oncologie, 2018, 20, 49-70.	0.2	0
2550	The Role of Predictive Markers in Outcome and Value of Anticancer Drugs in Non-small Cell Lung Cancer. Journal of Exploratory Research in Pharmacology, 2018, 3, 102-104.	0.2	0
2551	Molecular Targeted Therapy of Lung Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 177-179.	0.0	0
2552	Personalized Cancer Immunotherapy: Todayâ€™s Challenge and Tomorrowâ€™s Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4
2553	Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer. Oncotarget, 2018, 9, 36547-36548.	0.8	0
2554	éžå°ç´°èƒžè‚ºç™Œã®æ²»ç™‚â€•Updateâ€•. Japanese Journal of Lung Cancer, 2018, 58, 907-910.	0.0	0
2555	Immunotherapies in lung cancer. , 2019, , 227-231.		0
2556	Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 2019, 10, 692-707.	0.1	1
2557	Lung adenocarcinoma mimicking metastatic pancreatic cancer, a diagnostic dilemma. Journal of Case Reports and Images in Oncology, 2019, 5, 1.	0.0	0
2558	The importance of molecular characterization in lung cancer. Jornal Brasileiro De Pneumologia, 2019, 45, e20190139.	0.4	1
2559	Unmet Needs and Future Outlook of Mesothelioma Management. , 2019, , 331-340.		0
2561	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA Journal, 2019, 3, 58-66.	0.6	13
2562	The Current Status of Cancer Drug Delivery Systems and Future Directions. , 2019, , 311-319.		0
2564	Updates in Lung Cancer 2018â€"What the Pulmonologist Needs to Know. Oncology & Hematology Review, 2019, 15, 20.	0.2	0
2565	Landmark Trials in Lung Cancer. , 2019, , 41-74.		0
2566	Leadership in immuno-oncology network 2 (LION:2) immunotherapy oncology - A present status. International Journal of Molecular and Immuno Oncology, 0, 4, 3-5.	0.0	0

#	Article	IF	Citations
2567	Les avancÃ©es dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le rÃ©animateur. Medecine Intensive Reanimation, 2019, 28, 290-299.	0.1	0
2568	An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, S53-S53.	0.7	5
2570	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. Journal of the Advanced Practitioner in Oncology, 2019, 10, 367-386.	0.2	0
2572	Current Status and Future Direction of Immune Checkpoint Inhibitors. Japanese Journal of Lung Cancer, 2019, 59, 217-223.	0.0	0
2573	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. Japanese Journal of Lung Cancer, 2019, 59, 231-237.	0.0	0
2575	Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 â‰¥50%, but unanswered questions remain. Annals of Translational Medicine, 2019, 7, S127-S127.	0.7	7
2576	Immunotherapy Use in Patients with HIV and Non-Small-Cell Lung Cancer: Current Data. Journal of Immunotherapy and Precision Oncology, 2019, 2, 55-58.	0.6	2
2577	Internal Medicine, 2019, 108, 1772-1776.	0.0	0
2578	CaracterÃsticas clÃnicas y patolÃ³gicas de cÃ¡ncer de pulmÃ³n.. Revista Colombiana De Hematologìa Y Oncologìa, 2019, 6, 23-27.	0.0	0
2579	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) : segundo consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO), 2019.. Revista Colombiana De Hematologìa Y Oncologìa, 2019, 6, 10-22.	0.0	0
2580	CritÃ¨res dâ€™Ã©valuation radiologique des patients sous immunothÃ©rapie. Revue Des Maladies Respiratoires Actualites, 2019, 11, S457-S467.	0.0	0
2581	Les CBNPC de stades avancÃ©s hors addiction oncogÃ©nique: les traitements systÃ©miques de deuxiÃ¨me ligne. Revue Des Maladies Respiratoires Actualites, 2019, 11, 355-363.	0.0	0
2582	Brain Metastases from Lung Tumors. , 2020, , 259-266.		0
2583	First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. Translational Cancer Research, 2019, 8, 2514-2516.	0.4	3
2584	A Case of Large Cell Neuroendocrine Carcinoma Successfully Treated with Nivolumab. Japanese Journal of Lung Cancer, 2019, 59, 1156-1161.	0.0	2
2585	The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly. Annals of Translational Medicine, 2019, 7, S383-S383.	0.7	2
2587	The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases. Annals of Translational Medicine, 2019, 7, S313-S313.	0.7	3
2588	Immune-related adverse events associated with cancer immunotherapy. Practical Oncology, 2019, 2, 24-44.	0.1	0

#	Article	IF	Citations
2590	Systemic Therapy of Brain Metastases: Lung Cancer. , 2020, , 207-217.		0
2591	Systemic Therapies for Patients with Metastatic Spinal Disease. , 2020, , 513-522.		0
2592	Does Induction Immunotherapy Confer Increased Operative Risk for Lung Resection?. Difficult Decisions in Surgery: an Evidence-based Approach, 2020, , 205-214.	0.0	0
2593	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. , 2020, , 17-44.		0
2594	Systemic Therapy for Esophageal Squamous Cell Carcinoma. Methods in Molecular Biology, 2020, 2129, 321-333.	0.4	1
2595	Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region. Cureus, 2020, 12, e7030.	0.2	5
2596	How We Treat lung Cancer during SARS-Cov-2 (COVID-19) Pandemic in India?. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 149-152.	0.1	0
2597	Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies. International Journal of Medical Students, 2020, 8, 26-32.	0.2	0
2599	Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine antiâ€'PDâ€'1 administration. Molecular Medicine Reports, 2020, 22, 975-985.	1.1	3
2600	Case report of the meaning therapeutical response of the NSCLC after pembrolizumab monotherapy. Onkologie (Czech Republic), 2020, 14, 37-39.	0.0	0
2601	RANBP9 as potential therapeutic target in non-small cell lung cancer. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.5	1
2602	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncology, 2020, 16, 1659-1664.	1.1	2
2604	IMMUNOTERAPÄ° VE RADYOTERAPÄ° KOMBÄ°NASYONU. UludaÄŸ Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	1
2605	Prognostic effects of the expression of inhibitor of DNAâ€'binding family members on patients with lung adenocarcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	3
2606	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
2607	Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer. International Journal of Environmental Research and Public Health, 2021, 18, 11452.	1.2	1
2608	JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. , 2021, 9, e003288.		9
2609	Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. , 2021, 9, e002989.		11

#	Article	IF	Citations
2610	Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer in China. Frontiers in Pharmacology, 2021, 12, 728440.	1.6	36
2611	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
2612	TCF-1+ PD-1+ CD8+T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2653-2660.	1.2	4
2613	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer: Targets and Therapy, 2021, Volume 12, 123-131.	1.3	4
2615	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value in Health, 2022, 25, 582-594.	0.1	6
2617	The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship. , 2020, 3, 699-709.		0
2618	Cancers bronchiques. , 2020, , 139-146.e2.		0
2619	Is hyperprogressive disease a specific phenomenom of immunotherapy?. Exploration of Targeted Anti-tumor Therapy, 2020, 1, .	0.5	1
2622	Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. Journal of Immunology Research, 2020, 2020, 1-11.	0.9	8
2623	A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. Translational Lung Cancer Research, 2020, 9, 2479-2493.	1.3	10
2624	A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer. Journal of Gastrointestinal Oncology, 2020, 11, 1421-1430.	0.6	2
2625	Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer. Current Oncology, 2021, 28, 60-68.	0.9	8
2626	The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer. Expert Opinion on Biological Therapy, 2021, 21, 303-309.	1.4	3
2627	Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer â€“ predictors of response and impact of previous radiotherapy. Acta OncolÃ³gica, 2021, 60, 149-156.	0.8	5
2628	Survival benefit from immunocheckpoint inhibitors in stage IV nonâ€small cell lung cancer patients with brain metastases: A National Cancer Database propensityâ€matched analysis. Cancer Medicine, 2021, 10, 923-932.	1.3	6
2629	Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study. Journal of Thoracic Disease, 2021, 13, 6468-6475.	0.6	5
2630	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal Medicine, 2022, 61, 1485-1490.	0.3	3
2631	Validation of a Chinese version of the short-form Cataldo lung cancer stigma scale. Heart and Lung: Journal of Acute and Critical Care, 2022, 51, 59-66.	0.8	1

#	Article	IF	Citations
2632	Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. Translational Oncology, 2022, 15, 101254.	1.7	4
2633	Modern Multidisciplinary Care in Spine Tumors. , 2020, , 59-66.		0
2635	La revoluciÃ³n molecular del cÃ¡ncer de pulmÃ³n en el siglo XXI.. Revista Colombiana De Hematologìa Y Oncologìa, 2019, 6, 8-9.	0.0	0
2636	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) : segundo consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO), 2019.. Revista Colombiana De Hematologìa Y Oncologìa, 2019, 6, 10-22.	0.0	0
2637	Malignome des Respirationstrakts. , 2020, , 565-608.		0
2638	Improving responses to immunotherapy in head and neck squamous cell carcinoma. , 2020, , 107-133.		0
2639	Therapy Response Imaging in Thoracic Malignancy. Medical Radiology, 2020, , 79-97.	0.0	0
2640	Facing the First-line in Metastatic Non-small-cell Lung Cancer â€“ Immunotherapy and Chemotherapy. European Oncology and Haematology, 2020, 16, 39.	0.0	0
2641	How to read a published clinical trial: A practical guide for clinicians. Avicenna Journal of Medicine, 2020, 10, 68.	0.3	0
2643	Lessons for Precision Medicine from Lung Cancer. Respiratory Medicine, 2020, , 201-223.	0.1	0
2645	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
2646	Precision Oncology. RSC Detection Science, 2020, , 345-362.	0.0	1
2648	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs, 2020, 38, 1442-1447.	1.2	0
2649	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.1	2
2650	In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer. Translational Cancer Research, 2020, 9, 1311-1318.	0.4	0
2651	First-Line Therapy for Metastatic Nonâ€“Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches. Journal of the Advanced Practitioner in Oncology, 2020, 11, 260-265.	0.2	1
2652	Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression. Cancer Diagnosis & Prognosis, 2021, 1, 173-177.	0.3	2
2653	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10

#	Article	IF	Citations
2654	Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies. Drugs and Aging, 2021, 38, 1055-1065.	1.3	8
2655	Advances in systemic therapy for non-small cell lung cancer. BMJ, The, 2021, 375, n2363.	3.0	134
2656	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. Cancer Cell International, 2021, 21, 589.	1.8	17
2657	Salvage surgery for local control of brain metastases after prior stereotactic radiosurgery: a single-center series. World Neurosurgery, 2021, , .	0.7	0
2658	Prognostic factors of T2aN0M0 (T3â€4cmN0M0 , stage IB) nonâ€small â€cell lung cancer after surgery: Singleâ€center realâ€world research. Thoracic Cancer, 2021, , .	0.8	2
2659	The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma. Current Oncology, 2021, 28, 4542-4552.	0.9	6
2660	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. JAMA Oncology, 2021, 7, 1843.	3.4	26
2661	Immunotherapy in the First-Line Setting in Wild-Type NSCLC. Current Oncology, 2021, 28, 4457-4470.	0.9	10
2662	Advances in Pancreatic Ductal Adenocarcinoma Treatment. Cancers, 2021, 13, 5510.	1.7	28
2663	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. Drug Safety, 2021, 44, 1271-1281.	1.4	10
2664	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature Medicine, 2021, 27, 1910-1920.	15.2	62
2665	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	5.6	22
2666	Advances in plant-derived natural products for antitumor immunotherapy. Archives of Pharmacal Research, 2021, 44, 987-1011.	2.7	12
2667	Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices). Indian Journal of Medical and Paediatric Oncology, 2020, 41, 587-590.	0.1	0
2668	Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of nonâ€‘small cell lung cancer. Molecular and Clinical Oncology, 2020, 13, 13.	0.4	5
2669	The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. Tuberkuloz Ve Toraks, 2020, 68, 118-125.	0.2	2
2670	A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer. Meditsinskiy Sovet, 2020, , 258-264.	0.1	2
2671	Management of Relapsed/Refractory Acute Myeloid Leukemia. Hematologic Malignancies, 2021, , 89-109.	0.2	0

#	Article	IF	Citations
2673	Drug-Induced Glomerulonephritis. Nephrology Self-assessment Program: NephSAP, 2020, 19, 151-159.	3.0	0
2674	Immunotherapy-induced Pneumonitis: A Review of Diagnostic Workup and Treatment Guidelines. Clinical Pulmonary Medicine, 2020, 27, 141-147.	0.3	0
2675	Real world efficacy of immunotherapy in nonsmall cell lung cancer. Malignant Tumours, 2020, 10, 5-20.	0.1	1
2676	How I Treat Nonâ€“Small Cell Lung Cancer Refractory to Immunotherapy. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	1
2677	Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Nonâ€“Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 507-516.	1.0	4
2678	Immunotherapy Use in Patients With Lung Cancer and Comorbidities. Cancer Journal (Sudbury, Mass), 2020, 26, 525-536.	1.0	12
2679	Immunotherapy for Lung Cancerâ€”Improving Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer With Immunotherapy. Cancer Journal (Sudbury, Mass), 2020, 26, 548-554.	1.0	2
2680	Introduction by the Guest Editors. Cancer Journal (Sudbury, Mass), 2020, 26, 471-472.	1.0	0
2681	Cytotoxic Chemotherapy in the Era of Immunotherapy for Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 913-916.	0.0	0
2682	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. Onkologie (Czech Republic), 2020, 14, 199-204.	0.0	0
2683	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. Anesthesia and Analgesia, 2021, 132, 374-383.	1.1	8
2684	Immunotherapy strategy of EGFR mutant lung cancer. American Journal of Cancer Research, 2018, 8, 2106-2115.	1.4	18
2686	Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. American Journal of Cancer Research, 2019, 9, 1235-1245.	1.4	3
2693	T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer. American Journal of Cancer Research, 2020, 10, 473-490.	1.4	11
2694	Novel genetic variants of and involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. American Journal of Cancer Research, 2020, 10, 1770-1784.	1.4	2
2697	Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines and. American Journal of Cancer Research, 2020, 10, 2800-2812.	1.4	4
2698	Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. Annals of Translational Medicine, 2020, 8, 1112.	0.7	0
2699	Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)-current consensus and future perspectives. Journal of Thoracic Disease, 2020, 12, 7069-7075.	0.6	0

#	Article	IF	Citations
2703	Identification and validation of significant gene mutations to predict clinical benefit of immune checkpoint inhibitors in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2021, 13, 1051-1063.	0.0	1
2707	Immunotherapy in non-small cell lung cancer: Update and new insights. Journal of Clinical and Translational Research, 2021, 7, 1-21.	0.3	16
2708	Preclinical development and characterisation of Tc-NM-01 for SPECT/CT imaging of human PD-L1. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 154-166.	1.0	1
2709	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. , 2021, 4, .		0
2710	Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. American Journal of Cancer Research, 2021, 11, 4259-4276.	1.4	1
2713	Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer. Journal of Thoracic Disease, 2021, 13, 6816-6826.	0.6	6
2714	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, 52, 53-64.	0.6	0
2715	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110396.	0.8	4
2716	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Critical Reviews in Oncology/Hematology, 2022, 169, 103538.	2.0	13
2717	Chemotherapy in combination with pembrolizumab and antiangiogenesis in young patients with advanced primary pulmonary mucinous adenocarcinoma: Two case reports. Science Progress, 2021, 104, 003685042110619.	1.0	1
2718	When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?. AMA Journal of Ethics, 2021, 23, E783-793.	0.4	7
2720	Bridging Radiotherapy to Immunotherapy: The IFNâ€“JAKâ€“STAT Axis. International Journal of Molecular Sciences, 2021, 22, 12295.	1.8	13
2721	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology, 2022, 17, 362-387.	0.5	429
2722	Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 657634.	1.3	7
2723	Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-NaÃ¯ve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004). Cancer Management and Research, 2021, Volume 13, 8489-8493.	0.9	4
2724	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
2725	Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy, 2022, 14, 23-30.	1.0	5
2726	Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs, 2022, 31, 557-565.	1.9	52

#	Article	IF	Citations
2727	The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Nonâ€“Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 1017-1029.	1.3	7
2728	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discovery, 2022, 12, 90-107.	7.7	124
2729	New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 983-999.	0.9	2
2730	Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database. Cancer Medicine, 2021, 10, 8754-8762.	1.3	10
2731	Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. BMC Cancer, 2021, 21, 1211.	1.1	7
2732	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Current Oncology, 2021, 28, 4894-4928.	0.9	0
2733	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. Journal of Modern Oncology, 2021, 23, 428-435.	0.1	0
2734	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.1	5
2735	Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
2736	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer, 2021, 164, 84-90.	0.9	0
2737	Neoantigen-driven B cell and CD4ÂT follicular helper cell collaboration promotes anti-tumor CD8 TÂcell responses. Cell, 2021, 184, 6101-6118.e13.	13.5	192
2738	Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. Frontiers in Immunology, 2021, 12, 697298.	2.2	13
2739	CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC. Anticancer Research, 2021, 41, 6267-6272.	0.5	1
2740	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2985-2994.	1.2	1
2741	Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis. Future Oncology, 2022, 18, 883-896.	1.1	3
2742	Impact of docetaxel plus ramucirumab in a secondâ€line setting after chemoimmunotherapy in patients with nonâ€smallâ€cell lung cancer: A retrospective study. Thoracic Cancer, 2022, 13, 173-181.	0.8	10
2743	The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review. Annals of Translational Medicine, 2021, 9, 1703-1703.	0.7	9
2744	Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. Npj Precision Oncology, 2021, 5, 98.	2.3	35

#	Article	IF	Citations
2745	Development and validation of a supervised deep learning algorithm for automated wholeâ€slide programmed deathâ€ligand 1 tumour proportion score assessment in nonâ€small cell lung cancer. Histopathology, 2022, 80, 635-647.	1.6	21
2746	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers, 2021, 13, 5711.	1.7	10
2747	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Lithuania), 2021, 57, 1252.	0.8	5
2748	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11â€“13 2019, Verona, Italy. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	0
2749	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5773.	1.7	0
2750	Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Research, 2022, 82, 349-358.	0.4	57
2751	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 12880.	1.8	15
2752	Discontinuation of immune checkpoint inhibitor (ICI) above 18Âmonths of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunology, Immunotherapy, 2022, 71, 1719-1731.	2.0	21
2753	Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. PLoS ONE, 2021, 16, e0258605.	1.1	11
2754	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
2755	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Frontiers in Oncology, 2021, 11, 764618.	1.3	17
2757	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 2022, 17, 434-445.	0.5	21
2758	Potential biomarkers and resistance mechanisms of atezolizumab in a patient with lung squamous cell carcinoma. Immunotherapy, 2022, 14, 15-21.	1.0	4
2759	Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells, 2021, 10, 3192.	1.8	17
2760	Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2021, 12, 786046.	2.2	17
2761	Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1253-1261.	1.2	11
2762	HLA AND CANCER. Physical and Rehabilitation Medicine Medical Rehabilitation, 0, , .	0.1	0
2763	Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. , 2021, 9, e003323.		0

#	Article	IF	Citations
2764	Best regimens for treating chemoâ€naÃ¯ve incurable squamous nonâ€small cell lung cancer with a programmed deathâ€ligand 1 tumor proportion score of 1%â€“49%: A network metaâ€analysis. Thoracic Cancer, 2021, , .	0.8	2
2765	First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancerâ€†. Annals of Oncology, 2022, 33, 169-180.	0.6	118
2766	Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. Journal of Clinical Medicine, 2021, 10, 5614.	1.0	21
2767	Autophagy-related signaling pathways in non-small cell lung cancer. Molecular and Cellular Biochemistry, 2021, , 1.	1.4	8
2768	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology, 2021, 28, 4552-4576.	0.9	4
2769	The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Frontiers in Immunology, 2021, 12, 755304.	2.2	2
2770	Efficacy of PD-1/L1 inhibitors inÂbrain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials. Future Oncology, 2022, 18, 403-412.	1.1	9
2771	Effect of targeted therapy and immunotherapy on advanced nonsmallâ€cell lung cancer outcomes in the real world. Cancer Medicine, 2022, 11, 86-93.	1.3	19
2772	Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 613-618.	0.6	2
2773	Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 2021, 10, 4106-4119.	1.3	4
2774	Plasmatic Levels of HSP90Î± at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy. Frontiers in Oncology, 2021, 11, 765115.	1.3	6
2775	A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2021, , .	1.3	5
2776	KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?. Journal of Thoracic Oncology, 2021, 16, 1979-1983.	0.5	5
2777	Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 255-265.	0.5	3
2778	Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm, 2021, 2, 587-617.	3.1	42
2779	A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Frontiers in Immunology, 2021, 12, 760737.	2.2	8
2780	Infliximab treatment in immune-related pneumonitis with respiratory failure after high-dose steroids: A patient with metastatic gastric cancer. Journal of Cancer Research and Practice, 2020, 7, 170.	0.2	1
2781	Lungenkarzinom: Was bei Frauen anders ist. , 0, , .		1

#	Article	IF	Citations
2782	Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treatment and Research Communications, 2021, 29, 100496.	0.7	9
2783	Real-World Effectiveness and Prognostic Factors Analysis of Stages Iâ€“III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy. Annals of Thoracic and Cardiovascular Surgery, 2022, 28, 111-120.	0.3	9
2784	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. Journal of Cancer, 2021, 12, 7390-7398.	1.2	6
2785	Tumors: Non-small Cell Lung Cancer. , 2021, , 5270-5279.		0
2786	Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. OncoImmunology, 2021, 10, 1988403.	2.1	28
2787	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4
2788	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. SSRN Electronic Journal, 0, , .	0.4	0
2789	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. Advances in Experimental Medicine and Biology, 2021, 1342, 113-142.	0.8	5
2790	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunology, Immunotherapy, 2022, 71, 1897-1908.	2.0	12
2791	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. Diagnostics, 2022, 12, 124.	1.3	12
2792	OUP accepted manuscript. Oncologist, 2022, , .	1.9	1
2793	Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. Journal of Thoracic Oncology, 2022, 17, 34-37.	0.5	6
2794	Mitochondria determine response to anti-programmed cell death protein-1 (anti-PD-1) immunotherapy: An evidence-based hypothesis. Mitochondrion, 2022, 62, 151-158.	1.6	26
2795	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. Cancer Diagnosis & Prognosis, 2022, 2, 55-63.	0.3	2
2796	Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis. Journal of Cancer, 2022, 13, 364-372.	1.2	5
2797	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. European Journal of Cancer, 2022, 162, 1-10.	1.3	14
2798	A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. Biomaterials, 2022, 281, 121334.	5.7	11
2799	EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomedicine and Pharmacotherapy, 2022, 146, 112532.	2.5	24

#	Article	IF	Citations
2800	Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open, 2022, 7, 100348.	2.0	16
2801	IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer. ESMO Open, 2022, 7, 100353.	2.0	12
2802	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy, 2022, 14, 155-167.	1.0	7
2803	The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of nonsmall-cell lung cancer. Nigerian Journal of Cardiovascular & Thoracic Surgery, 2020, 5, 29.	0.1	0
2804	Outcomes of Clinical Pharmacy Research Aimed at Avoiding or Reducing Cancer Chemotherapy-induced Adverse Reaction. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		0
2805	Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. Annals of Translational Medicine, 2020, 8, 1112-1112.	0.7	1
2806	Pembrolizumab Induced Acute Tubulointerstitial Nephritis. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	2
2807	Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)â€"current consensus and future perspectives. Journal of Thoracic Disease, 2020, 12, 7069-7075.	0.6	0
2808	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
2809	Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer. Journal of Medical Investigation, 2021, 68, 260-264.	0.2	2
2810	Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis. Journal of Thoracic Disease, 2022, 14, 333-342.	0.6	8
2811	Immunotherapy of cancer in the era of checkpoint inhibitor. Clinical and Experimental Metastasis, 2021, 39, 231.	1.7	1
2812	Integrated Dissection of lncRNA-miRNA-mRNA Pairs and Potential Regulatory Role of lncRNA PCAT19 in Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 765275.	1.1	4
2813	Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy. Cancer Management and Research, 2022, Volume 14, 377-386.	0.9	3
2814	Cisplatin Promotes the Efficacy of ICI Therapy by Inducing Ferroptosis and Activating Neutrophils. SSRN Electronic Journal, 0, , .	0.4	0
2815	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
2816	Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466.	1.5	7
2817	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer, 2022, 22, 99.	1.1	14

#	Article	IF	Citations
2818	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression â‰¥ 50%. Frontiers in Pharmacology, 2021, 12, 803626.	1.6	1
2819	A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. OncoImmunology, 2022, 11, 2028962.	2.1	26
2820	Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer, 2022, 22, 101.	1.1	11
2821	An estimate of rate of deviation from NCCN guideline recommendations forÂcentral nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). BMC Cancer, 2022, 22, 70.	1.1	2
2822	Human Hematopoietic Stem Cell (HSC)-Engrafted NSG Mice for HIV Latency Research. Methods in Molecular Biology, 2022, 2407, 229-251.	0.4	3
2823	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. Patient Preference and Adherence, 2022, Volume 16, 123-135.	0.8	2
2824	Differentiation between immune checkpoint inhibitorâ€related and radiation pneumonitis in lung cancer by CT radiomics and machine learning. Medical Physics, 2022, 49, 1547-1558.	1.6	28
2825	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Molecular Cancer, 2022, 21, 28.	7.9	393
2826	MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression. Cell Reports Medicine, 2022, 3, 100506.	3.3	0
2827	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. Cancer, 2022, 128, 1429-1438.	2.0	21
2828	Patient-Centered Palliative Care for Patients With Advanced Lung Cancer. Journal of Clinical Oncology, 2022, 40, 626-634.	0.8	31
2829	Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery, 2022, 12, 924-937.	7.7	110
2830	The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Journal of Experimental and Clinical Cancer Research, 2022, 41, 27.	3.5	73
2831	MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell, 2022, 40, 136-152.e12.	7.7	79
2832	Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect. Journal of Controlled Release, 2022, 341, 769-781.	4.8	11
2833	Rapid Unmasking of Immune-related Adverse Events After Discontinuation of Chemotherapy in Chemo-immunotherapy Regimens. Journal of Immunotherapy, 2022, Publish Ahead of Print, .	1.2	2
2834	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clinical Lung Cancer, 2022, 23, 345-355.	1.1	13
2835	Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?. Future Oncology, 2022, , .	1.1	1

#	Article	IF	Citations
2836	Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?. Expert Review of Anticancer Therapy, 2022, 22, 183-189.	1.1	4
2837	Immunotherapy in stage IV non-small cell lung cancer in a patient with Graveâ€™s disease: safety and biomarkers of response. BMJ Case Reports, 2022, 15, e245632.	0.2	2
2838	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
2840	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab. Internal Medicine, 2022, 61, 2339-2341.	0.3	4
2841	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 2021, 12, 799455.	2.2	76
2842	Risk factors for pneumonitis in patients with nonâ€small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. Thoracic Cancer, 2022, 13, 724-731.	0.8	10
2843	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 2022, 28, 368-377.	3.2	40
2844	Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. Future Oncology, 2022, 18, 261-273.	1.1	10
2846	A Natural Polyphenol Exerts Antitumor Activity and Circumvents Antiâ€“PD-1 Resistance through Effects on the Gut Microbiota. Cancer Discovery, 2022, 12, 1070-1087.	7.7	86
2847	Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Investigational New Drugs, 2022, 40, 634-642.	1.2	8
2848	Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients. Supportive Care in Cancer, 2022, , 1.	1.0	0
2849	Predicting treatment outcomes using ¹⁸F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	7
2850	Local consolidative therapy for synchronous oligometastatic nonâ€small cell lung cancer treated with firstâ€line pembrolizumab: A retrospective observational study. Thoracic Cancer, 2022, , .	0.8	6
2851	Metabolic Implications of Immune Checkpoint Proteins in Cancer. Cells, 2022, 11, 179.	1.8	15
2852	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta OncolÃ³gica, 2022, 61, 409-416.	0.8	11
2853	The Numb Lip: Non-Small Cell Lung Cancer First Presenting in the Head and Neck. Dental Update, 2022, 49, 48-50.	0.1	0
2854	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nature Immunology, 2022, 23, 262-274.	7.0	47
2855	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clinical Cancer Research, 2022, 28, 1560-1571.	3.2	33

#	Article	IF	Citations
2856	Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Oncology, 2022, 12, 823287.	1.3	4
2857	Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report. Frontiers in Oncology, 2021, 11, 814544.	1.3	3
2858	Disparities in Lung Cancer Treatment. Current Oncology Reports, 2022, 24, 241-248.	1.8	24
2860	Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report. Journal of Oncology Pharmacy Practice, 2022, 28, 1239-1243.	0.5	1
2861	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 37-44.	2.3	7
2862	Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusionâ€“Positive Lung Cancers. JCO Precision Oncology, 2022, 6, e2100418.	1.5	29
2863	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. Expert Review of Anticancer Therapy, 2022, 22, 203-213.	1.1	4
2864	Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Current Oncology, 2022, 29, 479-489.	0.9	6
2865	Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy. Molecular Pharmaceutics, 2022, 19, 936-952.	2.3	6
2866	Tumour microenvironment and heterotypic interactions in pancreatic cancer. Journal of Physiology and Biochemistry, 2022, , 1.	1.3	5
2867	Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis. Frontiers in Oncology, 2021, 11, 778549.	1.3	2
2868	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncology, The, 2022, 23, 220-233.	5.1	106
2869	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
2870	Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2022, 23, 209-219.	5.1	87
2871	Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer. Journal of Thoracic Oncology, 2022, 17, 179-181.	0.5	5
2872	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 279-291.	5.1	118
2873	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 2022, 33, 488-499.	0.6	99
2874	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. Biomedicines, 2022, 10, 360.	1.4	17

#	Article	IF	Citations
2875	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clinical and Research Reports, 2022, 3, 100265.	0.6	15
2876	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596.	2.0	76
2877	Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience. Lung Cancer, 2022, 165, 49-53.	0.9	2
2878	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy. Lung Cancer, 2022, 165, 10-17.	0.9	1
2879	ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer, 2022, 165, 54-62.	0.9	6
2880	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treatment Reviews, 2022, 104, 102350.	3.4	18
2881	IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer. Translational Oncology, 2022, 18, 101358.	1.7	5
2882	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
2883	Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review. JNCI Cancer Spectrum, 2022, 6, .	1.4	1
2884	Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients. Frontiers in Oncology, 2022, 12, 823705.	1.3	14
2885	First-line nivolumabÂ+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open, 2022, 7, 100394.	2.0	7
2886	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs, 2022, 36, 137-151.	2.2	6
2887	Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas. Cells, 2022, 11, 561.	1.8	18
2888	Clinical outcomes of dose-escalated hypofractionated external beam radiotherapy (5 Gy x 5 fractions) for spine metastasis. Advances in Radiation Oncology, 2022, 7, 100906.	0.6	1
2889	Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Seminars in Cancer Biology, 2022, 86, 542-565.	4.3	51
2890	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. Nature Reviews Neurology, 2022, 18, 173-185.	4.9	31
2891	Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer. Cells, 2022, 11, 605.	1.8	13
2892	Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with nonâ€small cell lung cancer. Cancer Medicine, 2022, , .	1.3	5

#	Article	IF	Citations
2893	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology, 2022, 13, 823618.	2.2	105
2894	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. Diagnostics, 2022, 12, 423.	1.3	17
2895	Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. BMC Cancer, 2022, 22, 154.	1.1	1
2896	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PLoS ONE, 2022, 17, e0263402.	1.1	7
2897	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	15.2	225
2898	Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 795933.	1.3	4
2899	Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. Cancer Immunology, Immunotherapy, 2022, 71, 2239-2254.	2.0	11
2900	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer, 2022, 166, 84-93.	0.9	7
2901	Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Cancer Management and Research, 2022, Volume 14, 515-524.	0.9	10
2902	Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. Lung Cancer, 2022, 166, 40-48.	0.9	7
2903	Cardiotoxicity and Chemotherapyâ€"The Role of Precision Medicine. Diseases (Basel, Switzerland), 2021, 9, 90.	1.0	3
2904	Efficacy and safety of anti<scp>â€PD</scp>â€1/<scp>PDâ€L1</scp> in combination with chemotherapy or not as firstâ€line treatment for advanced nonâ€small cell lung cancer: A systematic review and network metaâ€analysis. Thoracic Cancer, 2022, 13, 322-337.	0.8	13
2905	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy, 2021, , .	1.0	3
2906	Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 721760.	1.3	4
2907	The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer. Current Oncology, 2021, 28, 5408-5421.	0.9	2
2910	Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncology Reports, 2021, 47, .	1.2	6
2911	Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [68Ga]Ga-NOTA-Nb109. Quantitative Imaging in Medicine and Surgery, 2022, 12, 3300-3313.	1.1	5
2912	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. Expert Review of Precision Medicine and Drug Development, 2022, 7, 29-38.	0.4	0

#	Article	IF	Citations
2913	A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients. Integrative Cancer Therapies, 2022, 21, 153473542210839.	0.8	8
2914	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
2915	Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP). Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210853.	1.4	6
2916	OUP accepted manuscript. Oncologist, 2022, , .	1.9	3
2917	Metallodrugs in cancer nanomedicine. Chemical Society Reviews, 2022, 51, 2544-2582.	18.7	70
2919	Neurological complications of lung cancer. , 2022, , 243-276.		0
2920	Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210865.	0.6	1
2921	C-MET Inhibitors as New Members of the NSCLC Treatment Armamentariumâ€"A Pooled Analysis. Advances in Lung Cancer (Irvine), 2022, 11, 1-13.	0.2	0
2922	Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer. Cancer Control, 2022, 29, 107327482210766.	0.7	11
2923	A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care, 2022, 38, e28.	0.2	3
2924	Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report. Respiratory Medicine Case Reports, 2022, 37, 101642.	0.2	1
2925	Pyroptosis Predicts Immunotherapy Outcomes Across Multiple Cancer Types. SSRN Electronic Journal, 0, , .	0.4	0
2927	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of Oncology, 2022, 33, 466-487.	0.6	67
2928	The Peak Is Always in View â€" Observations from a Patient in a Clinical Trial in Lung Cancer. , 2022, 1, .		0
2929	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncology, 2022, 18, 1793-1799.	1.1	6
2930	Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment. Pathology and Oncology Research, 2022, 28, 1610196.	0.9	1
2931	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. Journal of Pain and Symptom Management, 2022, 63, 997-1005.	0.6	5
2932	Clinical Updates in Nausea and Vomiting. Seminars in Oncology Nursing, 2022, 38, 151249.	0.7	7

#	Article	IF	Citations
2933	Cancer cachexia as a determinant of efficacy of firstâ€'line pembrolizumab in patients with advanced nonâ€'small cell lung cancer. Molecular and Clinical Oncology, 2022, 16, 91.	0.4	7
2934	Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 2022, 157, 101-107.	1.4	19
2935	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. International Journal of Clinical Oncology, 2022, 27, 695-706.	1.0	11
2936	Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Journal of Cancer Research and Clinical Oncology, 2023, 149, 819-831.	1.2	14
2937	Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan. Cancers, 2022, 14, 1157.	1.7	8
2938	The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration. Frontiers in Genetics, 2022, 13, 833013.	1.1	4
2939	Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Translational Lung Cancer Research, 2022, 11, 277-294.	1.3	29
2940	Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Annals of Oncology, 2022, 33, 511-521.	0.6	36
2941	High farnesoid X receptor expression predicts favorable clinical outcomes in PDâ€'L1‹sup›low/negative‹/sup› nonâ€'small cell lung cancer patients receiving antiâ€'PDâ€'1â€'based chemoâ€'immunotherapy. International Journal of Oncology, 2022, 60, .	1.4	2
2942	Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning. Frontiers in Medicine, 2022, 9, 843749.	1.2	7
2943	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer, 2022, 21, 61.	7.9	6
2944	Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinomaï¼š A Retrospective Study. Frontiers in Oncology, 2022, 12, 820302.	1.3	12
2945	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2022, 71, 2405-2420.	2.0	10
2946	Adjuvant therapy for early-stage nonâ€"small cell lung cancer: The breaking of a new dawn. Journal of Thoracic and Cardiovascular Surgery, 2022, , .	0.4	1
2947	Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC (CME article). International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
2948	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
2949	Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer. Frontiers in Immunology, 2022, 13, 829451.	2.2	15
2950	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Communications Biology, 2022, 5, 167.	2.0	5

#	Article	IF	Citations
2951	Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy. Frontiers in Oncology, 2022, 12, 820408.	1.3	1
2952	Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients. Respiratory Investigation, 2022, 60, 393-399.	0.9	4
2953	Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. Current Oncology, 2022, 29, 1828-1839.	0.9	72
2954	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2022, 114, 60-74.	0.4	33
2955	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications, 2022, 13, 1487.	5.8	17
2956	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer, 2022, 22, 342.	1.1	2
2957	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. JAMA Oncology, 2022, 8, 462.	3.4	22
2958	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI) Tj ETQq1 1 0.784314 rgBT /Ove	1.1	10
2959	Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma. Cancer Diagnosis & Prognosis, 2022, 2, 253-257.	0.3	5
2960	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in nonâ€“small cell lung cancer. Science Translational Medicine, 2022, 14, eabe8195.	5.8	16
2961	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology and Oncology, 2022, 15, 24.	6.9	136
2962	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	1.1	7
2963	Increasing Role of Targeted Immunotherapies in the Treatment of AML. International Journal of Molecular Sciences, 2022, 23, 3304.	1.8	6
2964	Unraveling the mechanism of alkaloids from Sophora alopecuroides Linn combined with immune checkpoint blockade in the treatment of non-small cell lung cancer based on systems pharmacology. Bioorganic and Medicinal Chemistry, 2022, 64, 116724.	1.4	5
2965	Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. Current Oncology, 2022, 29, 1501-1513.	0.9	0
2966	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
2967	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 749461.	2.2	11
2968	Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer. Annals of Translational Medicine, 2022, 10, 253-253.	0.7	2

#	Article	IF	Citations
2969	Neutrophil Extracellular Traps in Cancer Therapy Resistance. Cancers, 2022, 14, 1359.	1.7	30
2970	T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizumab). BMJ Case Reports, 2022, 15, e245603.	0.2	1
2971	Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1655.	1.0	6
2973	A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression. Journal of Clinical Medicine, 2022, 11, 1492.	1.0	3
2974	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 2022, 164, 95-104.	1.3	0
2975	Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. Targeted Oncology, 2022, 17, 187-192.	1.7	3
2976	Indirect comparison of sintilimab and other PD-L1 inhibitorsÂfor first-line treatment of non-squamous non-small-cell lung cancer. Future Oncology, 2022, , .	1.1	2
2977	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. Journal of Clinical Medicine, 2022, 11, 1627.	1.0	14
2978	Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Cancers, 2022, 14, 1321.	1.7	29
2979	m6A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer. Cancer Gene Therapy, 2022, 29, 1355-1372.	2.2	13
2980	Two Pyroptosis-Related Subtypes with Distinct Immune Microenvironment Characteristics and a Novel Signature for Predicting Immunotherapy Response and Prognosis in Uveal Melanoma. Current Eye Research, 2022, , 1-14.	0.7	0
2981	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in Oncology, 2022, 12, 821391.	1.3	6
2982	A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. Npj Precision Oncology, 2022, 6, 19.	2.3	20
2983	Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. JTO Clinical and Research Reports, 2022, 3, 100312.	0.6	7
2984	Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review. Frontiers in Oncology, 2022, 12, 824308.	1.3	2
2986	Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 487-497.	1.1	3
2987	Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 1855.	1.0	11
2989	Clinical Applications of Circulating Tumour Cells and Circulating TumourÂDNA in Non-Small Cell LungÂCancerâ€"An Update. Frontiers in Oncology, 2022, 12, 859152.	1.3	15

#	Article	IF	Citations
2990	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	5.7	90
2991	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. Clinical and Experimental Immunology, 2022, , .	1.1	1
2992	A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer. Journal of Thoracic Disease, 2022, 14, 679-688.	0.6	1
2993	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open, 2022, 5, e222265.	2.8	26
2994	Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncology, 2022, 8, 717.	3.4	32
2995	Evolution of surgical treatment of metastatic spine tumors. Journal of Neuro-Oncology, 2022, 157, 277-283.	1.4	0
2996	Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: A oneâ€‘year followâ€‘up case report. Molecular and Clinical Oncology, 2022, 16, 94.	0.4	1
2997	The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunology, Immunotherapy, 2022, 71, 2313-2323.	2.0	4
2998	Generalizability of ORIENT-11 trial results to a USÂstandard of care cohort with advanced non-small-cell lung cancer. Future Oncology, 2022, , .	1.1	2
2999	Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA)â€”An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1). Biomolecules, 2022, 12, 480.	1.8	4
3000	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. Chemotherapy, 2023, 68, 1-15.	0.8	0
3001	Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyteâ€“Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade. Journal of Thoracic Oncology, 2022, 17, 341-344.	0.5	0
3002	Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 802467.	1.3	4
3003	dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score â‰¥50%. Clinical Lung Cancer, 2022, 23, 122-134.	1.1	8
3004	Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. Frontiers in Oncology, 2022, 12, 806501.	1.3	10
3005	Engineered extracellular vesicles: potentials in cancer combination therapy. Journal of Nanobiotechnology, 2022, 20, 132.	4.2	22
3006	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001056.	1.6	40
3007	Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Nonâ€“Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 96-104.	1.0	5

#	Article	IF	Citations
3008	Targeted therapy in lung cancer: Are we closing the gap in years of life lost?. Cancer Medicine, 2022, 11, 3417-3424.	1.3	7
3009	Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study. Journal of Oncology, 2022, 2022, 1-10.	0.6	0
3010	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	3.3	29
3012	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. Seminars in Cancer Biology, 2022, 86, 532-541.	4.3	14
3013	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics, 2022, 12, 685.	1.3	1
3014	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncology, 2022, 18, 1757-1775.	1.1	14
3015	An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma. Frontiers in Oncology, 2022, 12, 800315.	1.3	2
3016	Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO) Tj ETQq1 1 0.784314 rgBT /Over	2.4	8
3017	Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 1404.	1.7	63
3018	Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?. Anticancer Research, 2022, 42, 1987-1995.	0.5	2
3019	Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology, 2022, 40, 585-597.	9.4	63
3020	Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments. Cancers, 2022, 14, 1800.	1.7	7
3021	Should the control arms of randomized trials have an expiry date?. Nature Reviews Clinical Oncology, 2022, , .	12.5	5
3022	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clinical Immunology, 2022, 237, 108962.	1.4	16
3023	The prevalence and realâ€•world therapeutic analysis of Chinese patients with KRASâ€Mutant Nonâ€Small Cell lung cancer. Cancer Medicine, 2022, 11, 3581-3592.	1.3	10
3024	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. Healthcare (Switzerland), 2022, 10, 694.	1.0	4
3025	Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. JTO Clinical and Research Reports, 2022, 3, 100309.	0.6	8
3026	Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays â€œcoldâ€•immune characteristics in Non-small cell lung cancer. Lung Cancer, 2022, 166, 189-196.	0.9	10

#	Article	IF	Citations
3027	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling, 2022, 20, 44.	2.7	109
3028	Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	0.7	0
3029	Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study. Lung Cancer, 2022, 166, 114-121.	0.9	4
3030	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. Immunotherapy, 2022, , .	1.0	2
3031	Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with <scp>EGFR</scp>â€mutated nonâ€smallâ€cell lung cancer: A case report. Thoracic Cancer, 2022, 13, 1419-1422.	0.8	8
3032	Searching for Synergy: Chemotherapy and Checkpoint Inhibitors. Clinical Cancer Research, 2022, , OF1-OF3.	3.2	2
3033	The impact of a pathologistâ€™s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. Lung Cancer, 2022, 166, 143-149.	0.9	12
3034	TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma. World Journal of Surgical Oncology, 2022, 20, 115.	0.8	1
3035	Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy, 2022, 14, 489-503.	1.0	1
3036	Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. Frontiers in Immunology, 2022, 13, 828560.	2.2	18
3037	Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Clinical Oncology, 2022, 34, 799-809.	0.6	10
3038	Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open, 2022, 7, 100445.	2.0	26
3039	Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study. JTCVS Open, 2022, 10, 370-381.	0.2	6
3040	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 406-416.e11.	2.3	31
3041	Histologic transformation of epidermal growth factor receptorâ€“mutated lung cancer. European Journal of Cancer, 2022, 166, 41-50.	1.3	10
3042	Dual-cell culture system with identical culture environment for comparison of anti-cancer drug toxicity. Chemical Engineering Science, 2022, 253, 117555.	1.9	2
3043	Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 173, 103660.	2.0	4
3044	NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy. Onkologie (Czech Republic), 2021, 15, 284-286.	0.0	0

#	Article	IF	Citations
3045	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers, 2022, 14, 122.	1.7	16
3046	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International Journal of Molecular Sciences, 2021, 22, 13311.	1.8	54
3047	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. International Journal of Molecular Sciences, 2022, 23, 245.	1.8	6
3048	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
3049	Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy. BMC Pulmonary Medicine, 2021, 21, 409.	0.8	9
3050	Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapyâ€"A Retrospective Bi-Centric Cohort Study. Cancers, 2022, 14, 93.	1.7	7
3051	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4423-4444.	1.3	6
3052	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168.	2.2	18
3053	Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study. Frontiers in Immunology, 2021, 12, 756872.	2.2	29
3054	Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report. World Journal of Clinical Cases, 2021, 9, 11419-11424.	0.3	1
3055	Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials. Journal of Chemotherapy, 2021, , 1-9.	0.7	0
3056	Therapeutic advances in nonâ€small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm, 2021, 2, 692-729.	3.1	38
3057	Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial. Translational Lung Cancer Research, 2021, 10, 4322-4327.	1.3	0
3058	Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines. Cancers, 2021, 13, 6189.	1.7	9
3059	The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Frontiers in Immunology, 2021, 12, 787307.	2.2	21
3060	A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 796647.	2.2	16
3061	Low baseline plasma <scp>PCSK9</scp> level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 353-360.	0.8	9
3062	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 760686.	1.3	8

#	Article	IF	Citations
3063	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. Cancers, 2021, 13, 6096.	1.7	14
3064	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. Cancers, 2022, 14, 89.	1.7	5
3065	Involvement of orthopaedic surgeons for cancer patients in orthopaedic training facilities certified by the Japanese Orthopaedic Association - A nationwide survey. Journal of Orthopaedic Science, 2021, , .	0.5	1
3066	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	2.9	8
3067	Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer. World Journal of Clinical Oncology, 2021, 12, 1182-1192.	0.9	3
3068	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with nonâ€smallâ€cell lung cancer: A multicenter retrospective trial. Thoracic Cancer, 2022, 13, 228-235.	0.8	7
3069	A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2021, 10, 4511-4525.	1.3	6
3070	Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient. Thoracic Cancer, 2022, 13, 510-513.	0.8	2
3071	The incidence and predictors of new brain metastases in patients with nonâ€“small cell lung cancer following discontinuation of systemic therapy. Journal of Neurosurgery, 2021, , 1-11.	0.9	1
3072	Antiâ€VEGF antibody triggers the effect of antiâ€PDâ€L1 antibody in PDâ€L1^{low}and immune desertâ€like mouse tumors. Oncology Reports, 2021, 47, .	1.2	10
3073	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	5.8	16
3074	A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice. Open Medicine (Poland), 2021, 17, 53-60.	0.6	1
3075	Multicenter realâ€world data of patients harboring rare mutations other than <scp>EGFR</scp> or <scp>ALK</scp> in advanced or metastatic nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 380-385.	0.8	2
3076	Comprehensive Analysis of the Immunogeomic Landscape and Clinical Features in Cervical Cancer. , 2021, , .		0
3077	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Frontiers in Immunology, 2021, 12, 775761.	2.2	45
3078	Immune checkpoint inhibitorâ€related adverse events in lung cancer: Realâ€world incidence and management practices of 1905 patients in <scp>China</scp>. Thoracic Cancer, 2022, 13, 412-422.	0.8	19
3079	Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIBâ€“IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China. Frontiers in Pharmacology, 2021, 12, 735536.	1.6	18
3080	Targeting KRAS G12C with Covalent Inhibitors. Annual Review of Cancer Biology, 2022, 6, 49-64.	2.3	16

#	Article	IF	Citations
3081	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers in Oncology, 2021, 11, 790373.	1.3	36
3083	Stereotactic body radiation therapy for metastatic non-small cell lung cancer: a versatile treatment, repurposed. Journal of Thoracic Disease, 2021, .	0.6	0
3084	Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systemic review of characteristics, incidence, risk factors, and management. Journal of Thoracic Disease, 2021, .	0.6	4
3085	Glioma and the gutâ€“brain axis: opportunities and future perspectives. Neuro-Oncology Advances, 2022, 4, vdac054.	0.4	10
3086	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. Cancers, 2022, 14, 1913.	1.7	7
3087	Effectiveness and Safety of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis. Indian Journal of Surgery, 0, , 1.	0.2	0
3088	Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous nonâ€“small cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	0
3089	The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treatment Reviews, 2022, 106, 102394.	3.4	16
3090	Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biology, 2022, 53, 102318.	3.9	8
3091	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. Cancer Immunology, Immunotherapy, 2022, 71, 2791-2799.	2.0	3
3092	KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2063.	1.7	10
3093	The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Investigational New Drugs, 2022, 40, 810-817.	1.2	5
3094	Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. Frontiers in Immunology, 2022, 13, 875093.	2.2	10
3095	The Landscape of Immunotherapy Resistance in NSCLC. Frontiers in Oncology, 2022, 12, 817548.	1.3	27
3096	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology, 2022, 85, 253-275.	4.3	61
3097	Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors. Future Oncology, 2022, 18, 2289-2300.	1.1	2
3098	Stratification From Heterogeneity of the Cell-Death Signal Enables Prognosis Prediction and Immune Microenvironment Characterization in Esophageal Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 855404.	1.8	7
3099	Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report. Immunotherapy, 2022, 14, 675-682.	1.0	2

#	Article	IF	Citations
3100	Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nature Communications, 2022, 13, 2063.	5.8	39
3101	Targeting the gut and tumor microbiota in cancer. Nature Medicine, 2022, 28, 690-703.	15.2	159
3102	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. JAMA Network Open, 2022, 5, e227722.	2.8	25
3103	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. , 2022, 10, e004424.		54
3104	Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiology, 2022, 78, 102149.	0.8	3
3175	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunology, Immunotherapy, 2022, 71, 2837-2848.	2.0	5
3176	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Archives of Pharmacal Research, 2022, 45, 263-279.	2.7	11
3177	Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?. Journal of Thoracic Oncology, 2022, 17, 592-595.	0.5	1
3178	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ, The, 2022, 377, e068714.	3.0	133
3179	IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatinâ€“paclitaxel, with or without bevacizumab in patients with advanced cancer. , 2022, 10, e003924.		8
3196	Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. Oncologist, 2022, 27, 538-547.	1.9	4
3197	DNA damage and metabolic mechanisms of cancer drug resistance. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0.784314 rgBT /Ove	0.9	7
3198	Construction of a Nomogram Based on lncRNA and Patientâ€™s Clinical Characteristics to Improve the Prognosis of Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382210972.	0.8	2
3199	Phase 2 study of firstâ€line pembrolizumab monotherapy in elderly patients with nonâ€smallâ€cell lung cancer expressing high <scp>PDâ€L1</scp>. Thoracic Cancer, 2022, 13, 1611-1618.	0.8	4
3200	CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma. Frontiers in Oncology, 2022, 12, 867788.	1.3	3
3201	Fatalism, Distrust, and Breast Cancer Treatment Refusal in Ghana. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2022, 32, 198-205.	0.1	3
3202	Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. Clinical Lung Cancer, 2022, 23, 386-392.	1.1	15
3203	Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients with Advanced NSCLC Receiving First-line Pembrolizumab-based Therapy. Clinical Lung Cancer, 2022, , .	1.1	3

#	Article	IF	Citations
3204	Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	3
3205	Neoadjuvant and adjuvant immunotherapy for non-small cell lung cancer (literature review). Voprosy Onkologii, 2022, 68, 159-168.	0.1	1
3206	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 100076.	0.7	2
3208	MAPK signaling regulates the efficacy of chemoimmunotherapy. Molecular and Cellular Oncology, 2022, 9, 2054652.	0.3	0
3209	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. Vaccines, 2022, 10, 679.	2.1	4
3211	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived eXplants. JCI Insight, 2022, , .	2.3	5
3212	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
3213	Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. Frontiers in Oncology, 2022, 12, .	1.3	4
3214	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	3.5	2
3215	RecQ mediated genome instability 2 (RMI2): a potential prognostic and immunological biomarker for pan-cancers. Aging, 2022, 14, 4107-4136.	1.4	3
3216	Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clinical Lung Cancer, 2022, , .	1.1	7
3217	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncology, 2022, 18, 2465-2473.	1.1	40
3218	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. International Journal of Clinical Oncology, 2022, 27, 1139-1144.	1.0	7
3219	Safety and efficacy of endobronchial ultrasoundâ€guided transbronchial needle aspiration () Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	5
3220	Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis. Joint Bone Spine, 2022, 89, 105403.	0.8	1
3221	Small cell lung cancer: Novel treatments beyond immunotherapy. Seminars in Cancer Biology, 2022, 86, 376-385.	4.3	19
3222	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-Î² as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2022, 32, 100576.	0.7	1
3223	Optimize Local Therapy for Oligometastatic and Oligoprogressive Nonâ€“Small Cell Lung Cancer to Enhance Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 531-539.	2.3	10

#	Article	IF	Citations
3224	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. Journal of Clinical Medicine, 2022, 11, 2629.	1.0	6
3225	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 2022, 11, 2066767.	2.1	9
3226	Rare case of primary hepatoid adenocarcinoma of the lung. Siberian Journal of Oncology, 2022, 21, 150-155.	0.1	0
3227	Vaccine Therapy in Non-Small Cell Lung Cancer. Vaccines, 2022, 10, 740.	2.1	4
3228	In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy. Nano Today, 2022, 44, 101492.	6.2	7
3229	Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis. Clinical Lung Cancer, 2022, 23, 532-541.	1.1	2
3230	Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy â€“ a clinical dilemma. European Journal of Cancer, 2022, 169, 126-130.	1.3	8
3231	More to the RAS Story: KRAS^{G12C} Inhibition, Resistance Mechanisms, and Moving Beyond KRAS^{G12C}. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 205-217.	1.8	13
3233	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. International Journal of Environmental Research and Public Health, 2022, 19, 5999.	1.2	3
3234	Largeâ^'Scale Profiling of Extracellular Vesicles Identified miRâ^'625â^'5p as a Novel Biomarker of Immunotherapy Response in Advanced Nonâ^'Smallâ^'Cell Lung Cancer Patients. Cancers, 2022, 14, 2435.	1.7	15
3235	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open, 2022, 7, 100474.	2.0	3
3236	Principles of medical and oncological management of giant masses of the mediastinum: a narrative review. Mediastinum, 0, 6, 35-35.	0.6	2
3237	Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review. Translational Lung Cancer Research, 2022, 11, 920-934.	1.3	6
3238	Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2022, 62, 75-80.	0.0	0
3239	Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8⁺T cells in lung cancer. Immunotherapy, 2022, 14, 695-708.	1.0	7
3240	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Frontiers in Pharmacology, 2022, 13, .	1.6	3
3241	Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 21.	0.9	1
3242	Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation, 2022, 102, 1143-1149.	1.7	5

#	Article	IF	Citations
3243	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	1.7	4
3244	The state of the art for artificial intelligence in lung digital pathology. Journal of Pathology, 2022, 257, 413-429.	2.1	31
3245	Role of radiomics in predicting immunotherapy response. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 575-591.	0.9	10
3246	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. Cancer Immunology Research, 2022, 10, 885-899.	1.6	7
3247	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 781-794.	1.8	10
3248	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Nonâ€“small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clinical Lung Cancer, 2022, 23, e415-e427.	1.1	7
3249	Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. BMC Cancer, 2022, 22, .	1.1	2
3250	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, .	2.2	13
3251	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. Frontiers in Oncology, 2022, 12, .	1.3	2
3252	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. Biomedicines, 2022, 10, 1237.	1.4	7
3253	A phase II clinical trial of combination nivolumab, ipilimumab, and paclitaxel in patients with untreated metastatic non-small cell lung cancer: The OPTIMAL Trial. JTO Clinical and Research Reports, 2022, , 100337.	0.6	0
3254	A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211051.	1.0	1
3255	Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features. SSRN Electronic Journal, 0, , .	0.4	7
3256	HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. Lung Cancer, 2022, 170, 1-10.	0.9	14
3257	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	5
3260	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. Scientific Reports, 2022, 12, .	1.6	1
3261	Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer. Anticancer Research, 2022, 42, 3061-3066.	0.5	2
3262	Management of Malignant Pleural Effusion: Where Are We Now?. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 559-569.	0.8	1

#	Article	IF	Citations
3263	State legislative trends related to biomarker testing. Cancer, 2022, 128, 2865-2870.	2.0	6
3264	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapyâ€"Proof-of-Concept Animal Study. Biomedicines, 2022, 10, 1173.	1.4	3
3266	The earlier, the better? A review of neoadjuvant immunotherapy in resectable nonâ€smallâ€cell lung cancer. Chronic Diseases and Translational Medicine, 2022, 8, 100-111.	0.9	0
3267	Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC. Healthcare (Switzerland), 2022, 10, 922.	1.0	2
3268	Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study. International Journal of Radiation Oncology Biology Physics, 2022, 114, 655-665.	0.4	15
3269	Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma. Haematologica, 2022, 107, 2276-2279.	1.7	3
3270	Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. Cancers, 2022, 14, 2661.	1.7	6
3271	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Seminars in Nuclear Medicine, 2022, 52, 707-719.	2.5	10
3273	Realâ€world outcomes of pembrolizumab monotherapy in <scp>nonâ€small</scp> cell lung cancer in Japan: A postâ€marketing surveillance. Cancer Science, 2022, 113, 3110-3119.	1.7	5
3274	Classification of <scp>PDâ€L1</scp> expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Science, 2022, 113, 3255-3266.	1.7	8
3275	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	12
3276	Relationship between Patientsâ€™ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Oncology, 2022, 2022, 1-14.	0.6	2
3277	Pembrolizumabâ€'induced aseptic meningitis in a patient with nonâ€'small cell lung cancer: A case report and literature review of aseptic meningitis as an immuneâ€'related adverse event. Molecular and Clinical Oncology, 2022, 17, .	0.4	2
3278	Serum Proteomics in Patients with Head and Neck Cancer: Peripheral Blood Immune Response to Treatment. International Journal of Molecular Sciences, 2022, 23, 6304.	1.8	8
3279	Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1. Pharmacological Research, 2022, 182, 106287.	3.1	20
3280	Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Journal of Immunotherapy, 2022, 45, 291-298.	1.2	7
3281	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, 1, .		267
3282	The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. Current Oncology Reports, 2022, 24, 1413-1423.	1.8	1

#	Article	IF	Citations
3283	Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. JTO Clinical and Research Reports, 2022, 3, 100355.	0.6	5
3286	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. International Journal of Biological Sciences, 2022, 18, 3845-3858.	2.6	64
3287	Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence. Frontiers in Oncology, 0, 12, .	1.3	8
3288	Neoadjuvant immunotherapy followed by surgery with curative intent in 35 patients with advanced NSCLC: the retrospective experiences of a multidisciplinary team. Annals of Translational Medicine, 2022, 10, 609-609.	0.7	4
3289	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC WithÂHighÂProgrammed Death-Ligand 1ÂExpression. JTO Clinical and Research Reports, 2022, 3, 100369.	0.6	3
3290	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Frontiers in Oncology, 0, 12, .	1.3	0
3291	Efficacy and safety of pembrolizumab monotherapy in advanced non-small cell lung cancer patients treated at Hanoi Medical University Hospital. Tap Chi Nghien Cuu Y Hoc, 2022, 154, 146-152.	0.0	0
3292	First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. Immunotherapy, 2022, 14, 871-877.	1.0	1
3293	Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Cells, 2022, 11, 1857.	1.8	10
3294	Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?. Cancers, 2022, 14, 2970.	1.7	3
3295	Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. OncoTargets and Therapy, 0, Volume 15, 637-642.	1.0	2
3296	Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 3353-3356.	0.8	2
3297	Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1755-1763.	1.2	5
3298	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature Communications, 2022, 13, .	5.8	28
3299	Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
3301	Trident Molecule with Nanobrushâ€“Nanoparticleâ€“Nanofiber Transition Property Spatially Suppresses Tumor Metastasis. Journal of the American Chemical Society, 2022, 144, 11897-11910.	6.6	44
3302	Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 3245.	1.0	8
3303	Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1835-1847.	1.2	2

#	Article	IF	Citations
3304	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
3305	Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1747-1754.	1.2	2
3306	Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
3307	Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. Clinical Cancer Research, 2022, 28, 4322-4335.	3.2	2
3308	Predicting the efficacy of <scp>firstâ€line</scp> immunotherapy by combining cancer cachexia and tumor burden in advanced <scp>nonâ€small cell</scp> lung cancer. Thoracic Cancer, 2022, 13, 2064-2074.	0.8	7
3309	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Nonâ€“Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	3
3310	A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Nonâ€“Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical Lung Cancer, 2022, 23, e400-e404.	1.1	4
3311	Emergence of the CD226 Axis in Cancer Immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	13
3312	Association of High Tumor Mutation Burden in Nonâ€“Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	3.4	117
3313	Correlations between Objective Response Rate and Survival-based Endpoints in First-line Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-analysis. Lung Cancer, 2022, , .	0.9	5
3314	Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils. Frontiers in Pharmacology, 0, 13, .	1.6	12
3315	Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. Npj Precision Oncology, 2022, 6, .	2.3	10
3316	Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature. Cureus, 2022, , .	0.2	1
3317	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. Cancer Management and Research, 0, Volume 14, 2079-2090.	0.9	3
3318	Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
3320	Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OncoTargets and Therapy, 0, Volume 15, 629-636.	1.0	2
3321	Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencingâ€“Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Nonâ€“Small-Cell Lung Cancer in the UnitedÂStates. Journal of Molecular Diagnostics, 2022, 24, 901-914.	1.2	17
3322	Early-stage Breast Cancer: Tailored External Beam Fractionation Approaches for Treatment of the Whole or Partial Breast. Seminars in Radiation Oncology, 2022, 32, 245-253.	1.0	1

#	Article	IF	Citations
3323	Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. JTO Clinical and Research Reports, 2022, 3, 100353.	0.6	4
3324	Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. Journal of Thoracic Oncology, 2022, 17, 865-866.	0.5	0
3325	STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer, 2022, 170, 114-121.	0.9	16
3326	Repurposing therapeutics for malignant pleural mesothelioma (MPM) â€“ Updates on clinical translations and future outlook. Life Sciences, 2022, 304, 120716.	2.0	3
3327	Importance of Prognostic Factors in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3328	Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2022, .	0.6	4
3329	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. Touch Reviews in Oncology & Haematology, 2022, 18, 73.	0.1	0
3331	The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR. Aging, 2022, 14, 5223-5232.	1.4	0
3332	Realâ€world utilization of <scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitors with palliative radiotherapy in patients with metastatic nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 2291-2300.	0.8	7
3333	Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Investigational New Drugs, 0, , .	1.2	0
3334	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. Frontiers in Immunology, 0, 13, .	2.2	9
3335	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Journal of Immunotherapy, 0, Publish Ahead of Print, .	1.2	0
3336	Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study. BMJ Open, 2022, 12, e061674.	0.8	4
3337	Prognostic Implication and Immunological Role of PSMD2 in Lung Adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	7
3338	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
3339	Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 7046.	1.8	19
3340	Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. Translational Lung Cancer Research, 2022, 11, 1038-1050.	1.3	4
3341	Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer. Experimental Biology and Medicine, 2022, 247, 1447-1465.	1.1	1

#	Article	IF	Citations
3342	The Cognitive Effects of Radiotherapy for Brain Metastases. Frontiers in Oncology, 0, 12, .	1.3	18
3343	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. International Journal of Molecular Sciences, 2022, 23, 7037.	1.8	5
3344	Immunotherapy in NSCLC Patients with Brain Metastases. International Journal of Molecular Sciences, 2022, 23, 7068.	1.8	12
3346	Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors. Immunotherapy, 2022, 14, 777-787.	1.0	1
3347	Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. Nature Communications, 2022, 13, .	5.8	14
3348	Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer. Current Oncology, 2022, 29, 4923-4935.	0.9	4
3349	Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment. Journal of Clinical Medicine, 2022, 11, 4003.	1.0	3
3350	Immunotherapy approaches for malignant pleural mesothelioma. Nature Reviews Clinical Oncology, 2022, 19, 573-584.	12.5	21
3351	Non-small cell lung cancer in the era of immunotherapy. Seminars in Oncology, 2022, 49, 337-343.	0.8	1
3352	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. Drugs in Context, 0, 11, 1-14.	1.0	2
3353	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. Seminars in Oncology, 2022, , .	0.8	0
3354	Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology, 2022, 2022, 1-27.	0.6	5
3355	Patient-Derived Lung Tumoroidsâ€"An Emerging Technology in Drug Development and Precision Medicine. Biomedicines, 2022, 10, 1677.	1.4	6
3356	<scp>Nonâ€small</scp> cell lung cancer with tumor proportion scoreâ€‰>â€‰90% could increase the risk of severe <scp>immuneâ€related</scp> adverse events in <scp>firstâ€line</scp> treatments with immune checkpoint inhibitors: A retrospective <scp>singleâ€center</scp> study. Thoracic Cancer, 2022, 13, 2450-2458.	0.8	4
3357	Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Review of Anticancer Therapy, 2022, 22, 927-937.	1.1	6
3358	Clinical impact of tumour burden on the efficacy of <scp>PD</scp> â€1/ <scp>PDâ€L1</scp> inhibitors plus chemotherapy in nonâ€smallâ€cell lung cancer. Cancer Medicine, 0, , .	1.3	1
3359	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. Cancers, 2022, 14, 3326.	1.7	2
3360	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 861-874.	1.1	6

#	Article	IF	Citations
3361	Primary pulmonary lymphoepitheliomaâ€like carcinoma treated with immunotherapy: A case report and literature review. Thoracic Cancer, 0, , .	0.8	4
3362	Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. ELife, 0, 11, .	2.8	11
3363	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. BMC Cancer, 2022, 22, .	1.1	4
3364	Chemotherapy Combined With Immunotherapy as a First-Line Treatment Brings Benefits to Patients With Lung Squamous Cell Carcinoma but Different Risks of Adverse Reactions: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	1
3365	Non-small-cell lung cancer: how to manage RET-positive disease. Drugs in Context, 0, 11, 1-12.	1.0	5
3366	Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology and Oncology, 2022, 15, .	6.9	48
3367	Tumor microenvironment in lung cancer-derived brain metastasis. Chinese Medical Journal, 2022, 135, 1781-1791.	0.9	7
3368	Comprehensive Genome Profiling in Patients With Metastatic Nonâ€“Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. Clinical Cancer Research, 2022, 28, 4018-4026.	3.2	4
3369	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. Journal of Clinical Oncology, 2022, 40, 3323-3343.	0.8	63
3370	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers, 2022, 14, 3473.	1.7	5
3371	Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 0, 13, .	2.2	10
3372	A rare case of Exon 19 deletion transforming to Exon 20 insertion in a case of adenocarcinoma of lung. International Journal of Molecular and Immuno Oncology, 0, 7, 108-111.	0.0	1
3373	Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?. Current Oncology, 2022, 29, 4779-4790.	0.9	1
3374	The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	9
3375	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. PLoS ONE, 2022, 17, e0270950.	1.1	5
3376	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. European Journal of Cancer, 2022, 172, 387-399.	1.3	4
3377	Colorectal cancer immunotherapy-Recent progress and future directions. Cancer Letters, 2022, 545, 215816.	3.2	32
3379	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0

#	Article	IF	Citations
3380	Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: aÂcase report. Journal of Medical Case Reports, 2022, 16, .	0.4	4
3381	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer and Metastasis Reviews, 2022, 41, 347-366.	2.7	11
3382	Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. Current Treatment Options in Oncology, 2022, 23, 1153-1168.	1.3	7
3383	Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors. Chinese Medical Journal, 2022, 135, 1404-1413.	0.9	7
3385	A Phase IB Trial of Autologous Cytokineâ€Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Deathâ€1, plus Chemotherapy in Patients with Advanced Nonâ€Smallâ€Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 709-719.	1.1	8
3386	Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients. Frontiers in Oncology, 0, 12, .	1.3	1
3387	A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma. Bioscience Reports, 2022, 42, .	1.1	7
3388	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. Cancers, 2022, 14, 3587.	1.7	6
3389	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. Frontiers in Immunology, 0, 13, .	2.2	6
3390	A phase II trial of Atezolizumab plus Carboplatin plus Pemetrexed plus Bevacizumab in the treatment of patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Clinical Lung Cancer, 2022, , .	1.1	3
3391	Handling and standardization of <scp>EBUS</scp> needle aspiration in <scp>NSCLC</scp> patients: The value of the cell block, a monoinstitutional experience. Thoracic Cancer, 2022, 13, 2480-2488.	0.8	3
3392	Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. , 2022, 10, e004487.		5
3393	Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. Cancer Research Communications, 2022, 2, 806-813.	0.7	7
3394	Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. , 2022, 10, e004863.		26
3395	PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC. Lung Cancer, 2022, 171, 42-46.	0.9	3
3396	Immunotherapy of Lung Cancer. Medical Radiology, 2022, , .	0.0	29
3397	Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease. Respiratory Medicine Case Reports, 2022, 39, 101728.	0.2	1
3398	Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 4373.	1.0	1

#	Article	IF	Citations
3399	PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 0, , .	0.8	0
3400	Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-11.	0.5	2
3401	Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases. Frontiers in Oncology, 0, 12, .	1.3	4
3402	Hsa_circ_0011292 regulates paclitaxel resistance partially through regulating CDCA4 expression by serving as a miR-3619-5p sponge in non-small cell lung cancer. Molecular and Cellular Toxicology, 0, , .	0.8	0
3403	The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	11
3404	Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance. Translational Lung Cancer Research, 2022, 11, 1315-1326.	1.3	3
3405	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics, 2022, 12, 1799.	1.3	7
3406	Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precision Oncology, 2022, , .	1.5	0
3407	Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. Cancers, 2022, 14, 3690.	1.7	6
3408	Grade 3â€“4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers, 2022, 14, 3878.	1.7	7
3409	Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis. Journal of Neuro-Oncology, 2022, 159, 685-693.	1.4	5
3410	Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Nonâ€“Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. JCO Precision Oncology, 2022, , .	1.5	26
3411	Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform. Expert Opinion on Drug Delivery, 2022, 19, 1337-1349.	2.4	5
3412	Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report. Case Reports in Oncology, 0, , 732-737.	0.3	0
3413	Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. Cancers, 2022, 14, 3772.	1.7	11
3414	Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. International Journal of Molecular Sciences, 2022, 23, 8541.	1.8	2
3416	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .	1.3	32
3417	Immune checkpoint inhibitors: the mechanisms, limitations, and improvements. , 0, 8, 14-22.		0

#	Article	IF	Citations
3418	Neutrophils: Musketeers against immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	12
3419	A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-NaÃ¯ve Nonâ€“Small Cell Lung Cancer: TORG1630. Clinical Cancer Research, 2022, 28, 4402-4409.	3.2	11
3420	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. Cell Death and Disease, 2022, 13, .	2.7	5
3421	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	3
3422	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes and Diseases, 2023, 10, 1318-1350.	1.5	11
3423	Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. JAMA Network Open, 2022, 5, e2227211.	2.8	8
3424	Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. Journal of Geriatric Oncology, 2022, 13, 1216-1222.	0.5	3
3426	Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. Expert Opinion on Biological Therapy, 2022, 22, 1259-1273.	1.4	9
3427	Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?. Frontiers in Immunology, 0, 13, .	2.2	4
3428	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. Frontiers in Pharmacology, 0, 13, .	1.6	4
3429	PD-L1 testing by immunohistochemistry in Immuno-Oncology. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	6
3430	Immune-based combination therapy to convert immunologically cold tumors into hotÂtumors: an update and new insights. Acta Pharmacologica Sinica, 2023, 44, 288-307.	2.8	14
3431	Immune Checkpoint Inhibitors in Lung Cancer. , 0, 8, 111-120.		0
3432	PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	7
3433	Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. British Journal of Cancer, 2022, 127, 1718-1725.	2.9	1
3434	Prognostic Potential of Metabolic Activity on 18F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. Journal of Immunotherapy, 2022, 45, 349-357.	1.2	4
3435	Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Frontiers in Oncology, 0, 12, .	1.3	8
3436	Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. Oncologist, 2022, 27, 971-981.	1.9	9

#	Article	IF	Citations
3437	Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. Anti-Cancer Drugs, 2022, 33, 752-757.	0.7	0
3438	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	4
3439	Selective suppression of melanoma lacking IFN-Î³ pathway by JAK inhibition depends on T cells and host TNF signaling. Nature Communications, 2022, 13, .	5.8	11
3440	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Research Communications, 2022, 2, 1293-1303.	0.7	2
3441	Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: a post hoc efficacy analysis of KEYNOTE-189. JTO Clinical and Research Reports, 2022, , 100389.	0.6	0
3442	Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney International, 2022, 102, 930-935.	2.6	6
3443	State-of-the-art combination treatment strategies for advanced stage nonâ€“small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	8
3444	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Frontiers in Oncology, 0, 12, .	1.3	4
3445	PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas. Frontiers in Immunology, 0, 13, .	2.2	5
3446	Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer. Advances in Therapy, 2022, 39, 4645-4662.	1.3	0
3447	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3469-3483.	1.2	9
3448	Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. Frontiers in Oncology, 0, 12, .	1.3	6
3449	Novel Anticancer Strategy by Targeting the Gut Microbial Neurotransmitter Signaling to Overcome Immunotherapy Resistance. Antioxidants and Redox Signaling, 0, , .	2.5	1
3450	Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients. Frontiers in Pharmacology, 0, 13, .	1.6	0
3451	Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nature Medicine, 2022, 28, 2374-2380.	15.2	85
3452	Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell, 2022, 40, 1010-1026.e11.	7.7	47
3453	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. Journal of Oncology, 2022, 2022, 1-15.	0.6	1
3454	Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	Citations
3455	External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open, 2022, 7, 100551.	2.0	4
3456	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 1045-1053.	0.6	2
3457	Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	14
3458	Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation. Frontiers in Oncology, 0, 12, .	1.3	5
3459	Safety and efficacy of pralsetinib in RET fusionâ€“positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Annals of Oncology, 2022, 33, 1168-1178.	0.6	56
3460	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	6
3461	PD-1/PD-L1 inhibitors in treatment-naÃ¯ve, advanced non-small cell lung cancer patients withâ€‰<â€‰1% PD-L1 expression: a meta-analysis of randomized controlled trials. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3
3463	Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in nonâ€“small cell lung cancer: Results from a randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 327-334.e2.	0.4	11
3464	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. Clinics and Practice, 2022, 12, 653-671.	0.6	8
3465	Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology, 2022, 5, 68-78.	0.6	6
3466	Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field. Frontiers in Oncology, 0, 12, .	1.3	1
3467	Immune checkpoint Inhibitorâ€“Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews, 2022, 109, 102440.	3.4	28
3468	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer, 2022, 172, 19-28.	0.9	9
3469	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine, 2022, 52, 101595.	3.2	14
3470	Novel approaches for treatment of endometrial carcinoma. Current Problems in Cancer, 2022, 46, 100895.	1.0	7
3471	Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study. European Journal of Cancer, 2022, 174, 21-30.	1.3	6
3472	Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy. Neoplasia, 2022, 32, 100824.	2.3	4
3473	Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. Lung Cancer, 2022, 172, 65-74.	0.9	5

#	Article	IF	Citations
3474	The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Translational Oncology, 2022, 25, 101508.	1.7	6
3475	The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. International Journal of General Medicine, 0, Volume 15, 7383-7393.	0.8	1
3476	FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. , 2022, 10, e005116.		12
3477	Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
3478	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open, 2022, 7, 100577.	2.0	11
3479	Aqueous extract of Taxus chinensis var. mairei targeting CD47 enhanced antitumor effects in non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2022, 154, 113628.	2.5	5
3480	Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Critical Reviews in Oncology/Hematology, 2022, 179, 103806.	2.0	14
3481	Engineered extracellular vesicles: A novel platform for cancer combination therapy and cancer immunotherapy. Life Sciences, 2022, 308, 120935.	2.0	13
3482	Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients. Lung Cancer, 2022, 173, 35-42.	0.9	4
3483	Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature. Current Problems in Cancer Case Reports, 2022, 8, 100190.	0.1	0
3484	Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System. Value in Health Regional Issues, 2023, 33, 1-6.	0.5	0
3485	An update on treatment of penile cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211272.	1.4	14
3486	Chemotherapy for Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3487	Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. Respiratory Medicine Case Reports, 2022, 40, 101753.	0.2	1
3488	Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma and its usefulness in immunotherapy. International Journal of Biological Sciences, 2022, 18, 5913-5927.	2.6	1
3489	Immunotherapy in Early Stage Non-Small Cell Lung Cancer. Advances in Lung Cancer (Irvine), 2022, 11, 31-44.	0.2	0
3490	Translational Research in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3491	Available Immunotherapy Drugs in Oncology. Current Clinical Pathology, 2022, , 5-23.	0.0	0

#	Article	IF	Citations
3492	The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211126.	1.4	15
3493	Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan. Journal of Cancer, 2022, 13, 2922-2932.	1.2	0
3494	The mechanism of radiotherapy for lung adenocarcinoma in promoting protein SIRT6-mediated deacetylation of RBBP8 to enhance the sensitivity of targeted therapy. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211307.	1.0	4
3495	Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. Technology in Cancer Research and Treatment, 2022, 21, 153303382211284.	0.8	3
3496	Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report. Clinical Lung Cancer, 2022, 23, e563-e567.	1.1	2
3497	Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial. Translational Lung Cancer Research, 2022, 11, 1657-1666.	1.3	0
3498	Cost-Effectiveness of Pembrolizumab for the treatment of Nonâ€“Small-Cell lung cancer: A systematic review. Frontiers in Oncology, 0, 12, .	1.3	2
3500	Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit. Journal of Thoracic Oncology, 2022, 17, 1365-1374.	0.5	0
3501	Clinical trial design in the era of precision medicine. Genome Medicine, 2022, 14, .	3.6	68
3502	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 6260-6276.	0.9	6
3503	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nature Cancer, 2022, 3, 1151-1164.	5.7	79
3504	Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of Thoracic Oncology, 2023, 18, 79-92.	0.5	11
3505	Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. Nature Communications, 2022, 13, .	5.8	25
3506	Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 4209.	1.7	9
3507	Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell, 2022, 40, 1161-1172.e5.	7.7	44
3508	Immune checkpoint inhibitorâ€“induced arthralgia is tightly associated with improved overall survival in cancer patients. Rheumatology, 2023, 62, 1451-1459.	0.9	1
3509	Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. Biomedicines, 2022, 10, 2249.	1.4	3
3510	Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy. Frontiers in Immunology, 0, 13, .	2.2	5

#	Article	IF	Citations
3511	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. Frontiers in Oncology, 0, 12, .	1.3	1
3512	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	5
3513	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. Frontiers in Genetics, 0, 13, .	1.1	0
3514	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Frontiers in Oncology, 0, 12, .	1.3	6
3515	First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. Journal of Immunotherapy, 2022, 45, 407-414.	1.2	1
3516	The need to optimize chemotherapy regimens for chemo-immunotherapy. Journal of Thoracic Disease, 2022, 14, 3648-3649.	0.6	0
3517	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
3518	Unlocking phenotypic plasticity provides novel insights for immunity and personalized therapy in lung adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
3519	Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy. Cancer Research Communications, 2022, 2, 1266-1281.	0.7	3
3520	Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. BMC Cancer, 2022, 22, .	1.1	6
3521	Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. Cancers, 2022, 14, 4363.	1.7	2
3522	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Frontiers in Immunology, 0, 13, .	2.2	5
3523	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers, 2022, 14, 4562.	1.7	15
3524	Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin. Journal of Oncology, 2022, 2022, 1-14.	0.6	2
3525	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. Frontiers in Immunology, 0, 13, .	2.2	0
3526	Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. British Journal of Cancer, 2022, 127, 2034-2042.	2.9	8
3527	Efficacy of immune checkpoint inhibitor as maintenance therapy for advanced or metastatic cancers: A meta-analysis of randomized controlled trials. Medicine (United States), 2022, 101, e30830.	0.4	0
3528	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. JTO Clinical and Research Reports, 2022, 3, 100416.	0.6	1

#	Article	IF	Citations
3529	Clinical predictive value of naÃ¯ve and memory T cells in advanced NSCLC. Frontiers in Immunology, 0, 13, .	2.2	13
3530	PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials. BMJ Open Respiratory Research, 2022, 9, e001294.	1.2	0
3531	Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. Frontiers in Oncology, 0, 12, .	1.3	5
3532	Phase 1 trial of <scp>CV301</scp> in combination with <scp>antiâ€PD</scp> â€1 therapy in <scp>nonsquamous nonâ€small</scp> cell lung cancer. International Journal of Cancer, 0, , .	2.3	1
3533	Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Frontiers in Immunology, 0, 13, .	2.2	4
3534	Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade. Cancer Discovery, 2022, 12, 2774-2799.	7.7	22
3535	Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatmentâ€"therapeutic indication or therapeutic efficacy?. Translational Cancer Research, 2022, 11, 3003-3005.	0.4	0
3536	Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128.		4
3537	Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. Annals of Medicine, 2022, 54, 2605-2615.	1.5	7
3538	Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team. Journal of Cancer Research and Clinical Oncology, 2023, 149, 877-883.	1.2	3
3539	The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	31
3540	Lung cancer with brain metastases remaining in continuous complete remission due to pembrolizumab and temozolomide: a case report. Annals of Translational Medicine, 2022, 10, 942-942.	0.7	1
3541	Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review. Heliyon, 2022, 8, e10581.	1.4	2
3542	Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. Frontiers in Genetics, 0, 13, .	1.1	3
3543	Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced nonâ€"small cell lung cancer in Spain. Global & Regional Health Technology Assessment, 0, 9, 82-90.	0.2	0
3544	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. Cancers, 2022, 14, 4481.	1.7	3
3545	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-12.	0.6	2
3546	Five decades of progress in surgical oncology: Tumors of the lung and esophagus. Journal of Surgical Oncology, 2022, 126, 921-925.	0.8	1

#	Article	IF	Citations
3547	Thyroid Dysfunction in Nonâ€“Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Metaâ€Analysis. Journal of Clinical Pharmacology, 0, , .	1.0	0
3548	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
3549	Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. Frontiers in Oncology, 0, 12, .	1.3	8
3550	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. Medicine (United States), 2022, 101, e30151.	0.4	0
3551	Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective. Current Oncology, 2022, 29, 7072-7085.	0.9	5
3552	Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report. Annals of Translational Medicine, 2022, 10, 1028-1028.	0.7	1
3553	PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
3554	International consensus on radiotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 1763-1795.	1.3	10
3555	Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities. Molecules, 2022, 27, 6229.	1.7	9
3556	Imaging Effector Memory T-Cells Predicts Response to PD1-Chemotherapy Combinations in Colon Cancer. Biomedicines, 2022, 10, 2343.	1.4	1
3557	Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. Clinical Cancer Research, 2023, 29, 621-634.	3.2	3
3558	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
3559	Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy. Genes, 2022, 13, 1757.	1.0	4
3560	Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study. Frontiers in Surgery, 0, 9, .	0.6	0
3561	Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	0
3562	Results from the IMpower132 China cohort: Atezolizumab plus platinumâ€based chemotherapy in advanced nonâ€small cell lung cancer. Cancer Medicine, 0, , .	1.3	3
3563	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. Biomedicines, 2022, 10, 2211.	1.4	2
3564	Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous nonâ€“small cell lung cancer patients with impaired renal function: RESTART trial. BMC Cancer, 2022, 22, .	1.1	0

#	Article	IF	Citations
3565	Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours. Nature Communications, 2022, 13, .	5.8	2
3566	Immunotherapy combined with chemotherapy versus chemotherapy alone as the firstâ€line treatment of <scp>PDâ€L1</scp> â€negative and driverâ€geneâ€negative advanced nonsquamous nonâ€smallâ€cell lung cancer: An updated systematic review and metaâ€analysis. Thoracic Cancer, 0, , .	0.8	5
3567	Serplulimab With Chemotherapy in Extensive-Stage SCLC. JAMA - Journal of the American Medical Association, 2022, 328, 1205.	3.8	2
3568	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. Cancers, 2022, 14, 4759.	1.7	1
3569	Evolution of precision oncologyâ€guided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	1.5	5
3570	The Management of Oligometastases in Non-small Cell Lung Cancer â€“ is Stereotactic Ablative Radiotherapy now Standard of Care?. Clinical Oncology, 2022, , .	0.6	2
3571	The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunology, Immunotherapy, 2023, 72, 783-794.	2.0	9
3572	PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling. Cancer Immunology Research, 2022, 10, 1299-1308.	1.6	4
3573	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. Statistics in Biopharmaceutical Research, 0, , 1-34.	0.6	0
3574	Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. European Journal of Cancer, 2022, 177, 175-185.	1.3	106
3575	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2022, 27, 289-300.	1.0	5
3576	Emerging Targeted Therapies for Early Breast Cancer. Drugs, 2022, 82, 1437-1451.	4.9	5
3577	Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. Journal of Thoracic Oncology, 2023, 18, 194-203.	0.5	12
3578	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	9
3579	There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC. Journal of Thoracic Oncology, 2022, 17, 1171-1174.	0.5	1
3580	Comparison of nextâ€generation sequencing and cobas <scp>EGFR</scp> mutation test v2 in detecting <scp>EGFR</scp> mutations. Thoracic Cancer, 2022, 13, 3217-3224.	0.8	6
3581	Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC Cancer, 2022, 22, .	1.1	3
3582	Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Nonâ€“Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). Journal of Clinical Oncology, 2023, 41, 651-663.	0.8	45

#	Article	IF	Citations
3583	Efficacy of Chemoimmunotherapy in NSCLC Patients With Brain Metastasis With or Without Prior Brain Radiotherapy. Anticancer Research, 2022, 42, 4805-4812.	0.5	2
3584	Novel <scp>NRF2</scp>â€activated cancer treatments utilizing synthetic lethality. IUBMB Life, 2022, 74, 1209-1231.	1.5	7
3585	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Frontiers in Immunology, 0, 13, .	2.2	2
3586	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomaterials Science and Engineering, 2022, 8, 4819-4826.	2.6	2
3587	Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 828-839.e5.	0.4	13
3588	Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	1
3590	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. Frontiers in Pharmacology, 0, 13, .	1.6	2
3591	Significance of NRF2 in physiological and pathological conditions an comprehensive review. Archives of Biochemistry and Biophysics, 2022, 730, 109417.	1.4	15
3592	Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. , 2022, , 1-33.		0
3593	NMR-Based Metabolomics to Evaluate Individual Response to Treatments. Handbook of Experimental Pharmacology, 2022, , 209-245.	0.9	4
3594	Chemotherapeutic Protocols for the Treatment of Lung Cancer. , 2022, , 291-305.		0
3595	NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 2023, 18, 106-119.	0.5	21
3597	Nivolumabâ€induced radiation recall pneumonitis in nonâ€small cell lung cancer patients with thoracic radiation therapy. Cancer Science, 0, , .	1.7	3
3598	Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology and Nephrology, 2023, 55, 1025-1032.	0.6	3
3599	Current status of immunotherapy for non-small cell lung cancer. Frontiers in Pharmacology, 0, 13, .	1.6	11
3600	Immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 1225-1238.	1.1	2
3601	Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer. Frontiers in Oncology, 0, 12, .	1.3	3
3602	EGFR mutations and high PD-L1 expression of lung squamous cell carcinoma patients achieving pCR following neoadjuvant immuno-chemotherapy: Case report. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
3603	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. Nihon Kikan Shokudoka Gakkai Kaiho, 2022, 73, 325-331.	0.0	0
3604	The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clinical and Research Reports, 2022, 3, 100427.	0.6	3
3605	Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. Acta OncolÃ³gica, 2022, 61, 1339-1346.	0.8	1
3606	A Hybrid Discreteâ€“Continuum Modelling Approach to Explore the Impact of T-Cell Infiltration on Anti-tumour Immune Response. Bulletin of Mathematical Biology, 2022, 84, .	0.9	3
3607	Assessment of added activity of an antitumor agent. Contemporary Clinical Trials, 2022, 123, 106990.	0.8	2
3608	Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment. Frontiers in Pharmacology, 0, 13, .	1.6	4
3610	The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors. Clinical Research in Cardiology, 2023, 112, 409-418.	1.5	8
3611	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. , 2022, 10, e004781.		2
3612	Phase I trial of the TNF-Î± inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications, 2022, 13, .	5.8	6
3613	Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlentherapie Und Onkologie, 2023, 199, 121-130.	1.0	7
3615	The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Journal of Immunotherapy, 0, Publish Ahead of Print, .	1.2	1
3618	Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives. Cancer Biology and Medicine, 0, , 1-13.	1.4	0
3619	SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. Journal of Thoracic Oncology, 2023, 18, 31-46.	0.5	28
3620	Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag. Journal of Oncology, 2022, 2022, 1-8.	0.6	1
3621	Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as firstâ€line therapy in adenocarcinoma patients. Cancer Medicine, 2023, 12, 5352-5363.	1.3	2
3622	Costâ€effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the firstâ€line treatment for advanced esophageal cancer. Cancer Medicine, 0, , .	1.3	4
3624	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. International Journal of Clinical Oncology, 0, , .	1.0	0
3625	The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors. Frontiers in Pharmacology, 0, 13, .	1.6	0

#	Article	IF	Citations
3626	Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO. Translational Lung Cancer Research, 2022, 11, 2010-2021.	1.3	6
3627	Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices. Frontiers in Oncology, 0, 12, .	1.3	5
3628	Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer. Investigational New Drugs, 2022, 40, 1298-1305.	1.2	5
3629	Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 2022, 19, 775-790.	12.5	182
3631	Novel small 99mTc-labeled affibody molecular probe for PD-L1 receptor imaging. Frontiers in Oncology, 0, 12, .	1.3	4
3632	The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Molecular Cancer Therapeutics, 2022, 21, 1645-1651.	1.9	6
3633	Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations. OncoTargets and Therapy, 0, Volume 15, 1197-1210.	1.0	4
3634	Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 4933.	1.7	5
3635	Sâ€‹1 eliminates <scp>MDSCs</scp> and enhances the efficacy of <scp>PD</scp>â€‹1 blockade via regulation of tumorâ€derived Bv8 and <scp>S100A8</scp> in thoracic tumor. Cancer Science, 2023, 114, 384-398.	1.7	6
3636	A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Frontiers in Immunology, 0, 13, .	2.2	5
3640	Potential of VEGFR2 expression as a predictive marker of PDâ€‘1 blockade in patients with advanced NSCLC. Oncology Reports, 2022, 48, .	1.2	4
3641	Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas. Frontiers in Surgery, 0, 9, .	0.6	2
3642	Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study. Journal of Thoracic Disease, 2022, 14, 4096-4112.	0.6	2
3643	More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. Journal of Cancer Research and Clinical Oncology, 2023, 149, 4933-4938.	1.2	1
3646	Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. Frontiers in Molecular Biosciences, 0, 9, .	1.6	9
3647	Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review). International Journal of Oncology, 2022, 61, .	1.4	7
3648	Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. JAMA Network Open, 2022, 5, e2237699.	2.8	7
3649	Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. Hypertension, 2022, 79, 2611-2621.	1.3	16

#	Article	IF	Citations
3650	Inmunoterapia en pacientes con cÃ¡ncer de pulmÃ³n y metÃ¡stasis cerebrales de inicio. , 2022, 25, .		0
3651	Optic neuritis in lung adenocarcinoma: A challenging diagnosis. Respiratory Medicine and Research, 2022, 82, 100966.	0.4	1
3652	Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. Frontiers in Pharmacology, 0, 13, .	1.6	3
3653	Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5061-5070.	1.2	7
3654	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Nonâ€“Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology, 2023, 41, 1213-1227.	0.8	107
3655	Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India. Ecancermedicalscience, 0, 16, .	0.6	3
3656	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022.	1.1	4
3657	Immune checkpoint inhibitor therapyÂand elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer. Journal of Pharmaceutical Health Care and Sciences, 2022, 8, .	0.4	1
3658	Modeling the impact of novel systemic treatments on lung cancer screening benefits. Cancer, 2023, 129, 226-234.	2.0	1
3659	Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis. Journal of the National Cancer Institute, 2023, 115, 29-42.	3.0	7
3660	Pyroptosis predicts immunotherapy outcomes across multiple cancer types. Clinical Immunology, 2022, 245, 109163.	1.4	7
3661	Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis. Journal of Bone Oncology, 2022, 37, 100459.	1.0	6
3662	Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study. Lung Cancer, 2022, 174, 67-70.	0.9	3
3663	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138.	2.0	14
3664	Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy. Biomaterials, 2022, 291, 121880.	5.7	28
3665	Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates. Nano Today, 2022, 47, 101641.	6.2	7
3666	Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. Respiratory Medicine Case Reports, 2022, 40, 101773.	0.2	1
3667	Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211367.	1.4	4

#	Article	IF	Citations
3668	The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2441-2448.	0.0	0
3669	Real-world landscape transition of death causes in the immunotherapy era for metastatic non-small cell lung cancer. Frontiers in Immunology, 0, 13, .	2.2	0
3670	NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. International Journal of Molecular Sciences, 2022, 23, 14054.	1.8	1
3671	KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. Frontiers in Oncology, 0, 12, .	1.3	1
3673	Case 35-2022: A 60-Year-Old Man with Progressive Dyspnea, Neck Swelling, and a Lung Mass. New England Journal of Medicine, 2022, 387, 1889-1896.	13.9	1
3674	Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clinical and Research Reports, 2023, 4, 100431.	0.6	3
3675	Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer. Cell Reports, 2022, 41, 111596.	2.9	7
3676	Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. , 2022, 10, e005401.		10
3677	A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. BMC Cancer, 2022, 22, .	1.1	1
3678	Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs. Immunopharmacology and Immunotoxicology, 2023, 45, 386-394.	1.1	0
3679	Inmunoterapia en cÃ¡ncer de pulmÃ³n metastÃ¡sico. , 2022, 25, .		0
3680	The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis. Frontiers in Immunology, 0, 13, .	2.2	1
3681	Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. Frontiers in Pharmacology, 0, 13, .	1.6	4
3682	Anlotinib plus chemotherapy for <scp>T790M</scp>â€negative <scp>EGFR</scp>â€mutant <scp>nonâ€sqNSCLC</scp> resistant to <scp>TKIs</scp>: A multicenter phase 1b/2 trial. Thoracic Cancer, 2022, 13, 3496-3503.	0.8	1
3683	Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic nonâ€smallâ€cell lung cancer characterizes the features of response to PDâ€1 blockade plus chemotherapy. Cancer Communications, 2022, 42, 1331-1346.	3.7	10
3684	Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. Journal of the National Cancer Institute, 2023, 115, 295-302.	3.0	3
3685	Low-dose nivolumab in advanced hepatocellular carcinoma. BMC Cancer, 2022, 22, .	1.1	5
3686	Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy, 0, , .	1.0	0

#	Article	IF	Citations
3687	Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. Pharmaceuticals, 2022, 15, 1407.	1.7	4
3688	How to manage KRAS G12C-mutated advanced non-small-cell lung cancer. , 0, 11, 1-11.		4
3689	Antibody Drug Conjugates in Lung Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 429-435.	1.0	0
3690	Longâ€term (>5â€year) survivors among unresectable or metastatic cancer patients treated with zoledronateâ€activated killer cells: Seven case reports. Clinical Case Reports (discontinued), 2022, 10, .	0.2	0
3691	Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	6
3693	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	3
3694	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. Frontiers in Pharmacology, 0, 13, .	1.6	1
3695	Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer. Respiratory Research, 2022, 23, .	1.4	6
3696	PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study. Frontiers in Oncology, 0, 12, .	1.3	2
3697	Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. ESMO Open, 2022, 7, 100605.	2.0	0
3698	High expression of prolyl 4-hydroxylase subunit alpha-2 in lung adenocarcinoma indicates poor prognosis. Clinics, 2022, 77, 100123.	0.6	1
3699	The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis. Clinical and Experimental Medicine, 2023, 23, 1551-1561.	1.9	7
3700	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Annals of Oncology, 2023, 34, 173-185.	0.6	8
3701	Development and validation of a prognostic 9-gene signature for colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	2
3702	Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Control, 2022, 29, 107327482211406.	0.7	0
3703	Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma. Journal of Cancer, 2022, 13, 3701-3709.	1.2	1
3704	Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. Lung Cancer, 2023, 175, 17-26.	0.9	1
3705	Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma. Translational Oncology, 2023, 27, 101600.	1.7	3

#	Article	IF	Citations
3706	A comparison of cancer vaccine adjuvants in clinical trials. Cancer Treatment and Research Communications, 2023, 34, 100667.	0.7	2
3707	Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody. Respiratory Medicine Case Reports, 2023, 41, 101797.	0.2	2
3708	SMARCA4: Current status and future perspectives in non-small-cell lung cancer. Cancer Letters, 2023, 554, 216022.	3.2	14
3709	The use of medical cannabis concomitantly with immune checkpoint inhibitorsÂin non-small cell lung cancer: A sigh of relief?. European Journal of Cancer, 2023, 180, 52-61.	1.3	10
3710	Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease. Respiratory Medicine and Research, 2023, 83, 100946.	0.4	0
3711	High-Risk Non-Small Cell Lung Cancer Treated With Active Scanning Proton Beam Radiation Therapy and Immunotherapy. Advances in Radiation Oncology, 2023, 8, 101125.	0.6	3
3712	PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancerâ€"an IMMUNOTARGET case series. Translational Lung Cancer Research, 2021, .	1.3	1
3713	Cancer Treatment Strategy by Fukushima Medical University Aims to Achieve. [Fukushima Igaku Zasshi] Fukushima Medical Journal, 2022, 72, 109-113.	0.1	0
3714	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. , 2023, , 267-286.		0
3715	The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211395.	0.6	2
3716	Palliative External Beam Thoracic Radiation Therapy of Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3717	Tumor glycolytic profiling through ¹⁸F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211383.	1.4	2
3719	Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review. Frontiers in Pharmacology, 0, 13, .	1.6	3
3720	Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 â€“ 2020 - A population-based registry study from Norway. Frontiers in Oncology, 0, 12, .	1.3	1
3721	A Study on the Availability of Survival Analysis of Lung Cancer Patients Using Synthetic Data. Journal of Health Informatics and Statistics, 2022, 47, 279-289.	0.1	0
3722	Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. Clinical Lung Cancer, 2022, , .	1.1	1
3723	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. Frontiers in Immunology, 0, 13, .	2.2	6
3724	Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia. Cancers, 2022, 14, 5791.	1.7	0

#	Article	IF	Citations
3725	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. Current Oncology, 2022, 29, 9046-9065.	0.9	6
3726	Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients. Medicine (United States), 2022, 101, e31665.	0.4	1
3727	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2022, 24, 269-304.	0.1	2
3728	Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. Cancers, 2022, 14, 5929.	1.7	4
3729	Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. Frontiers in Immunology, 0, 13, .	2.2	1
3730	Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study. Journal of Thoracic Disease, 2022, 14, 4416-4426.	0.6	2
3731	Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. Cancers, 2022, 14, 5854.	1.7	0
3732	Chlorotoxin and Lung Cancer: A Targeting Perspective for Drug Delivery. Pharmaceutics, 2022, 14, 2613.	2.0	2
3733	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. Thoracic and Cardiovascular Surgeon, 0, , .	0.4	0
3734	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 2170-2174.	1.3	0
3736	Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. BMC Cancer, 2022, 22, .	1.1	2
3737	Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	2
3738	A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab. Case Reports in Oncology, 2022, 15, 1063-1073.	0.3	2
3739	Chemo-Immuntherapie beim NSCLC: Begrenzte Erfolge bei schlechtem AZ und Infekt. , 0, , .		0
3740	A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. BMC Neurology, 2022, 22, .	0.8	6
3741	Transcriptional upregulation of <scp>CXCL13</scp> is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. Cancer Medicine, 2023, 12, 7639-7650.	1.3	3
3742	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. Frontiers in Immunology, 0, 13, .	2.2	2
3743	Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). BMC Cancer, 2022, 22, .	1.1	2

#	Article	IF	Citations
3744	Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature. International Journal of Molecular Sciences, 2023, 24, 193.	1.8	3
3745	PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. ESMO Open, 2022, 7, 100645.	2.0	3
3747	Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. Cancers, 2022, 14, 5954.	1.7	0
3748	Mathematical modeling of cancer immunotherapy for personalized clinical translation. Nature Computational Science, 2022, 2, 785-796.	3.8	9
3749	Metabolic inhibitor screening identifies dihydrofolate reductase as an inducer of the tumor immune escape mediator CD24. Immunomedicine, 2022, 2, .	0.7	0
3750	Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers, 2022, 14, 6013.	1.7	11
3751	New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases. International Journal of Molecular Sciences, 2022, 23, 15263.	1.8	6
3752	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
3753	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
3754	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Î² and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. Oncologist, 2023, 28, 258-267.	1.9	7
3755	Clinical characteristics of adrenal insufficiency induced by pembrolizumab in nonâ€smallâ€cell lung cancer. Thoracic Cancer, 2023, 14, 442-449.	0.8	5
3756	EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Science Advances, 2022, 8, .	4.7	14
3757	Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial. Cancers, 2022, 14, 6074.	1.7	1
3758	Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2022, 22, .	0.8	3
3759	Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 2023, 22, 213-234.	21.5	69
3761	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer With High Tumor Mutation Burden. JAMA Oncology, 2023, 9, 344.	3.4	13
3762	Chemotherapy: A partnership with immunotherapy in n<scp>onâ€small</scp> cell lung cancer. Thoracic Cancer, 2023, 14, 437-441.	0.8	4
3763	Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Frontiers in Immunology, 0, 13, .	2.2	2

#	Article	IF	Citations
3764	Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis. Nutrition and Cancer, 0, , 1-11.	0.9	4
3765	Discrete and continuum models for the coevolutionary dynamics between CD8+ cytotoxic T lymphocytes and tumour cells. Mathematical Medicine and Biology, 0, , .	0.8	2
3766	Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	7
3767	Onconephrology 2022: An Update. Kidney360, 2023, 4, 258-271.	0.9	5
3768	Prognostic value of inflammatory and nutritional indexes among advanced <scp>NSCLC</scp> patients receiving <scp>PD</scp>â€1 inhibitor therapy. Clinical and Experimental Pharmacology and Physiology, 2023, 50, 178-190.	0.9	10
3769	Towards the characterization of the tumor microenvironment through dictionary learning-based interpretable classification of multiplexed immunofluorescence images. Physics in Medicine and Biology, 2023, 68, 014002.	1.6	0
3771	From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Frontiers in Medicine, 0, 9, .	1.2	2
3772	Monitoring PD-L1 Expression on Circulating Tumorâ€“Associated Cells in Recurrent Metastatic Nonâ€“Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. JCO Precision Oncology, 2022, , .	1.5	10
3773	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Cancers, 2022, 14, 6145.	1.7	10
3774	Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. Current Problems in Cancer, 2022, , 100934.	1.0	0
3775	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	6.9	46
3776	Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	6
3777	Attempting to Identify Bacterial Allies in Immunotherapy of NSCLC Patients. Cancers, 2022, 14, 6250.	1.7	6
3778	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1â€“Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Journal of Clinical Oncology, 2023, 41, 1735-1746.	0.8	19
3779	Tolerability and efficacy of chemoimmunotherapy when administered with a corticosteroid-free anti-emetic regimen. Journal of Oncology Pharmacy Practice, 0, , 107815522211465.	0.5	0
3780	Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study. Annals of Thoracic Surgery, 2023, 116, 703-710.	0.7	5
3781	Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The <scp>ToxImmune</scp> study. Cancer Reports, 2023, 6, .	0.6	2
3782	Cutaneous adverse events associated with PD-1 inhibitor-based therapy in patients with non-small-cell lung cancer. Future Oncology, 2022, 18, 3853-3861.	1.1	1

#	Article	IF	Citations
3783	Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. BMJ Case Reports, 2022, 15, e252590.	0.2	1
3784	Combination bezafibrate and nivolumab treatment of patients with advanced nonâ€“small cell lung cancer. Science Translational Medicine, 2022, 14, .	5.8	6
3785	The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. Cancers, 2022, 14, 6184.	1.7	3
3786	Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer. Frontiers in Immunology, 0, 13, .	2.2	1
3787	Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect. Clinical Cancer Research, 2023, 29, 667-683.	3.2	12
3788	Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Drug Design, Development and Therapy, 0, Volume 16, 4269-4277.	2.0	4
3789	spaCI: deciphering spatial cellular communications through adaptive graph model. Briefings in Bioinformatics, 2023, 24, .	3.2	28
3790	Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. Frontiers in Oncology, 0, 12, .	1.3	0
3791	Radiopharmaceuticals heat anti-tumor immunity. Theranostics, 2023, 13, 767-786.	4.6	4
3792	Modelâ€based metaâ€analysis of nonâ€small cell lung cancer with standard of care <scp>PD</scp>â€1 inhibitors and chemotherapy for early development decision making. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1751-1763.	1.3	0
3794	Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-Î²B Activation in T Cells and Suppressing Antitumor Immunity. Cancer Research, 2023, 83, 906-921.	0.4	13
3795	Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma. Journal of Thoracic Disease, 2023, .	0.6	1
3796	Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012â€“2018. BMC Pulmonary Medicine, 2023, 23, .	0.8	0
3797	Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. Journal of Thoracic Oncology, 2023, 18, 628-639.	0.5	6
3798	Adoption of Innovative Therapies Across Oncology Practicesâ€”Evidence From Immunotherapy. JAMA Oncology, 0, , .	3.4	1
3799	Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. Lung Cancer, 2023, 177, 11-20.	0.9	8
3800	Exploring the landscape of immunotherapy approaches in sarcomas. Frontiers in Oncology, 0, 12, .	1.3	1
3801	Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer?. Journal of Clinical Oncology, 0, , .	0.8	0

#	Article	IF	Citations
3802	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology, Immunotherapy, 2023, 72, 1365-1379.	2.0	93
3803	Repurposing nitric oxide donating drugs in cancer therapy through immune modulation. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	3.5	8
3804	Mechanisms of Resistance to Immunotherapies in Cancer. , 2023, , 1-30.		0
3805	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers, 2023, 15, 543.	1.7	8
3806	Genomic and immunogenomic analysis of three prognostic signature genes in LUAD. BMC Bioinformatics, 2023, 24, .	1.2	0
3807	The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. Frontiers in Immunology, 0, 13, .	2.2	1
3808	Sintilimab combined with chemotherapy successfully treated a patient with advanced submandibular gland tumor. Immunotherapy, 0, , .	1.0	0
3809	Endobronchial ultrasound-guided transbronchial needle injection of cisplatin results in dynamic changes in the tumor immune microenvironment. Respiratory Medicine and Research, 2023, 84, 100994.	0.4	0
3810	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. Drug Delivery, 2023, 30, .	2.5	5
3811	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. Cureus, 2023, , .	0.2	1
3812	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. Cancers, 2023, 15, 329.	1.7	8
3813	Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. , 2023, 11, e005801.		10
3815	Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology and Oncology, 2023, 12, .	2.0	17
3816	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. Cancers, 2023, 15, 529.	1.7	3
3817	Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC. JTO Clinical and Research Reports, 2023, 4, 100460.	0.6	1
3818	Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism. Molecules, 2023, 28, 862.	1.7	4
3819	Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. , 2023, 242, 108347.		4
3820	Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails. Therapeutic Innovation and Regulatory Science, 0, , .	0.8	0

#	Article	IF	Citations
3821	Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer. Cureus, 2023, , .	0.2	0
3822	A case of late and lethal Trousseau's syndrome induced by pembrolizumab in lung adenocarcinoma. Immunotherapy, 2023, 15, 71-75.	1.0	3
3823	<scp>Câ€PLAN</scp> index as a prognostic factor for patients with previously untreated advanced nonâ€small cell lung cancer who received combination immunotherapy: A multicenter retrospective study. Thoracic Cancer, 2023, 14, 636-642.	0.8	2
3824	Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 358-376.	0.6	94
3825	Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. International Journal of Nanomedicine, 0, Volume 18, 263-276.	3.3	3
3826	Strahlentherapie und Immuntherapie. Springer Reference Medizin, 2023, , 1-20.	0.0	0
3827	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. Journal of Comparative Effectiveness Research, 0, , .	0.6	0
3828	Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy. Annual Review of Cancer Biology, 2023, 7, 247-263.	2.3	4
3829	Corticosteroids and Cancer Immunotherapy. Clinical Cancer Research, 2023, 29, 2580-2587.	3.2	8
3830	Research Progress in Prognostic Markers of Immunotherapy for Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2023, 13, 264-271.	0.0	0
3831	Wnt/Î²-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. Biomedicines, 2023, 11, 190.	1.4	9
3832	PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Frontiers in Genetics, 0, 13, .	1.1	4
3833	Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous Non-Small Cell Lung Cancer. JTO Clinical and Research Reports, 2023, , 100461.	0.6	0
3834	Peripheral and tumorâ€infiltrating immune cells are correlated with patient outcomes in ovarian cancer. Cancer Medicine, 2023, 12, 10045-10061.	1.3	1
3835	Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. Gene, 2023, 857, 147177.	1.0	2
3836	Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. European Medical Journal Respiratory, 0, , 109-116.	1.0	1
3837	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Targeted Oncology, 0, , .	1.7	1
3838	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. DNA and Cell Biology, 2023, 42, 73-81.	0.9	2

#	Article	IF	Citations
3839	Advancements in Cancer Immunotherapies. Vaccines, 2023, 11, 59.	2.1	8
3840	Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2023, 12, 137.	1.0	0
3841	Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Nonâ€“small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2023, 24, 278-286.	1.1	3
3842	DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study. Translational Lung Cancer Research, 2022, 11, 2539-2566.	1.3	0
3843	Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines, 2023, 11, 83.	1.4	3
3844	miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response. Journal of Hematology and Oncology, 2022, 15, .	6.9	3
3845	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. Npj Breast Cancer, 2022, 8, .	2.3	8
3846	Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2023, 72, 1823-1834.	2.0	6
3847	Association Between Age and Survival Trends in Advanced Nonâ€“Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology, 2023, 9, 334.	3.4	15
3848	Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. Clinical Lung Cancer, 2023, , .	1.1	2
3851	Tumor immunology. , 2023, , 245-452.		0
3852	Insight into autophagy in platinum resistance of cancer. International Journal of Clinical Oncology, 2023, 28, 354-362.	1.0	2
3853	Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. Cancers, 2023, 15, 689.	1.7	5
3854	Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 713-724.	0.5	4
3855	Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer. Clinical and Translational Oncology, 2023, 25, 1916-1928.	1.2	4
3856	Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Frontiers in Oncology, 0, 13, .	1.3	2
3857	Immunotherapy for older patients with cancer. Current Opinion in Supportive and Palliative Care, 2023, 17, 37-46.	0.5	2
3858	Durvalumab and biliary tract cancer: a breakthrough in the field of oncology. International Journal of Surgery Global Health, 2023, 6, e109-e109.	0.2	0

#	Article	IF	Citations
3859	Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology, 2023, 12, 191.	1.3	0
3860	Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer, 2023, 23, .	1.1	6
3861	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
3862	Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. Frontiers in Oncology, 0, 12, .	1.3	1
3863	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	3
3864	Tracking Peripheral Memory T Cell Subsets in Advanced Nonsmall Cell Lung Cancer Treated with Hypofractionated Radiotherapy and PD-1 Blockade. Journal of Oncology, 2023, 2023, 1-11.	0.6	0
3865	Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2023, 116, 858-868.	0.4	15
3866	NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer, 2023, 178, 87-95.	0.9	0
3867	The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. Anti-Cancer Drugs, 2023, 34, 783-790.	0.7	2
3868	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. Open Medicine (Poland), 2023, 18, .	0.6	0
3869	Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review. Journal of Contemporary Brachytherapy, 2023, 15, 81-88.	0.4	1
3870	Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. Cancer Immunology, Immunotherapy, 2023, 72, 2169-2178.	2.0	1
3871	Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known. Hepatology Communications, 2023, 7, e0063-e0063.	2.0	3
3872	FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis. Clinical and Translational Imaging, 0, , .	1.1	1
3873	Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer. Frontiers in Immunology, 0, 14, .	2.2	0
3874	Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review. Frontiers in Immunology, 0, 14, .	2.2	2
3875	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. Praxis, 2023, 112, 160-171.	0.2	1
3876	Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy, 2023, 15, 267-281.	1.0	5

#	Article	IF	Citations
3877	Application of radiomics in lung immunoâ€•oncology. Precision Radiation Oncology, 2023, 7, 128-136.	0.4	1
3878	New Therapies on the Horizon. Hematology/Oncology Clinics of North America, 2023, , .	0.9	1
3879	Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Nonâ€“Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology, 2023, 41, 1992-1998.	0.8	75
3880	Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients. Investigational New Drugs, 0, , .	1.2	0
3881	Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. Immunotherapy, 0, , .	1.0	0
3882	Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. Frontiers in Oncology, 0, 13, .	1.3	1
3883	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). European Journal of Cancer, 2023, 184, 62-72.	1.3	9
3884	Immunotherapy-based combinations in metastatic NSCLC. Cancer Treatment Reviews, 2023, 116, 102545.	3.4	6
3885	Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. European Journal of Cancer, 2023, 185, 83-93.	1.3	10
3886	Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. European Journal of Cancer, 2023, 184, 179-196.	1.3	4
3887	Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer, 2023, 179, 107173.	0.9	7
3888	Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective. Cancer Treatment Reviews, 2023, 116, 102544.	3.4	2
3889	Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology. Seminars in Immunology, 2023, 67, 101754.	2.7	4
3891	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers, 2023, 15, 629.	1.7	7
3892	Artificial intelligence aids in development of nanomedicines for cancer management. Seminars in Cancer Biology, 2023, 89, 61-75.	4.3	86
3893	Natural Killer Cell-Based Immunotherapy against Glioblastoma. International Journal of Molecular Sciences, 2023, 24, 2111.	1.8	4
3894	Adjuvant immunotherapy in early-stage resectable nonâ€“small cell lung cancer: A new milestone. Frontiers in Oncology, 0, 13, .	1.3	4
3895	Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. Cancer Treatment Reviews, 2023, 114, 102520.	3.4	8

#	Article	IF	Citations
3896	Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity. Cancer Letters, 2023, 556, 216076.	3.2	1
3897	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European Journal of Cancer, 2023, 183, 38-48.	1.3	8
3898	First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. , 2023, 11, e006127.		14
3900	Study protocol of <scp>KeyPemls</scp>â€004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic nonâ€small cell lung cancer and progressive disease (<scp>PD</scp>) after immunotherapy (<scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitor) alone or in combination with platinumâ€doublet chemotherapy. Thoracic Cancer, 2023, 14, 773-778.	0.8	1
3901	Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report. Frontiers in Oncology, 0, 13, .	1.3	0
3902	Development and validation of an immuneâ€related gene signature for prognosis in Lung adenocarcinoma. IET Systems Biology, 2023, 17, 27-38.	0.8	1
3904	Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer. Pharmaceuticals, 2023, 16, 233.	1.7	1
3905	Synergistic Toxicities from Multiple Therapies for Synchronous Malignancies. Case Reports in Oncology, 0, , 45-48.	0.3	1
3906	Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy, 2023, 15, 293-309.	1.0	2
3907	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. Lung Cancer, 2023, 178, 96-102.	0.9	1
3908	Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	0
3909	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nature Communications, 2023, 14, .	5.8	18
3910	Read the clonotype: Next-generation sequencing-based lymphocyte clonality analysis and perspectives for application in pathology. Frontiers in Oncology, 0, 13, .	1.3	1
3911	Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology, 0, 13, .	1.3	2
3912	Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss Medical Weekly, 2023, 153, 40039.	0.8	0
3913	<scp>Firstâ€line</scp>nabâ€paclitaxel plus carboplatin for patients with advanced nonâ€small cell lung cancer: Final results of the <scp>NEPTUN</scp> study. International Journal of Cancer, 2023, 153, 141-152.	2.3	1
3914	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. Scientific Reports, 2023, 13, .	1.6	1
3915	FGFR inhibitors combined with nab-paclitaxel -ÂA promising strategy to treat non-small cell lung cancer and overcome resistance. Frontiers in Oncology, 0, 13, .	1.3	1

#	Article	IF	Citations
3916	Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. Journal of Thoracic Oncology, 2023, 18, 731-743.	0.5	15
3917	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. Biomedicines, 2023, 11, 508.	1.4	3
3918	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. JTO Clinical and Research Reports, 2023, 4, 100474.	0.6	0
3919	Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. European Journal of Clinical Pharmacology, 2023, 79, 503-511.	0.8	2
3920	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 3618.	1.8	6
3921	Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?. ESMO Open, 2023, 8, 100879.	2.0	2
3922	Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. Lung Cancer, 2023, 178, 183-190.	0.9	2
3923	Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Cancers, 2023, 15, 1235.	1.7	9
3924	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Current Oncology, 2023, 30, 2366-2387.	0.9	5
3925	Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. Cancer Immunology, Immunotherapy, 2023, 72, 2067-2074.	2.0	2
3926	Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4+ Th1 Response in Metastatic Nonâ€“Small Cell Lung Cancer. Journal of Immunotherapy, 2023, 46, 279-283.	1.2	2
3927	Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report. Medicine (United States), 2023, 102, e32924.	0.4	0
3928	Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. Frontiers in Immunology, 0, 14, .	2.2	7
3929	Adjuvant and neoâ€adjuvant immunotherapy in resectable nonâ€small cell lung cancer (NSCLC): Current status and perspectives. , 2023, 2, 65-78.		0
3930	Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer. Journal of Clinical Medicine, 2023, 12, 1611.	1.0	0
3931	A common genetic variation in GZMB may associate with cancer risk in patients with Lynch syndrome. Frontiers in Oncology, 0, 13, .	1.3	0
3932	MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. Cell Discovery, 2023, 9, .	3.1	5
3933	Standard versus lowâ€dose nabâ€paclitaxel in previously treated patients with advanced nonâ€small cell lung cancer: A randomized phase <scp>II</scp> trial (<scp>JMTO LC14</scp>â€01). Cancer Medicine, 2023, 12, 9133-9143.	1.3	2

#	Article	IF	Citations
3934	Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. Frontiers in Oncology, 0, 13, .	1.3	0
3935	Gender Differences in Symptom Burden, Functional Performance and Global Quality of Life of Lung Cancer Patients Receiving Inpatient versus Outpatient Treatment. Cancer Management and Research, 0, Volume 15, 175-183.	0.9	1
3936	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine, 2023, 23, .	0.8	1
3937	Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. Journal of Clinical Medicine, 2023, 12, 1711.	1.0	1
3938	Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 2023, 22, .	7.9	104
3939	Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. General Thoracic and Cardiovascular Surgery, 0, , .	0.4	0
3940	Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer. Lung Cancer, 2023, 178, 134-142.	0.9	1
3941	Liquid Biopsies in Lung Cancer. Cancers, 2023, 15, 1430.	1.7	7
3942	Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). Journal of Thoracic Oncology, 2023, 18, 813-819.	0.5	8
3943	Non-small cell lung cancer: news from immunotherapy. Journal of Lung, Pulmonary & Respiratory Research, 2022, 9, 8-10.	0.3	0
3944	Immune-related adverse events as potential surrogates of immune checkpoint inhibitorsâ€™ efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open, 2023, 8, 100787.	2.0	13
3945	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). Translational Lung Cancer Research, 2023, 12, 266-276.	1.3	2
3946	Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation. Cureus, 2023, , .	0.2	0
3947	Primary refractory plasmablastic lymphoma: A precision oncology approach. Frontiers in Oncology, 0, 13, .	1.3	4
3948	Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 2023, 12, 1833.	1.0	4
3950	Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. Cancer Imaging, 2023, 23, .	1.2	0
3951	The characteristics of oncological clinical trials investigating the synergistic effect of radiotherapy and immune checkpoint inhibitors: a cross-sectional study. Translational Cancer Research, 2023, 12, 558-571.	0.4	0
3952	Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Nonâ€“small Cell Lung Cancer With a PD-L1 Expression â‰¥50% or â‰¥90%. Clinical Lung Cancer, 2023, , .	1.1	2

#	Article	IF	Citations
3953	Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival. CKJ: Clinical Kidney Journal, 2023, 16, 773-775.	1.4	0
3954	Influence of EGFR mutation status and PDâ€L1 expression in stage III unresectable nonâ€small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	2
3955	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature Communications, 2023, 14, .	5.8	14
3956	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Critical Reviews in Oncology/Hematology, 2023, 184, 103954.	2.0	3
3957	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Frontiers in Immunology, 0, 14, .	2.2	2
3959	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. Frontiers in Immunology, 0, 14, .	2.2	0
3960	Lung cancer in the emergency department. , 2023, 2, .		4
3961	Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. Scientific Reports, 2023, 13, .	1.6	2
3962	TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports, 2023, 4, 100494.	0.6	1
3963	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports, 2023, 5, 100719.	2.6	10
3964	Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cells, 2023, 12, 832.	1.8	10
3965	Polysaccharideâ€Based Stimulusâ€Responsive Nanomedicines for Combination Cancer Immunotherapy. Small, 2023, 19, .	5.2	13
3966	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
3967	Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. PharmacoEconomics - Open, 2023, 7, 273-284.	0.9	1
3968	Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?. Acta OncolÃ³gica, 2023, 62, 298-304.	0.8	0
3969	Anti-PD-(L)1 therapy of non-small cell lung cancerâ€“A summary of clinical trials and current progresses. Heliyon, 2023, 9, e14566.	1.4	2
3970	Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study. Journal of Cancer, 2023, 14, 676-688.	1.2	0
3971	Lung cancer management in low and middle-income countries - current challenges and potential solutions. International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0

#	Article	IF	Citations
3972	Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report. Respirology Case Reports, 2023, 11, .	0.3	1
3973	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0
3974	The Role of Immunotherapy in Esophageal and Gastric Cancer. Clinical Colorectal Cancer, 2023, 22, 175-182.	1.0	2
3975	Trends in Survival Rates of Nonâ€“Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. JAMA Network Open, 2023, 6, e232002.	2.8	7
3978	Nanomedicine in Lung Cancer Immunotherapy. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	12
3979	Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumorâ€infiltrating CD68â€positive cell counts in patients with EGFRâ€mutant nonâ€small cell lung cancer. Molecular and Clinical Oncology, 2023, 18, .	0.4	1
3980	Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. Journal of Thoracic Oncology, 2023, 18, 869-881.	0.5	14
3981	Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. Journal of Hematology and Oncology, 2023, 16, .	6.9	5
3982	The involvement of Lymphocyte activation gene 3 and the inhibitor in non-small cell lung cancer. , 0, 36, 58-65.		1
3983	Combi-TED: a new trial testing Tedopi^{Â®} with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Future Oncology, 2022, 18, 4457-4464.	1.1	1
3984	The Role of Pembrolizumab (Keytruda) in Treating Non-small Cell Lung Cancer. , 0, 36, 608-613.		0
3985	TOPAZ-1: a new standard of care for advanced biliary tract cancers?. Immunotherapy, 0, , .	1.0	0
3986	Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2023, 8, 101192.	2.0	7
3987	Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. Npj Precision Oncology, 2023, 7, .	2.3	6
3988	A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	1
3989	Editorial: Unravelling the sarcoma microenvironment: Impact of the genomic landscape on molecular signaling, immunosuppression, and treatment resistance. Frontiers in Oncology, 0, 13, .	1.3	0
3990	Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer. Frontiers in Public Health, 0, 11, .	1.3	0
3991	Real-world data of combined immuno-chemotherapy in patients with non-squamous advanced non-small cell lung cancer. A single center retrospective study.. JTO Clinical and Research Reports, 2023, , 100509.	0.6	0

#	Article	IF	Citations
3992	Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. Current Opinion in Oncology, 2023, 35, 166-177.	1.1	1
3993	TTF-1 and immune checkpoint therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2023, 12, 398-400.	1.3	1
3994	Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine, 2023, 388, 2159-2170.	13.9	118
3995	Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy. Frontiers in Oncology, 0, 13, .	1.3	0
3996	Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. New England Journal of Medicine, 2023, 388, 2145-2158.	13.9	139
3997	Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies. Cancer Reports, 0, , .	0.6	1
3998	Co-Delivery of Cisplatin and Curcumin Using Mesoporous Silica Nanoparticles to Improve their Anticancer Effects. Pharmaceutical Nanotechnology, 2023, 11, 364-372.	0.6	1
3999	Neoadjuvant immunotherapy in resectable non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311637.	1.4	4
4000	Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network. Frontiers in Immunology, 0, 14, .	2.2	0
4001	Chemotherapy in Cutaneous Melanoma: Is There Still a Role?. Current Oncology Reports, 2023, 25, 609-621.	1.8	8
4002	Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. Journal of Thoracic Oncology, 2023, 18, 755-768.	0.5	13
4003	PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. JCO Precision Oncology, 2023, , .	1.5	0
4004	All-round counterattack to conquer lung cancer. Journal of the Korean Medical Association, 2023, 66, 154-158.	0.1	0
4005	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. BMC Gastroenterology, 2023, 23, .	0.8	0
4006	Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. Journal of Onco-Nephrology, 2023, 7, 57-65.	0.3	2
4008	Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
4009	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. Medical Radiology, 2023, , .	0.0	0
4010	Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects. , 2023, 40, .		0

#	Article	IF	Citations
4011	The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. Antibodies, 2023, 12, 27.	1.2	1
4012	Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. Immunotherapy, 2023, 15, 631-639.	1.0	2
4013	Metastatic germ cell tumor showing a durable response to the anti-PD-1 antibody toripalimab. Immunotherapy, 0, , .	1.0	1
4014	Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Frontiers in Immunology, 0, 14, .	2.2	8
4015	Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 2023, 55, 807-819.	9.4	18
4016	Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments. Investigational New Drugs, 2023, 41, 356-364.	1.2	2
4017	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell International, 2023, 23, .	1.8	24
4018	SOX1 Functions as a Tumor Suppressor by Repressing HES1 in Lung Cancer. Cancers, 2023, 15, 2207.	1.7	1
4019	Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?. Nature Reviews Clinical Oncology, 0, , .	12.5	0
4020	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194.	2.4	0
4021	Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE, 2023, 18, e0284037.	1.1	0
4022	Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. Journal of Cancer, 2023, 14, 874-879.	1.2	3
4023	Palliative Care in the New Era of Lung Cancer Treatment. Journal of Hospice and Palliative Nursing, 0, Publish Ahead of Print, .	0.5	0
4024	The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 2023, 14, 952-965.	1.2	1
4025	Avances y perspectivas de la inmunoterapia perioperatoria en el cÃ¡ncer de pulmÃ³n no-microcÃtico. Karger Kompass NeumologÃa, 2023, 5, 47-58.	0.0	0
4026	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. Cancer Reports, 2023, 6, .	0.6	4
4027	Person-Centered Oncology. , 2023, , 559-574.		0
4028	Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-NaÃ¯ve Patients with Advanced Non-Small-Cell Lung Cancer. Cancers, 2023, 15, 2297.	1.7	3

#	Article	IF	Citations
4029	Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients. Pathology and Oncology Research, 0, 29, .	0.9	0
4030	The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer. Cancers, 2023, 15, 2319.	1.7	1
4031	Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer. Journal of Inflammation Research, 0, Volume 16, 1693-1709.	1.6	1
4033	C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Disease, 2023, .	0.6	1
4034	Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. World Journal of Cancer Research, 2023, 13, 37-43.	0.1	0
4035	Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis. PLoS ONE, 2023, 18, e0283719.	1.1	1
4036	Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications. Chemical Reviews, 2023, 123, 6612-6667.	23.0	22
4037	Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma. Mediators of Inflammation, 2023, 2023, 1-13.	1.4	2
4038	Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis. PharmacoEconomics - Open, 2023, 7, 617-626.	0.9	1
4039	Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	2
4040	Clinical benefit of platinum doublet combination therapy in older adults with advanced nonâ€small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan. Thoracic Cancer, 0, , .	0.8	0
4041	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathology Research and Practice, 2023, 246, 154470.	1.0	0
4042	Novel predictors of immune checkpoint inhibitor response and prognosis in advanced nonâ€smallâ€cell lung cancer with bone metastasis. Cancer Medicine, 0, , .	1.3	2
4043	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals, 2023, 16, 614.	1.7	18
4045	Cerium End-Deposited Gold Nanorods-Based Photoimmunotherapy for Boosting Tumor Immunogenicity. Pharmaceutics, 2023, 15, 1309.	2.0	0
4061	Genetic and Epigenetic Dysregulation in Environmental Disease. , 2024, , 465-492.		0
4070	Epigenetic therapy in lung cancer. , 2023, , 237-274.		0
4077	Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	27

#	Article	IF	Citations
4094	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
4214	Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon. Frontiers in Immunology, 0, 14, .	2.2	0
4245	The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature, 2023, 619, 475-486.	13.7	13
4298	Lung cancer in never smokers (LCINS): development of a UK national research strategy. , 2023, 1, .		2
4309	Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. BioDrugs, 2023, 37, 775-791.	2.2	1
4317	Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies?. Frontiers in Oncology, 0, 13, .	1.3	0
4323	Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Supportive Care in Cancer, 2023, 31, .	1.0	0
4336	Targeted therapies in advanced lung cancerâ€"current landscapes and future projects. , 2023, , 57-70.		0
4343	The Revolution of Lung Cancer Therapeutics. , 2023, , 235-249.		0
4366	Immunotherapy for Non-small Cell Lung Cancer. , 2023, , 1-25.		0
4379	Second-line therapy in advanced nonâ€"small cell lung cancer. , 2024, , 195-216.		0
4381	First-line therapy. , 2024, , 175-194.		0
4383	Oligometastatic disease. , 2024, , 137-154.		0
4390	Treatment of Stage IV Non-small Cell Lung Cancer. Respiratory Medicine, 2023, , 165-186.	0.1	0
4428	Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment. , 2023, 40, .		0
4431	Pulmonary Toxicity Associated with Immune CheckpointÂInhibitors-Based Therapy: Current Perspectives and Future Directions. Drug Safety, 2023, 46, 1313-1322.	1.4	1
4444	Importance of In silico Tools in Anticancer Drug Discovery from Nature. , 2023, , 139-164.		0
4504	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 1-17.		0

#	Article	IF	Citations
4508	Explainable Classification for Non-Small Cell Lung Cancer Based on Positron Emission Tomography Features and Clinical Data. , 2023, , .		0
4512	Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC. , 0, , .		0
4622	Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility. Cancer Immunology, Immunotherapy, 2024, 73, .	2.0	0
4629	Malignome des Respirationstrakts. , 2024, , 601-646.		0
4633	Lung Cancer in Elderly: Patient-Centered Approach for Optimal Delivery of Care. , 2024, , 869-884.		0
4648	Resource-Limited Automated Ki67 Index Estimation in Breast Cancer. , 2023, , .		0
4672	Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer. , 2024, , 265-295.		0
4674	Editorial: Radiotherapy strategies for precise treatment on brain metastases. Frontiers in Oncology, 0, 14, .	1.3	0
4675	Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives. , 2024, , 335-377.		0